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Abstract 
 
Findings from randomised controlled trials (RCTs) on primary care treatments for 
non-specific low back pain (NSLBP) often show modest or non-significant 
differences in responses to treatments. The overall response to treatment within 
arms, however, is often large. This raises the question of the non-specific effects 
associated with using the treatments and whether the size of these non-specific 
effects is much larger than the size of effects associated with the specific 
components of treatments. Non-specific effects in clinical trials, defined in this 
thesis as the effects on the overall improvement of symptoms (i.e. response to 
treatment) that is not attributed to the treatment itself, contribute to the clinical 
course of symptoms and can be related to the patient, the symptoms, the 
healthcare practitioner, the communication between the patient and practitioner, 
the nature of treatment provided and the setting and environment of the clinical 
encounter.  
 
The objectives of this study were examining: 1) the pattern of within-arm overall 
responses to treatments in RCTs on non-specific low back pain; 2) sources of 
variation in responses to treatments by investigating the association of non-
specific factors with overall responses to treatments; 3) the influence of patient 
characteristics on responses to treatments using individual patient data from 
RCTs; and 4) whether merely participating in RCTs adds to the size of response 
to treatments (the ‘trial effect’).  
 
The findings suggest that responses to treatments for NSLBP follow a pattern of 
an early large improvement in symptoms within 13-27 weeks of starting treatment 
III 
 
followed by a smaller further improvement. This pattern was common to arms of 
RCTs regardless of the type of treatment. There was evidence that participants 
who had back pain episodes of less than 13 weeks showed larger responses to 
treatments than those with longer duration. There was weak inconclusive 
evidence for the association with age, gender, history of back pain, overall trial 
quality, adequacy of patient blinding and adequate compliance. There was no 
evidence that participating in RCTs led to larger improvement in back pain 
symptoms compared with participating in cohort studies. In conclusion, there is 
some evidence for the association of factors that are not related to the treatments 
with responses to treatments for NSLBP. Insufficient data hindered the 
assessment of other non-specific factors that were considered to be important, 
such as practitioner-patient communication.  
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1.1. Introduction 
 
Non-specific low back pain (NSLBP) is a common symptom with an estimated 
lifetime prevalence of up to 85% (van Tulder et al 2002, WHO 2003, Krismer & 
van Tulder 2006) with most people likely to experience one or more episodes 
during their lifetime, with the majority (around 60%) still reporting pain or disability 
a year after their initial consultation with a general practitioner (Hestbaek 2003). 
This large proportion of the affected population with a long-term pain and 
functional disability presents a large burden on society with large direct and 
indirect healthcare costs (Andersson et al 1999, Maniadakis et al 2000).   
 
1.1.1 Non-specific low back pain (NSLBP) 
Against a background of a plethora of names and diagnostic labels used for back 
pain (Quebec Task force on Spinal Disorders, 1987), the name ‘non-specific low 
back pain’ was gradually introduced in the eighties and commonly adopted by 
researchers since. Low back pain is considered to be non-specific in the majority 
of cases, estimated around 90-95% (Krismer & van Tulder 2006). In the remaining 
5-10% cases a specific pathology is identified, such as a degenerative or 
inflammatory condition, disc herniation or spinal stenosis, infective, neoplastic or 
metabolic bone disease, trauma or a congenital disorder. The National Institute for 
Health and Clinical Excellence (NICE) defined NSLBP as ‘tension, soreness 
and/or stiffness in the lower back region for which it is not possible to identify a 
specific cause’ (Low back pain: NICE guideline 2009). This label, however, in the 
absent specific diagnosis, covers a heterogeneous population of patients with a 
wide range of characteristics (Coste et al 1991, Waddell 2005, Ben Debba et al 
2000).  
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Although it is estimated that 90% of patients with NSLBP are expected to stop 
consulting healthcare professionals with back pain symptoms within three months 
(Croft et al 1998), evidence shows that many (28%-90%) will still be experiencing 
low back pain and related disability 12 months after the start of pain and many will 
still be on sick leave from work for back pain (Croft et al 1998, Hestbaek et al 
2003, Henschke et al 2008, da Costa et al 2009). An increasing number of studies 
have been conducted to understand the course and outcome of NSLBP. There is 
growing evidence that back pain is a chronic condition that runs a persisting and 
fluctuating course (Dunn et al 2008, von Korff & Dunn 2008). Studies also suggest 
that a large proportion of patients with chronic low back pain also report 
widespread pain (Natvig et al 2001, Bergman et al 2001).  
 
The back pain symptoms, the fear of them worsening and recurring impact the 
individual leading to loss of function, restriction in daily activities and participation 
in work and social activities, representing a burden as defined by the WHO 
International Classification of Functioning, Disability and Health (ICF) (2004). The 
burden on society is represented by direct costs related to healthcare service use 
and much larger indirect costs related to loss of productivity and work days. 
Maniadakis and Gray (2000) estimated that the direct costs in the UK in 1998 
were £1.6 billion while the overall direct and indirect costs ranged from £6.6 billion 
to £12.3 billion, depending on the costing method. Similar larger proportions of 
indirect costs were found in Sweden and the Netherlands (Moffett et al 1995).  
 
The current guidelines on early management of non-specific low back pain in the 
UK focus on the principles of promotion of self-help and keeping active, offering 
drug treatments (Paracetamol, NSAIDs, weak opioids and tricyclic 
4 
 
antidepressants) and considering exercise programmes, a course of manual 
therapy or a course of acupuncture (Low back pain: NICE guideline 2009).  
 
1.1.2 Effectiveness of treatments for NSLBP and the non-specific effects 
A consistent finding from many of the increasing number of randomised controlled 
trials (RCTs) on primary care treatments for non-specific low back pain is the 
modest and often non-significant differences in responses to various treatments 
(van Tulder et al 2006 et al, Keller et al 2007, Machado et al 2009). This is true in 
trials in which comparative arms include active treatments (e.g. Frost et al 2004, 
UK BEAM 2004, Carr et al 2005, Heymans et al 2006, Chown et al 2008), usual 
care (e.g. Moffett et al 1999, Hay et al 2005, Thomas et al 2006, Jellema et al 
2005, Johnson et al 2007) or placebo or sham treatments (e.g. Beurskens et al 
1995, Licciardone et al 2003, Rouff et al 2003, Hoiriis et al 2004, Katz et al 2005). 
Of equal interest is the observation of the large size of the overall within-arm 
response or symptom progression in these same trials (the measured change in 
outcome from baseline), indicating that patients on average show large 
improvement in clinical trials.  
 
Although the observed difference in within-arm symptom progression in RCTs is 
attributed directly to the specific effect of the index trial treatment (the “treatment 
effect”), the overall within-arm change in symptoms will depend not only on the 
specific effect of the treatment. It will also represent the effects of more general 
factors that are not specific to the treatment used. For this reason and in keeping 
with the supposition in this thesis that the change in symptoms over time in trial 
arms is not exclusively related to the treatment used, the term ‘progression of 
symptoms’ will be used to refer to loosely to overall within-arm change of outcome 
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scores over time. As will be described in detail in the following chapter, these 
factors can be related to the patient (demographics, cultural background), the 
symptoms (severity and duration), the healthcare practitioner (skills and previous 
experience), the nature of treatment provided (invasiveness and intensity) and the 
setting and environment of the clinical encounter (Turner et al 1994, Di Blasi et al 
2001, Thomas 1994, de Saintonge et al 1994, Kleijnen et al 1994, Stewart 1995, 
Schouten et al 2005, Smith 2009, Shaw et al 2009, Kaplan 1989, Hodges 1996). 
A number of names and definitions have been suggested for these factors and 
their effects on the course of symptoms (Di Blasi et al 2001, Katz et al 2005, Ong 
et al 1995, Grünbaum 1981, 1985, Moerman et al 2001, Paterson et al 2005) 
reflecting the complexity of this area, as will be discussed in the next chapter. 
 
There is currently no formal definition for the non-specific effects on which 
researchers and clinicians agree. In this thesis the name ‘context effect’ (Di Blasi 
et al 2001) was adopted to refer to the change in patient symptoms that although 
happens when a’ treatment’ is used, is not thought to be related to the specific 
ingredient or component of the treatment. It is associated with the process of 
seeking or using the treatment. The factors that contribute to the context effect will 
be referred to as non-specific factors. These are the factors that are related to the 
patient, the symptoms, the treatment, the practitioner and setting. The effect of 
each particular non-specific factor, e.g. age, or symptom duration, will be called 
the ‘non-specific effect’. The ‘context effect’ describes the collective of all the 
relevant non-specific effects.  
 
It is appropriate that rigorous attempts are made in explanatory RCTs to account 
for the effects of non-specific factors across the treatment arms to be able to 
6 
 
provide evidence for the specific effect of the treatment examined. However, the 
general observation of large size of symptom improvement to a wide variety of 
differing treatments for back pain in clinical trials with no clear superiority of most 
treatments raise the questions of the influence of the non-specific factors and the 
size of any such influence.  
 
The observation of small or insignificant treatment effect is not unique to trials on 
back pain (Finnerup 2010). However, interest in understanding the role of non-
specific factors in symptoms progression in clinical trials in general and 
specifically in pain trials has been growing (Turner 1994).This is important for a 
number of reasons: (1) in clinical practice, identifying and subsequently enhancing 
the general context effect of care could improve clinical outcome. Clear empirical 
evidence for the effect of non-specific factors in clinical practice is, however, yet to 
be provided; (2) for healthcare service provision and planning, improving the 
effectiveness of treatments by enhancing the influence of non-specific factors 
would broaden the options of available treatments and thus facilitate provision and 
planning based on availability and cost in the era of limited resources; (3) for 
research, identifying the evidence for non-specific factors, and estimating the size 
of their influence on the change in outcome could provide the opportunity for a 
better identification of the context effects associated with using treatments. This 
would also help inform revising the design of clinical trials to take into account the 
influence of non-specific factors such as identifying subgroups of patients with 
particular characteristics. 
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The aim of this study was to examine the association between non-specific factors 
and symptom improvements in clinical trials of non-specific low back pain 
(NSLBP). 
 
 
1.2 Objectives 
 
The specific objectives were:  
1. To examine within-arm symptom progression in RCTs on non-specific low back 
pain to assess the pattern and size of symptom progression and any variation 
between them. 
 
2. To examine sources of variation in symptom progression by investigating the 
association with non-specific factors (represented by trial level characteristics 
including mean age and gender of participants, duration of low back pain and 
aspects of trial quality) in RCTs. 
 
3. To examine the influence of patient characteristics (age, gender, duration of 
pain, previous history of back pain, expectation regarding helpfulness of treatment 
and preference for treatment) on symptoms progression using individual patient 
data from RCTs.  
 
4. To examine whether merely participating in RCTs adds to the size of symptom 
progression (the ‘trial effect’).  
 
8 
 
The focus in this thesis, therefore, is on the progression of symptoms representing 
the overall change in outcome scores over time in trial arms rather than between-
arm differences or treatment effect, as within-arm progression of symptoms 
incorporates the effects of non-specific factors which are central to this research. 
However, in various areas of the thesis points related to treatment effects were 
raised and addressed. This is because studying within-arm symptom progression 
is not commonly undertaken and comparison could only be made with studies that 
examined treatment effects, such as the influence of trials characteristics or 
patients’ characteristics such as age or expectation. However, the distinction 
between treatment effect and progression of symptoms in clinical trials was made 
clear throughout.  
 
1.2.1 Identifying and prioritising non-specific factors 
The definition of non-specific factors is broad in that it covers a large group of 
factors and hence can be complex. However, this thesis is concerned with 
studying factors within RCTs on back pain and for which sufficient information is 
available to analyse. It is important, therefore, to note that these factors might not 
be the only factors that influence symptom progression. To try to be as inclusive 
of all the important factors as possible, I conducted a study as part of a workshop 
at the 2009 International Low Back Pain Forum meeting, in Boston USA. The aim 
was to identify and obtain consensus on the non-specific factors that are most 
influential on progression of symptoms of NSLBP in clinical trials. 
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1.3 Layout of the thesis 
The structure of the thesis is summarised in Figure 1. The thesis comprises nine 
chapters as follows (Figure 1): 
Chapter One: Introduction and thesis layout 
Chapter Two: The non-specific factors associated with the use of treatments 
Chapter two explores the concept of the context effects associated with using 
treatments with a summary of a historical background.  
Chapter Three: Identifying and prioritising non-specific factors associated with 
treatments for NSLBP: a consensus study and a linked discussion of the literature 
Chapter three describes the outcome of a Delphi study undertaken in association 
with a workshop in the 2009 International Low Back Pain Forum meeting in 
Boston, to identify important non-specific factors that could influence symptoms 
progression in clinical trials on NSLBP. 
Chapter Four: The pattern of low back pain symptom progression in clinical trials: 
A systematic review and meta-analysis of randomised clinical trials.  
Chapter four presents a systematic review of RCTs on primary care treatments for 
NSLBP to examine overall symptom progression. The objective was to find out 
whether symptom progression in RCTs follows a common pattern similar to that 
anecdotally observed in a number of RCTs. To assess whether the pattern and 
size of change in outcome scores were independent of the treatments used, the 
association between symptom progression and types of treatments was studied. 
Treatments were classified into index, active comparator, placebo treatment, 
usual care or waiting list control. A second classification was according to whether 
the treatment was pharmacological or non-pharmacological.  
Chapter Five: The quality of randomised clinical trials of primary care treatments 
for non-specific low back pain 
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To support the validity of the outcome of the review presented in Chapter Four, 
Chapter Five describes the quality of the included RCTs. The Cochrane Back 
Group quality assessment tool was used (van Tulder et al 2009). This tool was 
updated by the Cochrane Collaboration (Furlan 2009) after the quality 
assessment of the studies was completed. The overall trial quality, as well as 
individual quality criteria (e.g. adequacy of patient blinding and of concealment of 
allocation to treatments), were also studied as non-specific factors for their 
potential association with symptom progression, included in the list of non-specific 
factors for the meta-regression analyses in Chapter Six. 
Next, the association between non-specific factors and symptom progression in 
clinical trials was investigated. This was achieved in three stages outlined in the 
next three chapters as follows: 
 
Chapter Six: Factors associated with low back pain symptom progression in 
clinical trials: a meta-regression analysis of randomised clinical trials 
In this chapter the association between non-specific factors represented by trial 
characteristics and symptom progression was studied. Meta-regression analyses 
were carried out on the aggregated data from the identified publications on RCTs. 
All characteristics for which sufficient information was provided were studied, 
including trial setting and quality, participants’ age and gender and symptom 
duration. The associations were adjusted for types of treatments.  
Chapter Seven: Factors associated with low back pain symptom progression in 
clinical trials:  analysis of individual patient data (IPD) 
The outcome of the second stage of analysing the association between symptom 
progression and non-specific factors is presented in this chapter. Some of the trial 
characteristics that were studied in Chapter Six were characteristics of the 
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participants and their symptoms and not true characteristics of the trials. 
Examples include age and duration of pain. The best method to study the 
influence of these characteristics on symptom progression is to use IPD, which 
was used in this chapter. The opportunity was used to study the influence of other 
characteristics for which some evidence exists for their influence on symptom 
progression and for which sufficient aggregated data were not available in the 
RCTs studied in Chapter Six. The focus here was on the additional characteristics 
highlighted during the workshop conducted at the 2009 International Low Back 
Pain Forum, namely expectation regarding the helpfulness of treatments, 
preference for treatments and history of back pain.  
Chapter Eight: The effect of participating in randomised clinical trials on patient 
outcome: comparing the course of back pain symptoms in RCTs and cohort 
studies. 
In this third and final stage of studying the association between non-specific 
factors and symptom progression the focus was on the “trial effect” i.e. the effect 
of participating in RCTs. The theory is that the intensive protocol-led care and 
attention provided to participants in RCTs augments the size of symptom 
improvement. The evidence on this is not clear and mainly derived from fields 
other than musculoskeletal pain. NSLBP symptom progression in RCTs included 
in the systematic review was compared with the course of NSLBP symptoms in 
cohort studies in which participants received primary care treatments or usual 
care. Cohort studies represent the course of symptoms without the effect of the 
more stringent protocol-led methods in RCTs.  
Chapter Nine: Summary and conclusions 
Chapter Nine summarises the outcome of the study, draws overall conclusions, 
and discusses the implications and areas for future research. 
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Figure 1 Outline of the thesis 
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2.1 Introduction 
 
The observation from a number of RCTs on back pain of small or insignificant 
treatment effects (Moffett et al 1999, Frost et al 2004, UK BEAM 2004, Hay et al 
2005, Heymans et al 2006, Thomas et al 2006, Johnson et al 2007) (Figure 2.1) 
with ‘universal’ large overall improvement in symptoms following various types of 
treatments was the origin of my interest in the subject area of this project. The 
observation raises the questions of the role of non-specific factors associated with 
the use and provision of the treatments and whether the size of their effects is 
larger than the specific effects of the active treatments themselves that it 
compromises the ability to show a clear superiority of the specific effects of the 
treatments.  
 
In this chapter the concept of the effects of non-specific factors associated with 
the use of treatments is explored with a brief review of the literature. The name 
the context effect will be used throughout the thesis to loosely refer to the effects 
of non-specific factors associated with the use of treatments but not related to the 
specific ingredient of the treatment.  
 
 
2.2 The context effect and the specific effects of treatments 
 
There is a well-documented history trail of the concept of ‘non-specific effects’ of 
treatments that have taken various names (Beecher 1955, Brokovec 1985, 
Gotzsche 1994, Grunbaum 1981, Grunbaum et al 1985) including the probably 
more commonly used term ‘placebo’ effect. The ‘incidental effects’ (Grunbaum  
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Figure 2.1       Within-arm symptom progression in a number of RCTs on NSLBP 
treatments 
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Hay et al 2005 
MP: Manual physiotherapy, BPM: Brief pain management  
 
 
 
 
Jellema et al 2005 
MIS: Minimal intervention strategy, UC: Usual care 
 
 
 
 
Johnson et al 2007 
BPB: Back pain booklet & usual GP care, Ph: Physiotherapy led community based treatment 
program 
 
 
 
Figure 2.1(Continued) Within-arm symptom progression in a number of RCTs on NSLBP 
treatments 
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1981, Grunbaum et al 1985), the ‘context effect’ (Di Blasi et al 2001) and the 
‘meaning response’ (Moerman et al 2002) are some of the names suggested over 
time. This, however, does not represent just superficial attempts at naming a 
phenomenon, but in fact it nicely reflects difficulties and problems in identifying 
and defining this concept.  
 
The terms specific and non-specific, for instance, did not receive universal 
agreement, as some found them unhelpful (Grunbaum 1981, Grunbaum et al 
1985). The main problem was to what exactly the specificity is related, the 
treatment or the symptoms. Understanding the mechanism of action of a 
treatment might lead to identifying its specific effect. If this was found to help in a 
particular disease or symptom then this effect would be specific to that particular 
treatment only when used for that particular disease. If the mechanism was found 
to also help in another disease or symptom, then that treatment effect might not 
be considered specific when it is used for either of these conditions. As ‘non-
specific effects’ would then be described as effects of treatment that are not 
expected or specified according to the mechanism of action of treatment and 
nature of symptoms, some preferred to describe them as ‘non-specified’ rather 
than ‘non-specific’ (White et al 1985). This highlights how easy it is for the 
discussion to become semantic and lose its core meaning.  
 
For some treatments, it is not easy to clearly identify the specific ingredient and 
acupuncture is a good example. While traditionally the needling is considered as 
the specific ingredient, other elements of performing acupuncture such as 
communicating with the patient and exploring the health problem to decide the 
way the procedure is conducted is considered by some as important elements of 
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the specific ingredient of acupuncture (Paterson et al 2005). This could arguably 
apply to other types of treatments such as physiotherapy or chiropractic or indeed 
to pharmacological treatments prescribed by a practitioner.  
 
Furthermore, even if the specific ingredient of a treatment could be easily 
identified, it might not be as easy to relate the change in symptoms directly and 
exclusively to that ingredient. This becomes particularly difficult in treatments that 
involve and rely on elements such as the skill of the practitioner, communicating 
with the patient or the setting in which it is provided. Clear and solid distinctive 
lines might not exist between these factors and between them and the specific 
ingredient of the treatment (Thomas et al 1994). Describing them as specific or 
non-specific, therefore, might not be universally clear or agreed. However, others 
do believe that these factors are distinguishable and should be addressed as such 
(Miller et al 2006).  
 
It is likely that non-specific factors interact with each other and with the specific 
treatments and the final effect will depend on the nature of these factors and their 
interaction. This could therefore be the addition of the effects, an augmented 
overall effect or a reduction in the final effect.  
 
Non-specific factors are sometimes called placebos and their effects described as 
placebo effects (Brody et al 1980, Brody et al 1985, Colloca 2004, Price et al 
2001). A placebo, however, might be better reserved for describing comparator 
‘treatments’ in placebo-controlled trials or clinical practice. In that narrow context, 
the meaning of the placebo is a control treatment with a similar appearance to the 
study treatment but without its essential component (Hrobjartsson & Gotzsche 
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2010). Early definitions of placebo and placebo effect are those of Shapiro et al 
(1960, 1961, 1968, 1978) who defined a placebo as “any therapy (or component 
of therapy) deliberately used for non-specific psychological or psychophysiological 
effect ... and without specific activity for the condition being treated...” The placebo 
effect, accordingly, was defined as “the non-specific psychological or 
psychophysiological effect produced by placebos”. This is an example of the 
earliest references to this concept, suggesting that a therapy has specific effects 
on a particular medical condition that are different from effects that are not specific 
to that therapy. As a theoretical implication of that, the magnitude of the non-
specific effects in placebo controlled trials could be measured by subtracting the 
change in outcome scores in patients treated with a placebo treatment from that in 
patients in the ‘no treatment’ arm. In fact several systematic reviews have used 
such methods to estimate the placebo effect, for example in patients with 
osteoarthritis (Zahng et al 2008) or a range of musculoskeletal conditions 
(Hrobjartsson & Gotzche 2010, Hauser et al 2011).  
 
For this thesis, the name context effect was adopted with a broader definition to 
refer to the change in patient symptoms that although happens when a’ treatment’ 
is used, is not thought to be related to the specific ingredient or component of the 
treatment. The non-specific factors could be classified into five groups (Figure 
2.2): factors related to the patient, healthcare practitioner, nature and type of the 
treatment, the symptoms and setting or environment of the clinical encounter (de 
Saintonge et al 1994, Kleijnen et al 1994, Turner et al 1994).  
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Figure 2.2      Categories of non-specific factors (including examples) associated with the use of treatments in clinical trials.  
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Factors related to the patients include their cultural background, demographics, 
beliefs, expectations and experiences with other illnesses, history of the illness or 
previous use of the current treatment or other treatments (Petrie et al 2005, 
Schouten et al 2005, 2007, Smith et al 2009). Practitioner factors include their 
experience with the use of the treatment, expectation and knowledge of the 
clinical course of the illness and their skills (Schouten et al 2005, Shaw et al 2009, 
Stewart et al 1995, Hodges et al 1996). Characteristics of the treatment 
(Branthwaite et al 1981, Colloca et al 2004) such as invasiveness, physical 
contact and psychological component are other non-specific factors. The 
environment and nature of the communication between the patient and the 
practitioner (Schouten et al 2005, 2007, Shaw 2009, Stewart et al 1995, Hodges 
et al 1996, Colloca et al 2004, Ong 1995, Gallagher et al 2005, Gorawara-Bhat et 
al 2007, Charles et al 1997, Coulter 1997) represent examples of other factors. 
These examples are by definition non-specific, i.e. not specific to the ingredient of 
the particular treatment used, but are associated with the process of the provision 
and reception of care or treatment.  
 
 
2.3 Non-specific factors, natural history and clinical course 
 
It could be argued that some factors, such as symptom severity and duration, 
influence the natural history of the symptoms without using a treatment. Patients’ 
beliefs regarding their illness and symptoms, cultural background, previous 
experience with the symptoms, communications from relatives and friends, age or 
gender may also influence the progression of symptoms without using any 
treatment. In other words, they could be considered to contribute to the natural 
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history of the symptoms rather than non-specific factors. However, any influence 
these factors might have would still be at play when a treatment is used and they 
would then be considered to contribute to the clinical course of the symptoms. If 
the treatment was received through communicating with a healthcare practitioner 
in a consultation setting, then additional factors related to the practitioner and the 
setting will also start to have a role. In a clinical trial, additional factors related to 
the protocol and setting as well as other factors such as preference for a 
treatment and self-selection for enrolment will also play a role.  Again, they will all 
contribute to the clinical course of the symptoms. In other words, there is no 
exclusivity between natural history, clinical course and the influence of non-
specific factors. The focus in this thesis was to study the factors that could be 
associated with the course of back pain symptoms in clinical trials and to find out 
whether any influence these factors have is unrelated to the type of treatment, as 
the anecdotal observations seem to suggest. 
 
 
2.4 Non-specific factors and clinical trials 
 
The randomised placebo-controlled trial, heralded as the gold-standard method 
for evaluating treatment ‘success’, compares the effect of an ‘index’ treatment with 
the effect of another, ‘comparator’ treatment or ‘control’ condition. The efficacy of 
the treatment is measured by assessing the difference in the changes in pre-
determined primary outcome measures between groups (Figure 2.3).  
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Figure 2.3  Treatment effect and symptom progression in an example of a two-
arm trial. 
 
 
 
 
The unique property of the RCT is that it aims to directly attribute any observed 
difference in outcomes to the index trial treatment. In an explanatory efficacy 
randomised controlled clinical trial, this difference represents the specific effect of 
the index treatment.  
 
However, symptom progression in each arm will be influenced by multiple factors, 
in addition to the specific treatment itself (Figure 2.4). Such ‘non-specific factors’ 
can be related to the patient, the treatment, the practitioner, the symptoms or the 
setting of the trial. The actual participation in the trial could be considered as a 
factor that could result in what has been described as the ‘trial effect’ (Braunholtz 
et al 2001, Vist et al 2005). 
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Figure 2.4  Specific and non-specific factors that could influence symptom 
progression in RCTs and cohort studies. The non-specific factors 
mentioned represent examples for illustration only. The distribution of 
factors is not exclusive to the places allocated for them. 
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These factors contribute to the symptom progression, or the course of the 
symptoms, in all treatment arms. If the specific effect of the trial treatment is 
represented by the difference between the change in outcome scores in the ‘two’ 
treatment arms, then the remaining size of progression of symptoms in both arms 
will not be related to the specific treatment effect but to the effects of non-specific 
factors (Figure 2.3). The size of the effects of the non-specific factors is not yet 
clearly estimated. The suspicion is that the size might be so large that it 
overshadows the specific effect of the treatments themselves.  
 
One implication for this is that attention needs to be paid to the apparently 
common large change in outcome scores in all arms in these trials. Any sources 
of variation in the size of this change would represent the effects of factors that 
need to be identified to potentially aid identifying subgroups of patients with larger 
change in their symptoms. This fuelled the main aim of this PhD project.  
 
Another implication is that to be able to study these non-specific factors and their 
influence on the course of symptom, within-arm change in outcome scores, rather 
than between-arm treatment effect, need to be studied. It is this within-arm 
symptom progression that includes the non-specific effects of all factors as well as 
the specific effect of the treatments and this is the reason why this study focuses 
on within-arm symptom progression rather than between-arm treatment effects.  
 
 
 
 
 
26 
 
2.5 Summary 
 
It is clear that the concept of non-specific factors is complex and finding a name 
that describes it with all its varied and complex aspects is difficult. It was not within 
our aims to examine in depth the various names or to suggest a new name. The 
term ‘context effect’ is adopted here based on the understanding that, compared 
with the other available names, it represents all the factors, other than the specific 
ingredient of the treatment used, that would contribute to the course of back pain 
symptoms in clinical trials. These factors are related to the patient, the 
practitioner, the symptoms, types of treatment and the setting and environment. 
There are, of course, the caveats associated with this term as with all the other 
terms as outlined earlier.  
 
Contributing to the natural history of symptoms are groups of non-specific factors 
related to the patient and the symptoms. The same factors will contribute to the 
clinical course of the symptoms when a treatment is used. The distinction 
between the context effect and natural history, or between the context effect and 
the clinical course is therefore artificial as they represent overlapping concepts 
with shared components.  
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Chapter Three 
 
 
Identifying and prioritising non-specific 
factors associated with treatments for 
NSLBP: a consensus study and a linked 
discussion of the literature 
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3.1 Introduction 
 
The apparent ‘universal’ improvement in symptoms in clinical trials following 
various types of treatments raises the question of the contribution of the specific 
versus non-specific factors associated with the use of treatments to symptom 
progression. A number of such factors such as patient perception about illness or 
treatment, patient expectation, practitioner skills and patient-practitioner 
interaction have been identified and their influence on benefit from treatment 
studied (Turner et al 1994, Crow 1999, Karjalainen et al 2004, Di Blasi et al 2001) 
as was discussed in Chapter Two. However, there is no empirical evidence from 
the literature on the hierarchy the various non-specific factors have according to 
their influence on the course of back pain symptoms.  
 
To identify the non-specific factors that have influence on NSLBP symptom 
progression and to explore how they may rank according to the strength of that 
influence a two-stage design was adopted. First a Delphi study was conducted 
prior to a workshop at the 10th meeting of the International Forum for Primary 
Care Research on Low Back Pain, held in Boston, USA in 2009. The linked 
workshop represented the second stage in which the outcome of the Delphi study 
was explored to help validate the study findings. The workshop discussions were 
also used to further enrich and refine my understanding of the role of non-specific 
factors in clinical trials on NSLBP. This chapter describes the Delphi study and the 
workshop and provides an overview of the key findings and recommendations. 
The chapter concludes with a linked discussion of the literature. 
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3.2 Objectives 
 
The main objectives were: 
1) To identify the non-specific factors that influence NSLBP symptom progression 
in clinical trials, and 2) To obtain a consensus on the strength of their importance 
according to the strength of their influence.  
 
A further objective was to utilise the opportunity of the workshop to discuss the 
current understanding of the influence of non-specific factors on symptom 
progression, their interaction with each other and to what extent they can be 
modified by treatment / targeted for intervention.  
 
 
3.3 Methods 
 
The methods involved a pre-workshop Delphi study and a workshop using 
nominal group discussions.  
 
The recommended guidelines for the Delphi technique (Goodman 1987, Hasson 
et al 2000, Villiers et al 2005, Keeney et al 2006) were followed. These included 
anonymity i.e. responses that are fed back to participants are anonymised; 
iteration with controlled feedback i.e. using successive questionnaire or feedback 
to obtain successive responses; avoidance of interaction between participants; 
statistical summary of the group’s views on the included items which is fed back to 
the participants; and finally the use of experts as the participants in the Delphi.  
30 
 
These characteristics will be described in detail below in conjunction with the 
methods used for this study. 
 
 
3.3.1 Pre-workshop Delphi study 
The study panel 
Participants of a Delphi study are often referred to as the study panel. The 
intention in a Delphi study is not to select a random sample of participants who 
might have views or opinions on the subject. Rather, it is experts, defined as 
those who have the relevant knowledge and experience in the particular field and 
whose opinions are respected by their peers, are selected to participate 
(Goodman 1987). In addition to the experts, it is usual to also invite individuals 
who have specific interest in the subject area to participate in the study. The main 
reason for these characteristics of participants is the aim of the Delphi study, 
which is to arrive at a consensus or a judgement that would represent the 
evidence in an area where empirical evidence is lacking or difficult to establish 
(Goodman 1987). The application of the study could be to forecast future events 
based on open views of the experts, or to arrive at a consensus on a selection 
from a closed list of items.  
 
For the study described here in this thesis, participants in the Forum meeting 
mentioned earlier were invited to take part. They were a group of clinicians and 
researchers with a common interest and expertise in back pain, self-selected to 
participate in the Forum meeting and in this workshop in particular. They, 
therefore, represented the experts and individuals with interest in the subject area 
as recommended for this type of study. The workshop and its objectives were 
31 
 
advertised and therefore it was assumed and expected that the participants had 
the expertise and/or strong interest in this subject area.  
 
Anonymity and communication  
The Delphi study described here was facilitated by the author. Questionnaires 
were communicated and fed back to participants throughout the study rounds with 
anonymity using email communication. I.e. although the participants were 
identifiable to the facilitator, neither they nor their responses and the information 
fed back to them were identifiable to individual participants.  
 
This anonymity has an obvious advantage in that it is conducive for a truthful 
expression of opinions and choices. However, the downside for anonymity is that 
it might lead to lack of accountability, as is discussed in the limitation section 
below. Using this anonymous communication also ensures that direct interaction 
and discussion among participants before completing the questionnaires was 
prevented. This is important as the individual participants will provide their 
opinions and views without the influence of the others, although they might 
change or modify their view when they see the group’s views in the subsequent 
rounds. The study described here included three rounds as described below, the 
third round was also used to explore modifiability and interaction of factors. 
 
Iteration and feedback: round one 
Successive questionnaires are used in a Delphi study in which information and or 
opinions are sought from participants which are then summarised and 
incorporated in the subsequent questionnaires. With the successive 
questionnaires fed back to the group for further opinions as they are kept informed 
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of the current or developing group’s collective opinion. It is through this open 
process that offers the individual participants the opportunity to provide their true 
and uninfluenced opinions and views that Delphi study aims to facilitate and 
develop a consensus.  
 
In the first round of the study described here, participants were invited to list all 
non-specific factors they considered influential on symptom progression in primary 
care patients with back pain. As a prompt, a list of 13 examples of non-specific 
factors compiled from the literature (Turner et al 1994, Thomas 1994, de 
Saintonge & Herxheimer 1994, Kleijnen et al 1994, Stewart 1995) (Table 3.1) was 
sent out to participants to build on and add additional factors. Further to this, 
participants were also asked to rate the strength of the influence of each factor on 
patient outcomes on a scale from zero to five (zero indicating no influence at all 
and five maximum possible influence).  
 
 
Table 3.1  The initial prompt list of non-specific factors presented to participants in  
the first round of the pre-workshop survey 
 
 
Patient factors 
1. Expectations 
2. Beliefs regarding the illness 
3. Experience with the current treatment 
4. Preference regarding the treatment 
5. Cultural background 
6. Duration and severity of the back symptoms 
 
Practitioner factors 
7. Experience and skills  
8. Experience with the current treatment 
 
9. Patient-practitioner interaction factors 
 
Treatment factors 
10. Treatment characteristics 
11. Duration/dose  
12. Whether the treatment is self-administered or involves a practitioner 
 
13. Environment and setting factors 
 
 Other factors 
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Iteration and feedback: round two  
Responses from round one were collected and a list of non-specific factors was 
compiled to include the initial prompt list and all newly added factors. This was the 
main aim of this round. Newly added factors that refer to a similar construct were 
grouped and represented by a single factor. Although participants were asked to 
score the factors in round one, only factors provided in the prompt list would be 
scored by all participants while the newly added factors would be scored only by 
those who provided them. The new list was then sent out to participants in round 
two to rate the expected strength of the influence of each factor on patient 
outcomes using the scale of 0-5. It is in this second round and the next when the 
group had the chance to score all factors, initial and newly added. The score for 
the factor is calculated as the mean of the scores given by the group. When two 
factors have a similar mean score, the factor with the largest number of highest 
scores was ranked higher. For instance, if factor A received four scores of (5) and 
factor B three scores of (5), factor A was ranked higher if their mean scores were 
similar. 
 
Iteration and feedback: round three 
Round two data was used to create a list of ranked factors according to the mean 
of scores given by participants in round two. This was then sent out to participants 
in this third round to score the factors for the final time and also to: 1) identify 
factors whose influence would depend on other variables (interaction), using free 
text, and 2) identify factors that could be modified to improve patient outcomes, to 
be selected from the provided list of factors.  
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3.3.2 The workshop  
The workshop involved group discussions as participants were divided into three 
small groups (identified as Groups 1, 2 and 3), pre-selected to ensure equivalent 
distribution of clinicians and researchers. They were provided with the outcome of 
the Delphi survey represented by the ranked list of non-specific factors that was 
finalised from the pre-workshop survey. The groups were invited to discuss two 
tasks and attempt to reach consensus. The tasks were: 1) Discussing, arguing 
and challenging the outcome of the survey, i.e. the non-specific factors and the 
perceived strength of their influence on patient outcome, and 2) Identifying non-
specific factors which effects could be modified within the framework of an 
intervention trial.  
 
3.3.3 Organisation and identification of common themes 
The workshop was my idea. I designed the pre-workshop survey questionnaires 
and the workshop material and facilitated the pre-workshop survey in all its rounds 
and analysed the results preparing them for the workshop. However, for 
circumstances out of my control and occurring near the time of the workshop, I 
was not able to attend the workshop. After communications with the meeting 
organisers and with the workshop co-convenors, it was agreed that the workshop 
would go ahead led on my behalf by one of the co-convenors, who was my 
supervisor. I was able to secure a live telephone connection to listen and 
participate in the workshop proceedings and some of the groups’ discussion. The 
workshop and the small groups’ discussions were audiotape-recorded and written 
notes were also obtained by the workshop leader and the groups’ moderators.   
 
Studying the notes and audiotape recordings I identified common themes 
regarding the most important non-specific factors, their modifiability and 
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interaction. The findings, themes and discussion were independently checked by 
the three members of the panel who led the workshop.  
 
 
 
 
3.4 Results 
 
3.4.1 Workshop participants (Study panel) 
Twenty-one Low Back Pain Forum members from nine countries participated in 
the workshop. Participants included non-clinical researchers and practicing 
clinicians with active experience with, or interest in, back pain research. They 
included five who were practicing general medical practitioners, three 
rehabilitation medicine practitioners, three physiotherapists, two chiropractors, two 
acupuncturists, three epidemiologists and three trialists. Some participants had 
mixed background and interest and some were both active practitioners and 
researchers. All participants had particular interest, and some of them research 
expertise, in the non-specific effects associated with using treatments for non-
specific low back pain. 
 
3.4.2 Outcome of the Delphi study 
Eighteen participants completed all three rounds of the pre-workshop survey. In 
the first round 50 factors (Table 3.2) were added to the prompt list of 13. Grouping 
new factors that represented similar constructs resulted in 17 new factors. Adding 
these to the prompt list of 13 resulted in a final list of 30 factors.  
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Table 3.2  Non-specific factors that were added to the prompt list by participants in 
the first round of the Delphi study 
 
Factors added by participants  
in the first round 
Grouping of similar factors for the 
second round 
1. (Patient) Beliefs regarding the treatment (Patient) Beliefs regarding the treatment 
2. Meet and greet the patient 
3. Clinician empathy 
4. Treat the patient seriously 
5. Duration of patient practitioner contact 
6. Quality of relationship 
7. How to greet and meet the patient 
8. Clinician takes patient complaint seriously 
9. Take the patient seriously 
10. Quality of caring. 
11. The feeling of being taken seriously 
12. A nice meeting between patient and  
      practitioner 
Patient-practitioner interaction 
13. Communication skills 
14. Explain difficult things in an easy way 
15. Explain things easy and understandable 
16. Communication and ability to connect with  
      patient 
17. Explain illness and causes in a easy way 
18. Ability to demonstrate confidence to patient 
19. Style of language and medicine (Bio or not) 
Practitioner communication skills 
20. Cost of treatment 
21. Perceived (by patient) cost of treatment 
22. Payment for the treatment 
23. Cost of treatment 
24. Paying or not 
Cost (true or perceived) of treatment 
25. (Treatment) New or known  
26. Perceived as 'high technology' (by patient  
      and practitioner) 
27. (Treatment) Traditional or technical 
28. Too much treatment (Health Care) 
Whether treatment is new or known, ‘high-
tech or traditional 
29. Practitioner enthusiasm about treatment 
30. 'Personality' of practitioner (enthusiastic,  
      confident and convincing) 
31. (Practitioner) Charisma 
Practitioner personality and character 
32. Losing dignity 
33. Losing dignity 
Patient losing dignity in the course of 
treatment 
34. Self-efficacy 
35. Coping style 
Patient self-efficacy and coping 
36. (Practitioner) Beliefs about illness and  
      treatment 
Practitioner belief regarding illness and 
treatment 
37. (Patient) Age 
38. (Patient) Age 
Patient age 
39. (Patient) Gender 
40. (Patient) Gender 
Patient gender 
41. (Patient) Uncertainty Patient uncertainty 
42. (Practitioner) Expectations/trust with  
      treatment 
Practitioner expectation 
43. Instrument measuring outcome Instrument measuring outcome 
44. (Patient) Experience from friends and family Experience of patient friends and family 
45. (Patient) Work / Type of work Patient employment 
46. Socialisation (Isolated vs social support  
      network) 
47 External circumstances, disability payment  
     for example 
External circumstances e.g. disability 
payment 
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48. Psychological illness - anxiety, depression Psychological symptoms, anxiety, 
depression 
49. Dare to let the patient decide by own  
      experience 
50. Support the patient’s decisions? 
Patient autonomy or freedom in making 
decision on management 
 
 
 
 
 
Table 3.3 shows the final list of 30 factors ranked according to the mean scores 
given by participants in the study’s second and third rounds. In the first round, the 
new factors were not scored by all study participants and therefore the scores 
given to them by their authors in the first round were not shown. 
 
The list of ranked factors after the final round shows that ‘Patient-practitioner 
interaction’ is the factor considered by this group as the most influential on patient 
outcome. This was followed in rank by ‘patients beliefs regarding illness’, ‘patients 
expectations’, ‘duration and severity of LBP symptoms’ and ‘experience and skills 
of practitioner’.  
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Table 3.3  The outcome of the Delphi study: the ranked non-specific factors and the mean group scores, on scale 0-5, according to the perceived strength of their influence on patient outcome. Factors added to the 
initial prompt list by participants in round one are shown in bold. 
 
Factors in prompt list in round one Scores* Outcome of round two Scores Outcome of round three Scores 
      
Patient-practitioner interaction 4.22 Patient-practitioner interaction 4.58 Patient-practitioner interaction 4.32 
Patients beliefs regarding illness 4.22 Patients beliefs regarding illness 4.54 Patients beliefs regarding illness 4.32 
Patients expectations 3.94 Patients expectations 4.54 Patients expectations 4.29 
Patient preference regarding the treatment 3.44 Patient preference regarding the treatment 4.51 Duration and severity of LBP symptoms 4.25 
Patient experience with the current treatment 3.39 Duration and severity of LBP symptoms 4.48 Experience and skills of practitioner 4.20 
Duration and severity of LBP symptoms 3.39 Experience and skills of practitioner 4.46 Practitioner communication skills 4.20 
Experience and skills of practitioner 3.28 Practitioner communication skills 4.46 Patient preference regarding the treatment 4.19 
Environment and setting 3.11 Practitioner personality and character 4.35 Patient experience with the current treatment 4.18 
Practitioner experience with the treatment 3.11 Practitioner expectation 4.35 Environment and setting 4.15 
Duration / dose of treatment 2.83 Patient experience with the current treatment 4.32 Practitioner experience with the treatment 4.15 
Patient cultural background 2.78 Cost (true or perceived) of treatment 4.28 Whether the treatment is self-administered or involves a practitioner 4 
Treatment characteristics 2.67 Patient uncertainty 4.21 Patient cultural background 3.89 
Whether the treatment is self-administered or involves a 
practitioner 
2.67 Practitioner belief regarding illness and treatment 3.63 Practitioner personality and character 3.80 
  Patient self-efficacy and coping 3.60 Duration / dose of treatment 3.56 
  Instrument measuring outcome 3.56 Cost (true or perceived) of treatment 3.50 
  Experience of patient friends and family 3.50 Whether treatment is new or known, ‘high-tech’ or traditional 3.43 
  Environment and setting 3.50 Treatment characteristics 3.40 
  Treatment characteristics 3.21 Patient losing dignity in the course of management 3.35 
  Practitioner experience with the treatment 3.20 Patient self-efficacy and coping 3.28 
  Whether treatment is new or known, ‘high-tech’ or traditional 3.18 Practitioner belief regarding illness and treatment 3.20 
  Duration / dose of treatment 3.14 Patient age 3 
  Patient losing dignity in the course of management 3.14 Patient gender 2.80 
  External circumstances e.g. disability payment 3.10 Patient uncertainty 2.76 
  Patient cultural background 3.06 Practitioner expectation 2.76 
  Whether the treatment is self-administered or involves a practitioner 3 Instrument measuring outcome 2.70 
  Patient age 2.84 Experience of patient friends and family 2.65 
  Patient gender 2.67 Patient employment 2.65 
  Patient employment 2.67 External circumstances e.g. disability payment 2.63 
  Psychological symptoms, anxiety, depression 2.60 Psychological symptoms, anxiety, depression 2.43 
  Patient autonomy or freedom in making decision on management 2.10 Patient autonomy or freedom in making decision on 
management 
2.31 
      
* In round one, only factors provided in the prompt list were scored by all study participants.  
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3.4.3 Outcome of the workshop  
Task 1:  Identification of most important non-specific factors  
The three groups discussed the outcome of the pre-workshop survey i.e. the 
ranking of the 30 factors. The outcome was agreed and confirmed that the five 
non-specific factors most influential on symptom progression were, in a 
descending order: patient-practitioner interaction, patient’s beliefs regarding the 
illness, patient expectations, duration and severity of LBP symptoms and 
experience and skills of the practitioner. 
 
Group 1 agreed that patient-practitioner interaction was most important but also 
considered patient-related factors (cultural background, uncertainty, decision 
making, health literacy) and treatment-related factors (such as costs, or self-
administered care) as next in importance.  
 
Group 2 felt that the context in which each non-specific factor operated was 
important as this could influence the effect on symptom progression. This group 
questioned whether some ‘non-specific factors’ such as number of treatment 
sessions or duration were actually specific to the particular treatment or whether 
their effect is generic across treatments. There was a consensus that accurate 
description of a factor as ‘non-specific’ may be difficult because it may not be easy 
to separate a factor from the context of its delivery. 
 
Group 3 discussed the difficulty in assessing the importance of individual factors 
because of the expected interactions among factors. All groups agreed on a 
general view that non-specific factors are inter-related in complex ways.  
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Task 2:  Identification of modifiable non-specific factors 
The groups discussed the ways the most important non-specific factors might be 
modified in the context of an intervention study. One group focused on ways to 
improve patient-practitioner interaction. They considered the key components of 
the interaction to be time, empathy, listening, showing concern, creating a 
partnership and shared decision making. Practitioner communication skill was 
considered crucial and training was highlighted as a good example of a way to 
modify this factor. The opportunity of using patient feedback to improve 
communication was also discussed.  
 
Other suggestions included public health campaigns and web-based programmes 
to improve health literacy and influence patient expectations and beliefs. Patient 
advocates, methods to improve shared decision-making, and managing the 
duration of the consultation were also discussed as examples of ways to modify 
these non-specific factors and influence patient outcome.  
 
3.4.4 Common themes 
The following are common themes identified from notes and audiotape recording 
of the workshop: 
Theme 1: Defining the individual non-specific factors 
A common consensus on the meaning and definition of individual non-specific 
factors is important. For example, it is not clear what  the actual meaning of 
patient-practitioner interaction is and what constitutes an optimum interaction. 
Although it was acknowledged that standard models of communications were 
already available, it was not clear how generalisable those models were to various 
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types of interventions and situations and how their influence on symptom 
progression could be measured.  
 
Theme 2: Stages of harnessing the effects of non-specific factors 
Harnessing the context effect would involve three stages: identifying the important 
modifiable factors, designing instruments to measure their influence, and 
developing methods to modify their influence on patient outcomes. This is a very 
important aspect of studying non-specific factors. However, addressing it was 
considered to be beyond the time and capacity in this workshop. 
 
Theme 3: The patient perspective 
A better understanding of the non-specific factors and their relevance for patient 
outcome is achieved through exploring patients’ views on their importance. An 
approach for such exploration would involve qualitative research. 
 
Theme 4:  The interaction and interdependency of non-specific factors 
The majority of non-specific factors were judged to be directly or indirectly 
dependent on each other in their influence on symptom progression. For example, 
patient’s preference for a particular treatment would likely interact with and be 
influenced by previous use of the same treatment, contact with friends or family 
members who had used the treatment, or having trust in a practitioner’s 
recommendation, which itself might be influenced by various factors including the 
practitioner’s communication skills or expertise in this particular treatment. 
Preference for treatment might also be related to expectation of benefit from that 
treatment.  
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Theme 5: Modifiability  
Many of the listed non-specific factors are modifiable. It was suggested that ways 
of modifying patient-practitioner interaction could revolve around targeting its 
components, namely the patient, the practitioner, and the interaction between 
them.  Examples of strategies suggested for improving practitioner communication 
skills included increasing the flexibility of consultation duration, learning 
techniques for effective reassurance of patients, and using patient feedback. 
  
 
3.5 Discussion 
 
The aim of this study was to develop a consensus on the hierarchy of the non-
specific factors that influence NSLBP symptom progression according to the 
strength of their influence. It also aimed to utilise the opportunity of the workshop 
discussions to enhance the understanding of the nature of non-specific factors 
and their influence on NSLBP symptom progression.  
 
A consensus was reached that patient-practitioner interaction was the most 
influential on NSLBP symptom progression among a total of 30 non-specific 
factors.  
 
 
3.5.1 The Delphi study 
The aim of this study was to identify the non-specific factors that could influence 
low back pain symptoms progression and to evaluate the comparative strength of 
their perceived influence on patient outcome. As the evidence from the literature 
was lacking on the comparative strength of their influence on the course of back 
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pain symptoms, the Delphi method was adopted to arrive at a consensus among 
experts in this area to achieve the objectives outlined in this study.  
 
The key feature that gives the Delphi method its ability to provide strong evidence 
on a specific topic, when empirical evidence is absent, contradictory or 
insufficient, is its ‘safety in numbers’. In other words, a number of views, opinions 
and judgements on a specific area when combined and summarised is likely to 
provide stronger evidence than individual opinions and views. Before this method 
was developed in the 1950s (Goodman 1987),  focus groups or individual experts 
opinions were examples of what was normally used, of which focus groups 
discussions were considered the most superior. However, a number of significant 
caveats were identified in this method which were directly addressed and 
overcome by the Delphi method. These include domineering personalities of 
some experts that might negatively impact the validity of the final conclusions or 
outcomes; the negative effect of hierarchy in professional status or position 
among the experts, where some participants might not be willing to voice opinions 
that would seem to undermine this; and the vocal minority who might influence the 
outcome against the silent majority. The Delphi method, with its anonymity and 
lack of direct interaction among participants and iteration and repeated collection 
of participants’ views address and overcome these caveats and serve to provide a 
valid consensus on a particular area. 
 
There are a number of limitations, however, that are specifically related to the 
Delphi method and these will be outlined at the end of the chapter. 
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3.5.2 The outcome of the workshop in context  
A number of themes identified from the workshop would merit an in-depth 
discussion.  
 
3.5.2.a The most important factor: Patient-practitioner interaction 
The strong consensus in this workshop that patient-practitioner interaction as the 
most important non-specific factor echoes a long-held belief both among health 
professionals and the public regarding the importance of this interaction. 
Developing and improving practitioner communication skills are established 
components of medical training. There is evidence for their influence on symptom 
progression, both from clinical studies (Turner et al 1994, Stewart 1995, Di Blasi 
et al 2001) and from experimental work such as that conducted by Colloca et al 
(2005). In a survey conducted by Petrie et al (2005), patients attending a pain 
management clinic for the first time were asked what they considered most 
important in the care they received in the clinic. Understanding the nature of their 
pain through practitioner communication was rated the highest source of patients’ 
satisfaction with the care they received, rated as highly as pain relief itself. 
 
The concept of ‘patient-centeredness’ (Stewart 1995) was developed in the 
eighties to counter concerns about limitations with the paternalistic and provider-
centred approach prevalent in medical settings up to that time. Various socio-
political changes, including development in medical laws and ethics in the 1960’s 
and the more recent advances in public access to health information facilitated 
greater patient autonomy (Charles et al 1997). Healthcare professionals started to 
receive training in active listening and to encourage patients to express their 
beliefs and expectations. The concept of shared decision-making (Charles et al 
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1997, Katon & Kleinman 1981, Coulter 1997) to support patients to actively 
participate in the decision-making process about their management became 
increasingly popular.  
 
The influence of ‘patient-practitioner interaction’ on symptom progression depends 
on variables such as practitioner communication skills and patients’ ability to 
engage and take part in the interaction (Schouten 1997), patient expectations and 
beliefs, gender and cultural and socio-economic background (Smith et al 2009, 
Shaw et al 2009, Schouten et al 2007). It also depends on the duration of the 
interaction and the environment in which it takes place (Ong et al 1995). Key 
elements of practitioner-patient interaction discussed in the workshop related to 
specific aspects of the interaction such as empathy, listening, exploring concerns, 
creating a partnership, and encouraging shared decision making.  
 
Beyond identifying patient-practitioner interaction as the most important modifiable 
factor, it is important to have agreed methods or instruments to measure its effect. 
This is not the case currently, although attempts in this direction have been made 
to measure verbal and non-verbal elements of the interaction (Hodges et al 1996, 
Gallagher et al 2005, Gorawara-Bhat et al 2007). Furthermore, because of the 
nature of this factor, being composed of a number of components, it is important 
to agree on whether to measure the effects of its individual components (for 
example patient’s cues, practitioner cues, length of interaction) or to measure its 
overall effect as a total unit. Whether to use an objective or subjective measure or 
a combination of both is another issue that requires addressing.  
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3.5.2.b Patient perspective 
Exploring the patient perspective was considered as an important part of a 
comprehensive approach to addressing the issue of the context effect. Studying 
the factors that patients consider as relevant and important as they seek medical 
care would enable us to target these factors in clinical trials.  
 
3.5.2.c The interaction and interdependency of non-specific factors 
An issue that was discussed in the workshop was whether the influence of non-
specific factors was generic and fixed across all types of patients, practitioners, 
treatments and settings. Although factors such as expectation and patient-
practitioner interaction could be studied as individual entities, their effects might 
vary depending on their interactions with other factors such as patients’ education 
and literacy (Smith et al 2009), past pain experience, cultural factors, (Sanders et 
al 1992, Schouten et al 2007) and practitioner attitude and beliefs about the 
illness and treatment (Ostelo et al 2003).  
 
An example of a non-specific factor that has been studied for dependency on 
other factors is patients’ expectation from the treatment. Studies have suggested 
that expectation can be influenced by patient beliefs (Kincheloe et al 1991, 
MacDonald et al 1980) and by verbal suggestions (Kirsch et al 1988, Benedetti et 
al 1999, Pollo et al 2001, Benedetti et al 2002). This type of influence has been 
described as conscious conditioning (Reiss 1980, Rescorla 1988, Benedetti et al 
2003) in which non-specific responses could be consciously influenced, for 
example, by explaining to the patient the mechanism of action of a particular 
treatment. The influence has been shown to be bidirectional, i.e. contrasting 
verbal suggestions modulated response in different directions (Benedetti et al 
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2003). Therefore, although it might be easier to study individual factors and try to 
harness their effects, the outcomes might be misleading if the interaction with 
other factors is not taken into account. This might be one explanation for the 
contradictory findings from trials that attempted to explore the effect of an 
individual non-specific factor such as patient expectation on treatment outcome 
(Jackson et al 2001, Jackson & Koenke 2001, Verbeek et al 2004, Gremeaux et al 
2007, Linde et al 2007, Zens & Strumpf 2007, Foster et al 2010, Wasan et al 
2010). 
 
The influence of factors such as patient expectations, cultural background, or 
practitioner skills, starts at the time the patient makes the decision to seek medical 
or health care, i.e. before actually contacting a health practitioner or using the 
treatment. This represents one challenge for attempts to measure the effects of 
such factors on symptom progressions. However, it could arguably present an 
opportunity as some factors, such as expectations regarding treatment, could be 
‘modified’ before the patient meets the practitioner. This could be done through 
general public health education or in a more specific way targeting patients at 
healthcare provision centres.  
 
 
 
 
 
3.6 Limitations 
 
The outcome and conclusions arrived at through this work have a number of 
limitations. Some of these are recognised limitations of the Delphi method itself. 
The first is the anonymity of the process, as it is suggested that although this is 
expected to be a strength of this method, it could also lead to a lack of 
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accountability, as participants might provide incorrect or baseless views without 
the ability to be directly challenged (Goodman 1987, Hasson et al 2000). 
However, participants are usually selected, or self-selected, for their interest or 
expertise in the area and their willingness to participate. The repeated process of 
providing opinions on the issues in the survey would also allow the group to judge 
the information provided. The workshop meeting in this study also provided further 
opportunity to discuss, argue and challenge the outcome of the survey and any 
associated assumptions to further validate the conclusions, without impacting the 
particular outcome of the survey. The survey conclusions and outcomes were 
confirmed in the workshop discussions, which strengthened the validity for those 
outcomes.  
 
Another limitation of the Delphi method is its reliability, i.e. the extent to which it 
produces similar results on another occasion among another group of 
participants. In fact, there is no evidence of the reliability of the Delphi process 
(Hasson et al 2000). Obviously participants in this survey were not all those who 
have expertise or interest in back pain research. It is possible, therefore, that 
another group of experts, or indeed including all experts in this field might indeed 
provide a different outcome. Formal qualitative methods have been suggested to 
address this problem (Hasson et al 2000). However, this study represented an 
opportunity for discussion and not as solid undisputable evidence and therefore 
formal qualitative methods were not used.   
 
Participants of the workshop were not purposefully selected in a comprehensive 
or exhaustive way. Rather, participants were self-selected for this workshop. 
However, the sample included researchers and clinicians from various disciplines, 
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countries, and health care settings, representing a wide range of views and 
perspectives.  
 
Finally, the time available was too limited to discuss all aspects of this complex 
subject, although the pre-workshop survey helped prepare participants for the 
meeting and introduce them to the various concepts. Important consensus points 
were reached and relevant issues were raised that could be developed in further 
research. 
 
 
 
3.7 Summary 
 
The intention of this study was to reach a provisional agreement on the non- 
specific factors that are influential on responses to treatments for NSLBP. The 
opportunity of group discussion was also utilised to address the influence of these 
factors in more depth. The following conclusions provide a practical foundation 
upon which further investigations into our understanding of the concept could be 
developed:  
 
1. Of the various factors that could influence patients’ responses to treatments for 
non-specific low back pain, patient-practitioner interaction was identified as the 
most important. It encapsulates the practitioner, patient, symptoms and setting 
related factors as well as the interaction process and context in which they 
interact.  
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2. The need to identify important non-specific factors and their potential influence 
on symptom progressions from the patient point of view was recognised as an 
important issue to explore.  
 
3. Agreeing on methods for measuring the context effect associated with the use 
of primary care treatments for back pain will be key for investigating their influence 
on patient outcome in clinical intervention studies.  
 
4. The outcome of this study will inform the approach in this thesis with a focus on 
the most influential factors that were identified here. However, as the focus in the 
thesis is on factors in clinical trials, studying factors would be restrained and 
limited by the availability of data on such factors from clinical trials.  
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Workshop participants 
Carlo Ammendolia, associate scientist and clinical epidemiologist at the institute of Work and 
Health, Jeffrey Borkan, professor and chair of the Department of Family Medicine, Warren Alpert 
medical school, Brown University and president of the Association of Departments of Family 
Medicine Memorial Hospital of Rhode Island, Tim Carey, director of the Cecil G. Sheps Centre for 
Health Services Research, University of North Carolina, USA, Daniel Cherkin, Senior Scientific 
Investigator, Centre for Health Studies, Group Health Research Institute,  and Affiliate Professor, 
Departments of Family Medicine and Health Services, University of Washington, USA, Patrick 
Cote, Senior Investigator at the Centre of Research Expertise in Improved Disability Outcomes, 
University Health Network Rehabilitation Solutions, Toronto Western Hospital, Canada, Peter 
Croft, Professor of Primary Care Epidemiology, Keele University, UK, Robert Drake, Professor of 
Psychiatry and of Community and Family Medicine, New Hampshire-Dartmouth Psychiatric 
Research Centre, USA, Simon French, Senior Researcher at the Australasian Cochrane Centre 
and Monash Institute of Health Services Research, Maria Gram, Senior researcher from the 
Hospital for Rehabilitation, Oslo University Hospital, Norway, Silje Heiszter, Senior Researcher 
from the Hospital for Rehabilitation, Oslo University Hospital, Norway, Invild Lie Indergaard, Senior 
Researcher from the Hospital of Rehabilitation, Oslo University Hospital, Norway, Francisco M 
Kovacs, Director of Scientific Department, Kovacs Foundation, Spain, Tonny Kvaerne, Senior 
researcher from the Hospital for rehabilitation, Norway, Henrik Lauridsen, Director of studies, 
Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Martyn 
Lewis, Senior Lecturer in Statistics, Keele University, UK, Liv Magnussen A senior researcher at 
the department of Public Health and Primary Health Care, University of Bergen, Norway, David 
Newell, Senior Lecturer in Biomedicine and Research at the Anglo-European College of 
Chiropractic, UK, Glenn Pransky, Director,Center for Disability Research, Liberty Mutual Research 
Institute for Safety, USA, Prandeep Suri, Instructor, Department of Physical Medicine and 
Rehabilitation, Harvard Medical School and Researcher, Division of Research, Department of 
Orthopaedics, New England Baptist Hospital, USA, Maurits van Tulder Professor of Health 
Technology Assessment, Department of Health Sciences & EMGO Institute for Health and Care 
Research, The Netherlands, Danielle van der Windt, Professor in Primary Care Epidemiology, 
Keele University, UK. 
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Chapter Four  
 
 
The pattern of responses to primary care 
treatments for low back pain:  
A systematic review and meta-analysis of 
randomised clinical trials 
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4.1 Introduction 
 
Interest in evaluating the effectiveness of primary care treatments for back pain 
has grown substantially over the past two decades represented by the increasing 
number of publications of clinical trials (Koes et al 2005, van Tulder et al 2006, 
Keller et al 2007). The general finding from a large number of primary care trials 
on back pain is a significant improvement of symptoms in all treatment arms with 
modest differences between them (Licciardone et al 2005, Carr et al 2005, Frost 
et al 2004, UK BEAM team 2004, Hay et al 2005, Jellema et al 2005, Johnson et 
al 2007, Leboeuf et al 2005, Burton et al 1995). Responses to treatments in a 
number of these trials seem to follow a pattern of improvement occurring early 
after the end of treatment and apparently unrelated to the type of treatment. The 
UK BEAM trial (2004) compared ‘best GP care’ with exercises and spinal 
manipulation, and although small differences between groups were reported, their 
clinical significance remained unclear. In patients with acute back pain, Hay et al 
(2005) found no difference in outcomes between those who received a ‘brief pain-
management programme’ and those who received a physiotherapy treatment 
focussed on biomechanical dysfunction of the spine. A trial from the Netherlands 
(Jellema et al 2005) compared ‘usual care’ with a ‘minimal intervention strategy’ 
delivered by GPs intended to address psychosocial factors, and again found no 
significant difference between the groups. A fourth trial published in 2007 
(Johnson et al 2007) compared a program of eight 2-hour group exercise session 
over six weeks comprising active exercise and education delivered by 
physiotherapists using a CBT approach in the intervention arm with a back pain 
educational booklet and concluded that the intervention showed small and 
insignificant effect at reducing pain and disability. 
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In these example trials, the overall changes in outcomes were large in all 
treatment arms and seem to follow a common pattern of rapid and large 
improvement in symptoms over the follow up period. Further to these anecdotal 
observations, I am not aware of evidence that this pattern of symptom 
improvement is replicated in a large number of trials across varied types of 
treatments for low back pain. The aim of this study was to determine whether 
such evidence exists. 
 
 
4.2 Objectives 
 
The objective in this study was to assess overall responses to treatments among 
non-specific low back pain patients in randomised clinical trials to find out whether 
they follow a common pattern following a wide range of primary care treatments. 
This was done through conducting a systematic review and meta-analysis of 
overall progression in pain and functional disability over time in published trials on 
NSLBP. 
 
 
4.3 Methods 
 
4.3.1 Criteria for inclusion of trials 
4.3.1.a Trials design  
Included were randomised clinical trials published in English and in which primary 
care treatments for NSLBP were evaluated.  
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4.3.1.b Participants and symptoms 
Included were trials among adult patients with NSLBP which was defined as pain 
in the area below the lower ribs and above the gluteal folds, with no known 
underlying pathology (Krismer et al 2007).  
 
Excluded were trials conducted among patients with specific LBP of an identifiable 
cause (e.g. cancer or arthritis), post-operative or post-traumatic back pain, or back 
pain associated with pregnancy or labour. Also excluded were trials conducted 
among healthy participants.  
 
4.3.1.c Treatments and setting 
Primary care treatments were defined as treatments that would be within the 
expertise of primary healthcare practitioners and would be provided or performed 
within the usual facilities of primary healthcare, its equivalents or departments 
associated with it such as physiotherapy departments, rehabilitation units and 
occupational healthcare departments. However, given the differences in the 
organisation of care between countries, the emphasis was more on the type of 
treatment rather than the setting and trials evaluating primary care interventions 
among, for example, hospital outpatient attendees or the general population were 
also included. Examples of treatments include Yoga, non-steroidal anti-
inflammatory tablets, exercises, chiropractic adjustment, physical therapy, 
transcoetaneous electrical nerve stimulation (TENS), acupuncture and 
osteopathic manipulation. Examples of primary care practitioners include general 
practitioners, family doctors, physiotherapists, occupational therapists, 
acupuncturists, osteopaths and psychologists. 
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4.3.1.d Outcome measures  
The initial aim was to collect data on as wide a range of outcomes as possible, to 
allow combining the results from multiple trials. However, outcome measures 
were chosen that would be used by the largest number of trials, namely the pain 
Visual Analogue Scale (VAS) 0-10 or 0-100, pain Numeric Rating Scale (NRS) 
(Guyatt et al 1987, Dworkin et al 2005, Ferreira-Valente et al 2011) and Roland 
Morris Disability Questionnaire (RMDQ) (24-point) (Roland & Morris 1983) or its 
modified versions or Oswestry Disability Index (ODI) (0-100) (Fairbank et al 1980) 
for back pain related functional disability.  
 
4.3.2 Data source  
The Cochrane Register of Controlled Trials (CENTRAL), the first quarter issue of 
2007 accessed in April, was searched using the term ‘low back pain’ and using 
the MeSH Tree for the term ‘low back pain’. 
 
As the aim was to investigate the pattern of responses to a wide range of 
treatments for NSLBP rather than to estimate the effectiveness of a particular 
treatment, an exhaustive inclusion of all trials on back pain treatments was not 
required. The aim was to have a large and representative pool of clinical trials that 
would vary sufficiently with respect to the types of treatments to achieve the 
objectives in this review and the CENTRAL database satisfied this aim.  
 
CENTRAL database includes citations of published articles taken through 
systematic searches from bibliographic databases (notably MEDLINE and 
EMBASE) and other published and unpublished sources (Dickersin et al 2002). In 
addition, each Cochrane Review Group maintains and updates a collection of 
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controlled trials relevant to its own area of interest and these are called 
‘Specialized Registers’. Each group may also collect items that are relevant to its 
own field of interest and these are known as ‘hand search results’. The registers 
and hand search results are assembled and collated before incorporation into The 
Cochrane Library. Each quarter, the CENTRAL dataset is re-built, using records 
from the four sources mentioned above, in the following order: MEDLINE, 
EMBASE, hand-search results and Specialised Registers. Therefore, for example, 
if a Specialised Register record matches an existing MEDLINE or EMBASE 
record, the MEDLINE or EMBASE record will be preferentially published (The 
Cochrane Collaboration website). 
 
CENTRAL database was created as a repository for all citations of reports of trials 
identified by the Cochrane Collaboration. Due to the required quick turn-around 
time and relative lack of quality control, CENTRAL inevitably contains some 
typographical errors, duplicates, and reports of non-trials.  
 
4.3.3 Selection of trials 
The author and a reviewer (DvdW) piloted applying the inclusion criteria on a 
sample of 10 abstracts. The process of selecting trials for inclusion was then 
rolled out and independently conducted by the author and two reviewers (DvdW 
and KPJ) for the rest of the identified abstracts. Any disagreement on inclusion 
was resolved through discussion and consensus and a discussion with the third 
reviewer when necessary. When the information in the abstract was not sufficient 
to make a decision on inclusion or the abstract was not available, the full text of 
the trial was retrieved. The processes of reviewing the full text of the trials to 
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finally deciding on their inclusion were conducted by the author and a second 
reviewer (DvdW). For excluded trials, the reasons for exclusion were noted.  
 
The quality assessment criteria checklist of the Cochrane Back Review Group 
(van Tulder et al 2003) was used to assess the quality of the selected trials. The 
methods used in quality assessment and the results will be described in detail in 
Chapter Five. The quality of the trials was not used as an inclusion criterion. The 
influence of quality on responses to treatments in clinical trials is investigated in 
Chapter Six.  
  
4.3.4 Data extraction 
The author extracted all information into a standardised form (Appendix 4.1) and a 
second reviewer (DvdW) who checked all extracted data. Any disagreement was 
resolved through consensus. 
 
The extracted data included information to fulfil the objective relating to examining 
overall within-arm responses to treatments. This included:  
1. Type of outcome measure: pain and/or functional disability. 
2. Mean change and/or absolute scores on pain and/or disability in each trial arm           
    at each time point, along with the standard deviation (SD). 
3. Types of treatments: index, active comparator, placebo, usual care or waiting 
list and pharmacological or non-pharmacological treatments. 
 
4.3.5 Data analysis  
Differing units of outcome measures provided in the included trials were unified to 
enable comparison and converted into mean and SD. Data presented as ‘median’, 
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‘average’ and ‘least square means’ (LS means) were treated as estimates of 
mean scores (Hozo et al 2005). When SE was reported, the standard deviation 
was calculated as (Hozo et al 2005): 
σ = SE * √ n 
Where σ is the observed standard deviation, n is sample size. 
When IQR was reported, based on the properties of the normal distribution, SD 
was estimated as (Hozo et al 2005): 
σ =  IQR / 1.349 
When range was reported, SD was estimated by dividing the range by four if 
sample size was smaller than 70, and by six if sample size was larger than 70 
(Hozo et al 2005). When information was not available to calculate baseline SD in 
the study, it was calculated using the mean of SDs from comparable trials 
(Furukawa et al 2006, Higgins et al, Cochrane handbook, Cochrane Collaboration 
website)   
 
To allow comparison between trials, commonly used follow-up times of 13, 27 and 
52 weeks were selected. Other follow-up times were matched to these if they 
were within three weeks of the nearest selected times. Data from follow-up times 
that fell outside these limits were not used.   
 
4.3.5.a The pattern of symptom progression 
Examining the pattern of responses to treatments was made in three steps 
including a descriptive assessment of pattern, assessment of variation in sizes of 
responses and summarizing the overall pattern of responses, as follows: 
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4.3.5.a.1 Describing the general pattern of responses to treatments 
Exploration of the general pattern of response was first done through visual 
assessment of outcome scores of pain and functional disability. These were 
plotted as graphic lines, using Excel 2000 (Microsoft, Redmond, WA, USA), 
representing baseline and follow-up mean scores for pain intensity (0-100), 
RMDQ and ODI at each time point for each arm of each trial.  
 
4.3.5.a.2 Assessing variation in size of symptom progressions 
To examine variation in the size of responses to treatments (heterogeneity) 
across trial arms, changes in outcome scores were analysed by calculating the 
standardised mean change (SMC) which is similar to the standardised change 
effect size (Morris 2000) or standardised mean difference (SMD) used to estimate 
the size of treatment effects. In this thesis, SMC refers to the change in outcome 
scores within each arm rather than between arms, as is the case in SMD. The 
SMC is a method of standardizing the measurement of change over time so that 
studies using slightly different scales, but measuring the same underlying 
construct, can be combined and more easily compared. This meant that by using 
the SMC, studies which used the modified versions of the RMDQ could be 
included in the same analysis as those which used the original version. Similarly, 
studies which used a VAS for pain could be combined into the same analysis as 
those using an NRS. For each trial arm, SMC was calculated by subtracting the 
follow-up mean score of the outcome measure from the baseline mean score and 
dividing by the SD at baseline. This assumes that pre-test and post-test scores 
were normally distributed with separate means but equal variance (Morris 2000). 
SMC was calculated separately for each of the three outcome measures (RMDQ, 
ODI and pain severity 0-100).  
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To compute the 95% Confidence Intervals for response sizes (SMCs), the 
variance (squared standard deviation, σ2) of response size was calculated using 
the following formula (Morris 2000):  
σ2 = 2(1-ρ)/n [(n-1)/(n-3)] [1+n/2(1-ρ)δ 2] - δ2/[c (n-1)] 2 
Where: c (n-1) approximates 1 - [3 / 4(n-1) –1], ρ is the population correlation 
between baseline and follow-up scores which was estimated as 0.5, n is sample 
size and δ is the SMC. The standard error was then calculated from the SD using 
the equation mentioned earlier.  
 
Participants from the same trial are likely to have similar characteristics which 
might lead to a potential cluster effect on response in arms of the same trial. This 
is particularly relevant for this study as it might contribute to any common pattern 
of responses. To overcome this possibility a sensitivity analysis was carried out to 
compare the results across all arms with the results based on one arm randomly 
selected from each trial.  
 
The overall within-arm responses to treatments, plotted in forest plots 
representing the point estimate of response size and 95% confidence interval, 
was investigated for heterogeneity by computing I2 (Higgins et al 2003). This 
homogeneity statistic I2 is an approach that quantifies the extent of heterogeneity, 
providing a measure of the degree of inconsistency in the trial arms’ results. The 
resulting I2 quantity describes the percentage of total variation across trial arms 
that is due to between-trial arm variation. A zero% value indicates no variation at 
all and 100% value indicates that all variation is the result of variation between 
arms (rather than within- arm (sample) variation). It is calculated as: 
τ2 / (τ2 + σ2) 
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where τ2 (Tau) is between-arm variation and σ2 within-arm variation. 
 
4.3.5.a.3 Summarising the overall pattern of responses 
Where heterogeneity existed, assessed through the I2 statistic, pooled estimates 
of responses were calculated using a random effects model weighted by inverse 
variance (Der Simonian & Laird 1986, Berard et al 1998). Larger trials, which have 
smaller standard errors, were therefore given larger weight than smaller trials. If 
the heterogeneity in responses to treatments was small, a fixed effects model was 
used. 
 
To explain the concepts of the fixed and random effects models, variation in 
treatment effects (or in responses to treatments as in this review) is usually 
understood to have two main components: within-trial variance and between-trial 
variance. Analyses that assume that between-trial variance is zero correspond to 
‘fixed effect’ model, i.e. the true symptom progressions is assumed to be the 
same value, or fixed, in each trial. It is generally accepted, however, that 
heterogeneity will exist between trials reflecting variation in setting, population or 
methods, leading to the assumption that a ‘random effects’ model will better 
represent true responses to treatment if the available estimates show 
considerable variation (Der Simonian & Laird 1986). In this model responses to 
treatments for each trial are assumed to vary around some overall mean response 
and that response sizes are assumed to have a normal distribution. The same 
concept applies in this review except that the concept concerns variation between 
trial arms rather than trials.  
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Next, the evidence was explored for the hypothesis that responses follow a 
common pattern regardless of the type of treatment. Analyses were therefore 
repeated for trial arms stratified according to the type of treatment based on 
whether the treatment was an index treatment, active comparator treatment, usual 
care, waiting list or placebo treatment. This was to assess whether the pattern of 
responses is dependent on whether the treatment was ‘active’ or ‘inactive’, a ‘new’ 
trial treatment or a usual care treatment. A second classification into 
pharmacological or non-pharmacological treatment was also used as an 
alternative exploratory approach. Trials on non-pharmacological treatments may 
show considerable differences in design, expectations regarding treatments, 
practitioner skills and time spent as well as other potentially important non-specific 
factors which may influence responses to these treatments compared with non-
pharmacological treatments. Also, non-pharmacological treatments constitute the 
largest proportion of the treatments used for back pain.  
 
Meta-analysis was performed using STATA/IC 10.0 software (Stata Corp., 
College Station, TX, USA). 
 
 
4.4 Results  
 
4.4.1 Selection of trials (Figure 4.1) 
The search of the CENTRAL database yielded a total of 772 trial citations.  
Based on citations and abstracts, available information was sufficient to exclude 
523. It was not possible at this stage to make a decision on 249 citations, either 
because the available information was not sufficient or no abstract was available. 
64 
 
Their full texts were therefore retrieved, reviewing which resulted in excluding a 
further 123 and including the remaining 126 publications. Eight of these 
publications were each a second report of the same trial and therefore information 
was available from 118 trials. 
 
The most common reason for exclusion (for 203 citations) was not being a 
randomised clinical trial. These included reports of observational studies, 
methodology and protocol reports, reviews, clinimetric and biomechanics studies, 
studies to assess adherence to clinical guidelines, qualitative studies, validity or 
reliability studies, diagnostic studies, cost analysis studies, prevention studies and 
also editorials, letters and comments. One hundred and seventy two trials were on 
treatments that were not primary care treatments, the most common was surgical 
treatment. In 166 trials back pain was not non-specific, the most common 
example was back pain associated with pregnancy and labour, but this group also 
included back pain associated with known diagnoses such as ankylosing 
spondylitis, intervertebral disc herniation and malignancy. One hundred and seven 
trials were excluded because the populations were not from primary care or its 
equivalent. The final group of trials that were excluded was 89 trials that used 
outcome measures other than those selected for this review. Although these are 
single reasons to exclude trials, a number of publications had more than one 
reason to be excluded.  
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Figure 4.1  Flow diagram for inclusion of RCTs for the review 
*When two articles were published for the same trial, information was extracted from both 
and considered as one trial. RCTs: Randomised clinical trials, NSLBP: Non-specific low 
back pain 
 
 
 
 
 
Potentially relevant articles identified and 
screened for retrieval 
(n= 772) 
Articles excluded (n= 523) 
Reasons: Not RCT=185, Not NSLBP=88, Not 
primary care population=48, Not primary care 
treatments=150, Not our selected outcomes=43, 
Not English language=9 
Articles excluded (n= 123) 
Reasons: Not RCT=12, Not NSLBP=38, Not 
primary care population=22, Not primary care 
treatment=18, Not our selected outcomes=25, Not 
English language=8 
Full text of articles retrieved for more 
detailed evaluation 
(n= 249) 
Articles to be included in meta-analysis 
(n= 126)  
reporting on 118 RCTs 
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4.4.2 Characteristics of included trials 
Details regarding setting, populations and treatments for included trials are 
presented in Appendix 4.2. Trial sample size ranged from 20 to 1334 (mean 174, 
SD 175, median 113). The number of arms was two in 74 trials (63%), three in 31 
trials (26%), four in 12 trials (10%) and five in one trial (1%). Sample size in each 
trial arm ranged from four to 340 (mean 67, SD 54, median 51). Duration of follow-
up ranged from five days to three years. Participants’ age ranged from a trial 
mean of 27 to 79 years (mean across trials of 43 years, median across trials of 42 
years). The percentage of females in trials was 0-100% (median of 55%).   
 
Primary healthcare settings included general practice (29 trials), occupational 
health care departments (20 trials) and physiotherapy departments (10 trials). 
Fourteen trials were conducted among the general population, 31 in mixed 
settings and in 14 trials the setting could not be clearly identified.  
 
The majority of trials included in this review used another active treatment as the 
comparator (81 trials, 69%) and in 27 (33%) of these trials more than one active 
comparator treatment was used. Participants were allocated to placebo or sham 
treatment in 36 trials (31%) and waiting list in 11 trials (9%). Ninety-one trials were 
conducted to assess non-pharmacological treatments, 20 trials pharmacological 
treatments, five trials mixed treatments and it was not possible to classify two 
trials according to the type of treatment used.  
 
4.4.3 The pattern of symptom progression 
Information for VAS pain intensity was available for the follow up points of 13, 27 
& 52 weeks from 104 arms in 44 trials, for RMDQ from 82 arms in 35 trials and for 
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ODI from 61 arms in 26 trials. Of the included trials, 30 trials were shorter than 10 
weeks and therefore their data could not be included in assessing the pattern of 
symptom progression. However, the pattern of symptom progression in these 
short trials was examined and will be commented on and all these trials were 
included in the quality assessment.  
 
Results were reported as mean scores and standard deviations (SDs) by the 
majority of trials and were used when available. Twenty -five trials reported their 
results in other formats such as “average”, median, range, percentage, 95% 
confidence interval (95% CI), interquartile range (IQR), standard error (SE) and 
least square means (LS means) and data were converted to estimates of mean 
and SD as described in Methods. 
 
Graphic representations of overall responses to treatments are shown in Figure 
4.2a, b, c representing pre and post-treatment mean scores for the three main 
outcome measures for each trial arm. Response lines for all three outcome 
measures followed a common pattern of improvement in symptoms in most arms 
represented by a rapid early and large reduction in mean outcome scores within 
the first 13 weeks followed by a slower reduction thereafter. This common pattern 
in responses remained when responses from only one arm were randomly 
selected from each trial (Appendix 4.3). This pattern appeared to be similar 
regardless of the type of treatment.  
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Figure 4.2a  Change in pain intensity outcome scores (VAS for pain intensity) up to 52 
week follow up in each treatment arm of included trials.  
Each line represents a response line within each trial arm.  
Red: Index treatment arm, Blue: Active treatment arm, Green: Usual care/waiting 
list/placebo arms.  
____: Pharmacological treatment, - - - -: non-pharmacological treatment, 
 …….: Mixed/other. 
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Figure 4.2b  Change in RMDQ scores up to 52 week follow up in each treatment arm of 
included trials. 
Each line represents a response line within each trial arm.  
Red: Index treatment arm, Blue: Active treatment arm, Green: Usual care/waiting 
list/placebo arms.  
____: Pharmacological treatment, - - - -: non-pharmacological treatment, 
 …….: Mixed/other. 
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Figure 4.2c  Change in ODI scores up to 52 week follow up in each treatment arm of 
included trials. 
Each line represents a response line within each trial arm.  
Red: Index treatment arm, Blue: Active treatment arm, Green: Usual care/waiting 
list/placebo arms.  
____: Pharmacological treatment, - - - -: non-pharmacological treatment, 
 …….: Mixed/other. 
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4.4.4 Variation in the sizes of symptom progression 
Figure 4.3 shows a forest plot representing SMCs and 95% confidence intervals 
for pain intensity at 27 week follow up for the treatment arms of the included trials, 
as an example of responses at other points. It shows a wide heterogeneity in the 
sizes of responses between trial arms (I2-statistic = 90%). However, the majority 
of trial arms showed large improvement in symptoms.  
 
4.4.5 Summary of symptom progression 
Pooled SMCs were calculated based on one randomly selected arm from each 
trial to explore overall trend in changes in pain and functional disability over time 
(Table 4.1a, b). The common pattern of responses demonstrated earlier was 
confirmed by large initial SMCs at 13 weeks with minimum further change at 52 
weeks. For pain, pooled SMC was 1.07 (95% CI 0.87, 1.27) at 13 weeks, 1.03 
(95% CI 0.82, 1.25) at 27 weeks and 0.88 (95% CI 0.60, 1.11) at 52 weeks. 
Overall responses were large, as SMCs over 0.8 are considered as large, 0.5 – 
0.8 moderate and less than 0.5 small (Cohen 1997). Results when all arms were 
analysed were similar to those when only one randomly selected arm per trial 
(Table 4.1.b). Although outcome data from trials shorter than 10 weeks were not 
examined in the main analyses throughout the thesis, examining these data, as 
presented in Tables 4.1a, b, showed that symptom progression pattern is such 
that the large improvement in symptom starts much sooner than 13 weeks the 
earliest follow point selected here. 
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Overall  (I-squared = 89.6%, p = 0.000)
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Hurwitz et al 2002     170
Kaapa et al 2006        58
Hurwitz et al 2002     169
Hseih et al 2002         40
Karjalainen et al 2003 50
Kuukkanen et al 2000 25
Holbil et al 2005         67
Nordeman et al 2006   30
Hurley et al 2004        55
Mehling et al 2005       15
Author-Year-Arm Sample Size
Maul et al 2005          71
Rittweger et al 2002    25
Mannion et al 2001     47
Leclaire et al 1996       50
George et al 2003       28
Cambron et al 2006    90
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Figure 4.3  Standardised mean change (SMCs) for pain intensity in trial arms at 27 
week follow up. Number of arms 50, I2 = 90% and estimate of between-
arms variance (squared tau) =  0.2421 
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Table 4.1a  Pooled standardised mean change (SMC) for pain and disability (RMDQ 
and ODI) in randomly selected single arm from each trial for the follow up 
time points provided in the trials.  
 
 
 
Outcome 
Follow 
up 
Weeks 
 
Trials 
n 
  
 
Pooled SMC (95% CI) 
 
 
I2 
     
Pain 1 13 1.44 (0.98, 1.89) 100% 
  6 13 0.86 (0.65, 1.07) 82% 
 13 29 1.07 (0.87, 1.27) 91% 
 27 25 1.03 (0.82, 1.25) 90% 
 52 23 0.88 (0.60, 1.11) 92% 
 104 5 0.59 (0.45, .74) 91% 
     
RMDQ 1 8 0.97 (0.75, 1.19) 69% 
 6 19 0.97 (0.66, 1.28) 95% 
 13 21 0.93 (0.67, 1.20) 94% 
 27 12 0.91 (0.59, 1.24) 93% 
 52 11 1.01 (0.68, 1.34) 92% 
     
ODI 1 5 0.92 (0.59, 1.24) 58% 
 6 14 0.98 (0.62, 1.33) 90% 
 13 12 0.92 (0.70, 1.14) 81% 
 27 10 1.08 (0.80, 1.36) 83% 
 52 12 1.14 (0.88, 1.39) 84% 
 104 4 1.05 (0.57, 1.54) 90% 
     
 
 
 
 
 
Table 4.1b  Pooled standardised mean change for pain and disability (RMDQ and ODI) 
for all trial arms for the follow up time points provided in the trials.  
 
 
 
Outcome 
Follow 
up time, 
weeks 
 
Number of 
trials 
Total 
number of 
arms 
 
 
Pooled SMC (95% CI) 
 
 
I2 
      
Pain 1 13 35 1.25 (1.13, 1.37) 100% 
  6 13 33 0.83 (0.70, 0.96) 82% 
 13 29 67 0.99 (9.86, 1.11) 91% 
 27 25 59 1.07 (0.93, 1.20) 90% 
 52 23 55 0.91 (0.76, 1.05) 89% 
 104 5 13 0.77 (0.50, 1.03) 87% 
      
RMDQ 1 8 18 0.80 (0.63, 0.98) 81% 
 6 19 47 0.87 (0.77, 1.06) 95% 
 13 21 45 0.86 (0.57, 1.05) 95% 
 27 12 30 0.97 (0.73, 1.21) 95% 
 52 11 22 0.98 (0.73, 1.23) 93% 
      
ODI 1 5 12 0.72 (0.54, 0.89) 53% 
 6 14 32 0.86 (0.65, 1.08) 89% 
 13 12 29 0.73 (0.56, 0.89) 87% 
 27 10 23 0.95 (0.77, 1.12) 83% 
 52 12 28 0.99 (0.80, 1.19) 89% 
 104 4 10 0.93 (0.66, 1.21) 87% 
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4.4.6 Symptom progression and types of treatments 
Table 4.2 shows comparable sizes of overall responses in trial arms using index, 
active comparator, usual care, placebo treatments or waiting list control and also 
pharmacological and non-pharmacological treatments. The SMCs appear to be 
similar for different types of treatments. However, there is a large difference in the 
number of arms in groups and very small number of pharmacological and placebo 
treatment arms. For this reason it would not be possible at this stage to be 
confident of these findings which might be due to random variation. The 
significance of the association between types of treatment and responses to 
treatments will be formally tested in Chapter Six.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
Table 4.2  Pooled standardised mean change (SMCs) (95% CI) for pain for trial arms stratified by type of treatment. 
 
 
Types of treatments 
13 weeks 27 weeks 52 weeks 
n* SMC n* SMC n* SMC 
       
Index 29 0.81 (0.75, 0.86) 25 0.95 (0.89, 1.02) 23 0.77 (0.70, 0.84) 
Active comparator 25 0.81 (0.75, 0.86) 23 1.04 (0.97, 1.10) 21 0.85 (0.78, 0.92) 
waiting list 3 1.33 (1.04, 1.62) 3 1.13 (0.89, 1.36) 3 0.64 (0.39, 0.89) 
Placebo 2 1.56 (1.40, 1.72) -  1 - 
Usual care 8 1.15 (1.04, 1.27) 7 1.30 (1.74, 1.42) 7 1.04 (0.80, 1.18) 
       
Pharmacological 4 0.68 (0.57, 0.79) 2 0.61(0.39, 0.83) . . 
Non-pharmacological 53 0.91 (0.87, 0.96) 49 1.07 (1.03, 1.12) 47 0.86 (0.81, 0.91) 
       
* Number of trial arms.   
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4.5 Discussion  
 
The main aim of this review was to examine overall low back pain symptom 
progression in clinical trials to assess the evidence for whether they follow a 
similar pattern regardless of the treatment used. 
 
Responses to treatments were examined in trials conducted over a period of 15 
years in more than 18 countries among patients with back pain that varied in its 
duration and severity. A wide variety of primary care treatments were used 
ranging from tablet medications and simple advice to hands-on manual therapies, 
psychological treatments and extensive multidisciplinary pain management 
programmes. 
 
Evidence was found that these responses follow a common pattern of early rapid 
and large improvement in symptoms that slows down and reaches a plateau 
around 13 weeks after the start of treatment. A similar pattern was found following 
all treatments, regardless of whether it was an index treatment, active comparator, 
usual care or placebo treatment, pharmacological or non-pharmacological.  
  
4.5.1 The influence of non-specific factors 
Symptom progressions in clinical trials will be influenced by the effect of the 
particular treatment used (the specific effect). The natural history of the 
symptoms, regression towards the mean, random variation, differences in trial 
design or analysis would also contribute to responses in clinical trials.  
Regression towards the mean (Morton et al 2005) is described as a statistical 
phenomenon where high scores or measurements outside the population mean 
77 
 
are likely to return and regress towards the mean over time. This could be an 
explanation for the large improvement in symptoms early after the start of 
treatment, in particular among those patients with the most severe symptoms at 
the start of treatment. However, this should not be seen as a mere statistical or 
measurement phenomenon, otherwise it would have been described as an 
analysis or measurement error. In fact, and particularly in the context of symptoms 
progression, it represents the influence of factors similar to those that influence 
the natural history and clinical course of symptoms. Regression towards the 
mean, therefore, is another term or name that refers to the same concept studied 
in this thesis and is not distinct from the context effect.  
 
Providing evidence for the natural history of back pain is difficult but systematic 
reviews of observational studies (Hestbaek et al 2003, Pengel et al 2003) have 
attempted to examine its clinical course, defined as the development of a 
condition in the presence of treatment (von Korff 1994)) and showed it to be 
characterized by rapid improvement in symptoms within the first three months 
after inclusion that became more gradual thereafter. This echoes the pattern of 
responses found in this thesis.  
 
The importance of the influence of non-specific factors is that some of them might 
explain the common pattern of improvement, such as being enrolled in a trial or 
the attention given in the trial. On the other hand, some might explain the 
heterogeneity between responses, such as differences in expectations regarding 
treatment or differences in aspects of patient-practitioner interaction.  
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The exact size of the influence of the non-specific factors on symptom 
progression is not known. Whether it is larger than the specific effect of the 
treatments would be interesting to explore. The size of the overall responses in 
clinical trials was found to be large and was the same regardless of the type of 
treatments used, suggesting a possibly large influence of the natural history of 
back pain and other non-specific factors on symptom progression.  
 
4.5.2 Mean vs individual responses to treatment 
Data on responses to treatments in clinical trials represent aggregated responses 
of their individual participants. Aggregated data tend, by definition, to homogenize 
variations in responses at individual level. Back pain trials would likely include 
heterogeneous groups of participants. This could lead to a potentially wide 
variation in the progression of their symptoms in the trials that would not be well 
represented by the aggregated data presented in published data reports which 
were used in this review. This wide variation in individual symptom progression is 
one basis for the proposals of stratified care approaches that have been 
developed more recently to target more homogenous sub-groups of patients with 
similar characteristics and who represent different prognostic subgroups (Hay et 
al 2008), or who may respond better to specific types of treatment (Fritz & George 
2000). 
 
4.5.3 Large change in outcome scores over time 
An important finding from this review is the large symptom progression common in 
all trial arms, active as well as placebo, usual care or waiting list arms. It is 
interesting that evidence exists for a large overall improvement in back pain 
symptoms in all arms of clinical trials, while more and more trials are unable to 
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show clear evidence for the efficacy (specific effects) of the active treatments. 
Randomized controlled trials are designed to attribute the benefit of a treatment 
solely to the difference between its effect and that of the comparator treatment. 
Such explanatory trials are important and necessary to study the efficacy of 
treatments. However, it is also important to explore the role of other factors, in 
addition to the specific ingredient of the treatment used. Addressing these non-
specific factors, which may include factors related to the patients, practitioners, 
the setting or the way treatments are designed and delivered, may help us better 
understand the overall symptom progression in clinical trials. 
 
 
4.6 Limitations 
 
This review provides empirical evidence for the hitherto anecdotal observation 
increasingly being made that randomised clinical trials on primary care treatments 
for NSLBP show modest or non-significant differences between various types of 
treatments, but large within group changes over time. A large number of trials was 
included, on a wide variety of treatments, pharmacological and non-
pharmacological, manual and psychological. A number of limitations, 
nevertheless, merit addressing. 
 
4.6.1 The choice of data source 
Restricting the source of data to the CENTRAL database might have limited the 
overall number of trials included. However, this database satisfied the aims of this 
review, namely providing a large pool of clinical trials on a wide range of primary 
care treatments for NSLBP to explore the evidence for a common pattern for the 
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overall responses to treatments. It is arguably a strength of the CENTRAL 
database that it does not include only trials registered in MEDLINE and EMBASE, 
but also trials identified from hand searches and trials added by speciality groups, 
including the Back Review Groups. It is, therefore, not expected that a wider 
search would have yielded a much larger pool of trials. However, it would certainly 
be interesting to update the review with the expectation of capturing more trials 
which would add power to its outcomes.  
 
Only trials published in English were included. It may be argued that this language 
restriction could lead to selection bias as the context effect may be influenced by 
local cultural factors or differences in the delivery or quality of health care. 
However, there are a number of trials included which were published in English 
even though they were conducted among non-English-speaking populations. 
Therefore, the review does include trials from a variety of countries and cultures. 
Furthermore, the evidence on the benefit or otherwise of including trials published 
in languages other than English in systematic reviews is conflicting (Egger et al 
1997, Gregoire et al 1995, Juni et al 2002, Moher et al 2000). There was no other 
evidence for selection bias as the included trials covered a wide range of 
treatments in a wide range of primary care settings with no evidence of systematic 
lack of a particular group or type of trials. 
 
4.6.2 Choice of outcome measures 
Although the initial intentions were to include as many outcome measures as 
possible, outcome measures were analysed that were most commonly used in 
order to include a sufficiently large number of trials. A small number of trials used 
other measures such as patient’s global perceived effect or measures to assess 
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depression or return to work, but these outcome measures were not widely used 
and/or did not have standardized definitions or scales that would allow meaningful 
comparison. Hence, although these measures would add to describing the totality 
of patient experience and provide an important representation of patient symptom 
progression, they were not included in the analysis. Recommendations have been 
made towards a standard group of core outcome measures for use in low back 
pain trials (Dworkin et al 2005), which would facilitate comparison and 
combination of results. 
 
4.6.3 Other methodological limitations 
Although the random effects model was used in the meta-analysis, pooling 
response sizes with a high heterogeneity is still problematic. However, it is 
important to emphasize that the purpose of pooling for this review was merely to 
further assess and present the pattern of overall responses rather than to 
calculate estimates of particular treatment effect size. Furthermore, trials on a 
wide variety of disparate types of treatments were included and therefore even if 
heterogeneity were low, the result of such pooling would obviously not have been 
clinically or practically meaningful. Any conclusions drawn from pooling in this 
review, therefore, should be made within the context of the particular purpose for 
using it here. 
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4.7 Summary 
 
Overall responses to treatments in NSLBP clinical trials were shown to be large 
and follow a common pattern of rapid early improvement followed by a plateau 
following all types of treatments.  
 
Given such a similar pattern of responses, it is not surprising that any specific 
effect of treatment would be difficult to detect. It is important to explore factors that 
are associated with symptom improvement in clinical trials. That might be 
associated with any variation in the size of responses. Duration of symptoms 
(acute, subacute or chronic), severity of symptoms, patients’ age, gender, 
preference for treatments, expectations and patient-practitioner interaction are 
examples of factors that might influence the progression of symptoms in individual 
patients. Identifying the association between responses to treatments and such 
factors would be the first step towards identifying subgroups of patients and 
targeting of treatments for these groups of patients with common factors or 
utilizing and harnessing the influence of these factors to improve patient outcome 
in clinical trials. In Chapter Six, results of meta-regression analyses to examine 
associations between such trials’ factors and responses to treatments will be 
outlined.  
 
Exploring responses to treatments for pain conditions other than low back pain, 
and indeed for other medical conditions, was beyond the scope of this review. It 
would be interesting to explore whether these findings are unique to NSLBP and 
therefore reflect in part the poorly understood nature of this condition; or if they 
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could be reproduced in other medical conditions, raising wider issues about how 
treatment outcomes and symptom progression in general are assessed. 
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Chapter Five  
 
 
Quality of randomised clinical trials of 
primary care treatments  
for non-specific low back pain
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5.1 Introduction 
 
Assessing the quality of clinical trials is accepted as an important part of any 
systematic review (Chalmers 1989, Oxman et al 1991, Cook et al 1995). Reviews 
rely, for a large part, on the quality of their primary trials to support the robustness 
and validity of their conclusions (Kassirer et al 1994). Moher et al (1999) pointed 
out that the validity of the outcomes of systematic reviews and meta-analyses 
draws on the ability to demonstrate that the included trials followed valid methods 
and were conducted according to a clear and correct protocol. The quality of trials 
included in the systematic review in the previous chapter was therefore assessed 
to ensure that the conclusions regarding a common pattern of improvement in 
back pain trials were based on sound evidence.  
 
Certain aspects of trial methods and conduct might influence responses to 
treatments. Empirical evidence indicates that poor conduct of some 
methodological aspects influence estimates of treatment effect such as 
inadequate methods of random-sequence generation, allocation concealment, or 
blinding (Moher et al 1998, Schulz et al 1995, Kjaergard et al 2001). Assessing 
the quality of the RCTs included in the review would therefore provide an 
opportunity for examining the association with responses to treatments in these 
trials. Such analysis was undertaken and the results are presented in Chapter Six.  
 
A large number of methods, checklists and scales have been used to assess 
trials’ quality (Moher et al 1995, Verhagen et al 2001). As the interest in this thesis 
was in responses to treatments in clinical trials, rather than treatment effect or the 
generalisability of trials’ outcomes, the focus was on assessing the internal validity 
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of the trials. At the time of conducting this study, a quality checklist was 
recommended and used by the Cochrane Back Review Group (van Tulder et al 
2003) and was used. It is a composite tool that assesses 11 individual quality 
criteria related to the internal validity. The overall quality of the trial is evaluated by 
calculating the summary score based on the scores (positive, negative, or 
unclear) for the individual criteria.  
 
Information on some quality criteria can be unavailable in the published reports. 
Considering such criteria as negative or unsatisfactory might lead to inaccurate 
description of the quality of the trial for it mixes defective conduct with poor 
reporting (Hill et al 2002). Both poor conduct and poor reporting represent serious 
defects. However, poor conduct could arguably be more significant than poor 
reporting and mixing the two might not, therefore, be ideal. The aim in this chapter 
was to assess the quality of randomised controlled trials with a particular focus on 
the methods of assessing the overall quality and individual quality aspects of the 
trial and the issue of lack of information in the published reports. 
 
 
5.2 Objectives 
 
The main objective was to assess the quality of RCTs on primary care treatments 
for non-specific low back pain that were included in the systematic review 
described in Chapter Four. In using a quality assessment check list of individual 
quality criteria, the summary versus individual quality criteria scores were also 
assessed and compared.  
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The secondary objectives were to explore the association between trials’ quality 
and other trials’ characteristics including their setting and type of treatment 
(pharmacological and non-pharmacological). The extent of missing information in 
published reports of trials and the impact this might have on the overall outcome 
of quality assessment was also assessed. Finally, whether trial quality or 
availability of information in the published reports improved since the CONSORT 
statement was published in 1996, was also explored. 
 
 
5.3 Methods 
 
5.3.1 Data source 
The Cochrane Register of Controlled Trials (CENTRAL), the first quarter issue of 
2007 accessed in April, was the source of the trials included in the review. Details 
of inclusion and exclusion criteria were described in detail in Chapter Four.  
 
5.3.2 Assessment of methodological quality 
The quality assessment criteria checklist of the Cochrane Back Review Group 
(CBRG) (van Tulder et al 2003) (Appendix 5) was modified and used to assess 
the internal validity of the selected trials. The modifications, which are detailed 
here, were mainly made to take into account the main aims and objectives of this 
review. To clarify the modifications, the numbers of the modified criteria were 
marked with the letter ‘m’. The final checklist that was used is presented in table 
5.1. 
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Table 5.1  The quality criteria checklist used for this review modified from the 
Cochrane Back Review Group checklist  
 
 
1. Was the method of randomization adequate? 
2. Was the treatment allocation concealed? 
3. Was the patient blinded to the intervention? 
4. Was the care provider blinded to the intervention? 
5. Were co-interventions prevented/avoided? 
6. Were co-interventions standardised? 
7. Was compliance acceptable? 
8. Was the drop-out rate acceptable? 
9. Was the timing of the outcome assessment in all groups comparable? 
10. Was the analysis based on intention-to-treat analysis? 
 
 
 
 
 
Item (3) ‘Were the groups similar at baseline regarding the most important 
prognostic factors?’ was dropped as the focus in the review was to assess within-
group symptom progression rather than between group differences. Item (6) ‘Was 
the outcome assessor blinded to the intervention?’ was also dropped as all the 
outcome measures selected for the review were subjective patient completed 
measures.  
 
The item on co-interventions (7), was split to deal specifically with the issue of 
whether particular instructions were given to participants on ‘standardisation of co-
interventions’ (7m) in addition to avoiding using such interventions (6m). 
Consequently, when item (6m) was scored yes, i.e. instructions were given to 
avoid using co-interventions, item (7m) was automatically scored ‘not applicable’.  
 
Subgroup analyses were conducted to assess differences in overall trial quality 
and individual criteria scores according to subgroups of trials based on setting 
(general practice, physiotherapy units, occupational healthcare units, general 
population, mixed  and unclear setting), type of treatment (pharmacological vs 
non-pharmacological) and publication date (before or after 1996). The purpose of 
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classifying trials according to the type of treatment was to explore the often 
described difficulty in satisfying some of the quality criteria in trials on non-
pharmacological treatments, such as patient and practitioner blinding (Black 1996, 
Boutron et al 2003, 2004).   
 
The author and a second reviewer (DvdW) independently assessed the quality of 
trials. The criteria were scored "yes" (item fulfilled), "no" (item not fulfilled) or "don't 
know" (insufficient information). It was the reports of the trials that were assessed 
and criteria scored positive or negative only when the published information was 
clear, otherwise a ‘don’t know’ score was given. The assessment was unblinded 
as author, institution, journal names, or trial results were not concealed. Meetings 
were organised to discuss disagreements and obtain consensus on the final 
score. 
 
5.3.3 Data analysis  
Quality assessment data were analysed for the 10 individual criteria and also 
summed up into a total summary score, which was calculated based on the 
number of positively scored items, with equal weights of one. An arbitrary 50% 
cut-off point is commonly used to indicate high quality (van Tulder et al 2003). 
Therefore, for this review high quality was defined as having five or more positive 
scores. Data on the ‘don’t know’ scores, representing missing information, were 
analysed separately and the consequences for quality assessment of merging 
them with either negative or positive responses were also explored. The 
significance of differences between subgroups was analysed using chi-squared 
tests 
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5.4 Results  
 
5.4.1 Trials’ description 
As reported in Chapter Four, the search yielded a total number of 772 citations. 
One hundred and twenty six satisfied the inclusion criteria. Eight published papers 
were each a second report of the same trial. Multiple publications from a same 
trial were considered as one source and used to obtain information to assess the 
paper quality as well as outcome data for the purpose of the systematic review. 
Data, therefore, were available for 118 trials. Further detailed description of the 
included trials is provided in Appendix 4.2. 
 
5.4.2 Quality assessment  
The two authors who independently assessed trials’ quality agreed on similar 
scores for all quality criteria for 15 trials (13%). Initial disagreements for the 
remaining 103 trials (87%) ranged from disagreement on scoring one criterion (for 
17 trials, 14%) to seven criteria (for one trial only). Agreement was reached on 
883 items out of a total of 1180, (75%). Disagreements were mainly on the criteria 
on co-interventions and intention-to-treat analysis. All disagreements were 
resolved through consensus.  
 
5.4.3 Summary score analysis: overall trials’ quality 
Just under half of the included RCTs were of high quality using the definition of at 
least five positive scores (56, 48%). There was a wide variation in the quality of 
the included trials, from trials with only one positive score, five negative scores 
and four ‘don’t know’ to trials with information available on all criteria, scoring eight 
positive and two negative scores. The median number of positive scores given for 
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each trial was four, range 1, 8; of negative scores 3, range 0, 7; and of ‘don’t 
know’ scores 2, range 0, 8.  
 
5.4.4 Individual criteria assessment 
A summary of the scores for the individual quality criteria is presented in Table 5.2 
and Figure 5.1. Among the criteria for which information was available, the criteria 
that were found to be most commonly satisfied i.e. scored ‘yes’, were ‘was timing 
of outcome measurement in all groups comparable’ (94%), ‘was dropout rate 
acceptable’ (65%) ‘was the analysis based on intention to treat analysis’ (62%), 
‘was the method of randomisation adequate’ (61%) and ‘was the treatment 
allocation concealed’ (55%). The criteria that were least commonly satisfied in the 
trials, i.e. scored ‘no’, were ‘was care provider blinded’ (78%) and ‘were patients 
blinded’ (59%). 
 
Although information was available for most quality criteria in the majority of trials 
included in this review, information was not available for at least one quality 
criterion in 98 trials (83%). ‘Don’t know’ scores ranged from only one trial for the 
criterion on ‘timing of outcome measurement’ to 55 trials (47%) for the criterion on 
‘compliance’.  
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Table 5.2  Number (percentage) of trials scored positive, negative or ‘don’t know’ for 
each individual quality criterion. 
 
 
 
Quality criteria 
 
Yes 
N (%) 
 
No 
N (%) 
 
Don’t know 
N (%) 
    
Randomisation adequate 72 (61) 10 (9) 36 (31) 
Allocation to treatment concealed 65 (55) 1 (0.1) 52 (44) 
Patient blinded 31(26) 69 (59) 18 (15) 
Care-provider blinded 15 (13) 92 (78) 11 (9) 
Co-interventions prevented 26 (22) 52 (44) 40 (34) 
Co-interventions standardised a  10 (11) 38 (41) 44 (48) 
Compliance acceptable 53 (45) 10 (9) 55 (47) 
Drop out acceptable 77 (65) 34 (29) 7 (6) 
Timing of measurement comparable b 111 (94) 6 (5) 1 (0.1) 
Intention to treat analysis 73 (62) 21 (18) 24 (20) 
    
a This was not applicable in 26 trials; b Timing of measurement of outcomes was comparable 
across all subgroups in the trial. 
 
 
Adding the ‘don’t know’ scores to either the negative or positive scores would 
have the largest impact for criteria for which information was not available in a 
large number of trials, such as prevention and standardisation of co-interventions, 
compliance and concealment of allocation to treatments, as shown in Table 5.3. 
When the ‘don’t know’ scores were added to the negative scores, the majority of 
trials scored negative for these criteria, whilst when the scores were added to the 
positive scores the majority of trials scored positive for these criteria.   
 
 
Table 5.3  Number (percentage) of trials scored positive and negative  
for each quality criterion when ‘don’t know’ scores were added to the 
negative and next to the positive scores 
 
 
 
 
 
Quality criteria 
 
‘Don’t know’ added to 
‘No’ scores 
  
‘Don’t know’ added to 
‘Yes’ scores 
 
Yes 
n (%) 
 
No 
n (%) 
  
Yes 
n (%) 
 
No 
n (%) 
      
Randomisation adequate 72 (61) 46 (39)  108 (91) 10 (9) 
Allocation to treatment concealed 65 (55) 53 (45)  117 (99) 1 (0.1) 
Patient blinded 31(26) 87 (74)  49 (41) 69 (59) 
Care-provider blinded 15 (13) 103 (87)  26 (22) 92 (78) 
Co-interventions prevented 26 (22) 92 (78)  66 (56) 52 (44) 
Co-interventions standardised a  10 (11) 82 (89)  54 (59) 38 (41) 
Compliance acceptable 53 (45) 65 (55)  108 (91) 10 (9) 
Drop out acceptable 77 (65) 41 (35)  84 (71) 34 (29) 
Timing of measurement comparable b 111 (94) 7 (6)  112 (95) 6 (5) 
Intention to treat analysis 73 (62) 45 (38)  97 (82) 21 (18) 
      
a This was not applicable in 26 trials; b Timing of measurement of outcomes was comparable across  
all subgroups in the trial. 
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Figure 5.1  Distribution of total scores for quality assessment criteria for included trials 
 * Was timing of measurement of outcomes comparable between groups. ITT: Analysis was on basis of intention to treat. 
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5.4.5 Trials’ quality and other trials’ characteristics 
The association between quality and trials’ characteristics such as setting (primary 
care, occupational healthcare, physiotherapy, general population, mixed and 
unclear setting), type of intervention (pharmacological or non-pharmacological) 
and publication dates was examined and the results are outlined below: 
 
5.4.5.a Trials’ quality and setting 
Twenty-nine trials were conducted in primary care / family medicine setting, 20 in 
occupational healthcare departments, 10 in physiotherapy / physical therapy units 
and 14 were conducted among the general population. 31 trials were conducted in 
‘mixed setting’ including a primary care setting and in 14 trials the setting was not 
clear. 
 
Tables 5.4a & b, show the distribution of scores for individual quality criteria 
according to trials’ setting. The lack of information was widespread with 
statistically significant difference between types of setting (Table 5.5), with 
information most widely missing in trials in physiotherapy setting and least in 
general practice and mixed setting trials. The number of trials that lacked 
information on at least one quality criterion ranged from seven trials in 
physiotherapy setting (70%) to 14 trials for which the setting was not clear 
(100%).    
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Table 5.4a  Number (percentage) of trials scored positive, negative and ‘don’t know’ for each quality criterion  
according to trials’ setting. 
 
 General practice setting  
N = 29 
Occupational Health Setting  
N = 20 
Physiotherapy Setting  
N = 10 
 
 
Quality criteria 
 
Yes 
N (%) 
 
No 
N (%) 
Don’t 
know 
N (%) 
 
Yes 
N (%) 
 
No 
N (%) 
Don’t 
know 
N (%) 
 
Yes 
N (%) 
 
No 
N (%) 
Don’t 
know 
N (%) 
          
Randomisation adequate 20 (69) 1 (5) 8 (26) 14 (70) 3 (15) 3 (15) 4 (40) 3 (30) 3 (30) 
Allocation to treatment 
concealed 
17 (59) 0 12 (41) 11 (55) 0 9 (45) 4 (40) 0 6 (60) 
Patient blinded 6 (21) 17 (59) 5 (17) 1 (5) 18 (90) 1 (5) 2 (20) 6 (60) 2 (20) 
Care-provider blinded 3 (10) 22 (76) 3 (14) 0 19 (95) 1 (5) 0 9 (90) 1 (10) 
Co-interventions prevented 7 (24) 15 (52) 7 (24) 3 (15) 8 (40) 9 (45) 0 3 (30) 7 (70) 
Co-interventions standardised  2 (9) 13 (59) 7 (32) 0 6 (35) 11 (65) 1 (10) 2 (20) 7 (70) 
Compliance acceptable 19 (66) 1 (5) 9 (29) 7 (35) 4 (20) 9 (45) 2 (20) 0 8 (80) 
Drop out acceptable 18 (62) 8 (28) 3 (14) 13 (65) 6 (30) 1 (5) 6 (60) 3 (30) 1 (10) 
Timing of measurement 
comparable* 
28 (97) 1 (5) 0 18 (90) 2 (10) 0 10 (100) 0 0 
Intention to treat analysis 16 (55) 5 (17) 8 (26) 11 (55) 3 (15) 6 (30) 7 (70) 1 (10) 2 (20) 
          
Median score per trial 4 3 2 4 3 2 2 2 2 
          
*: Timing of measurement of outcomes was comparable across all subgroups in the trial.  
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Table 5.4b  Number (percentage) of trials scored positive, negative and ‘don’t know’ for each quality criterion  
according to trials’ setting. 
 
 General population setting  
N = 14 
Mixed setting  
N = 31 
Setting unclear  
N = 14 
 
 
Quality criteria 
 
Yes 
N (%) 
 
No 
N (%) 
Don’t 
know 
N (%) 
 
Yes 
N (%) 
 
No 
N (%) 
Don’t 
know 
N (%) 
 
Yes 
N (%) 
 
No 
N (%) 
Don’t 
know 
N (%) 
          
Randomisation adequate 8 (57) 1 (7) 5 (36) 22 (71) 2 (7) 7 (22)) 4 (29) 0 10 (71) 
Allocation to treatment 
concealed 
8 (57) 0 6 (43) 18 (58) 1 (3) 12 (39) 7 (50) 0 7 (50) 
Patient blinded 4 (29) 5 (36) 5 (36) 6 (19) 21 (68) 4 (13) 10 (71) 2 (14) 2 (14) 
Care-provider blinded 1 (7) 12 (86) 1 (7) 4 (13) 26 (84) 1 (3) 6 (43) 4 (29) 4 (29) 
Co-interventions prevented 4 (29) 8 (57) 2 (14) 5 (16) 14 (45) 12 (39) 7 (50) 4 (29) 3 (21) 
Co-interventions 
standardised 
2 (20) 5 (50) 3 (30) 2 (8) 11 (42) 13 (50) 3 (43) 1 (14) 3 (43) 
Compliance acceptable 7 (50) 0 7 (50) 14 (45) 5 (16) 12 (39) 4 (29) 0 10 (71) 
Drop out acceptable 13 (93) 0 1 (7) 19 (61) 12 (39) 0 8 (57) 5 (36) 1 (7) 
Timing of measurement 
comparable* 
14 (100) 0 0 28 (90) 2 (7) 1 (3) 13 (93) 1 (7) 0 
Intention to treat analysis 9 (64) 2 (14) 3 (21) 23 (74) 4 (13) 4 (13) 7 (50) 6 (43) 1 (7) 
          
Median score per trial 5 2 1 4 3 2 4 1 3 
          
*: Timing of measurement of outcomes was comparable across all subgroups in the trial 
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Table 5.5  Distribution of the ‘don’t know’ scores according to setting and type of 
treatment 
 
 Number of 
trials 
Total number of 
criteria scored 
Criteria scored 
unclear, n (%) 
    
Setting    
General practice 29 290 62 (21)  
Occupational healthcare 20 200 50 (25) 
Physiotherapy  10 100 37 (37) 
General population 14 140 32 (23) 
Mixed 31 310 66 (21)  
Unclear 14 140 41 (29) 
   P = 0.018 
    
Type of treatment    
Pharmacological 20 200 44 (22)  
Non-pharmacological 91 910 233 (26)  
   P = 0.286 
    
 
 
 
 
Using a 50% cut-off point for the summary score analysis, the number of high 
quality trials was 16 (55%) in general practice setting, eight (40%) in occupational 
healthcare setting, three (30%) in physiotherapy setting, eight (57%) in general 
population setting, 15 (48%) in mixed setting and seven (50%) in trials in which 
the setting was not clear. The differences in the percentages of high quality trials 
in these settings were not significant (Pearson chi-square <df=5 > = 2.896, 
p=0.716).  
 
5.4.5.b Trials’ quality and type of treatment (Table 5.6) 
Ninety-one trials evaluated the effectiveness of non-pharmacological treatments, 
20 trials pharmacological treatments and five trials mixed treatments and it was 
not possible to classify two trials according to the type of treatment.  
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Table 5.6  Number (percentage) of trials scored positive, negative and  
‘don’t know’ for each quality criterion according to type of intervention. 
  
 Pharmacological 
interventions  
N = 20 
Non-pharmacological 
interventions  
N = 91 
 
 
Quality criteria 
 
Yes 
N (%) 
 
No 
N (%) 
Don’t 
know 
N (%) 
 
Yes 
N (%) 
 
No 
N (%) 
Don’t 
know 
N (%) 
       
Randomisation adequate 13 (65) 0 7 (35) 54 (59) 10 (11) 27 (30) 
Allocation to treatment 
concealed 
12 (60) 0 8 (40) 50 (55) 1 (1) 40 (44) 
Patient blinded 16 (80) 1 (5) 3 (15) 11 (12) 63 (69) 17 (19) 
Care-provider blinded 13 (65) 0 7 (35) 0 86 (95) 5 (6) 
Co-interventions prevented 11 (55) 7 (35) 2 (10) 15 (17) 39 (43) 37 (40) 
Co-interventions standardised  4 (44) 3 (33) 2 (22) 4 (5) 31 (41) 41 (50) 
Compliance acceptable 7 (35) 1 (5) 12 (60) 43 (47) 9 (10) 39 (40) 
Drop out acceptable 13 (65) 6 (30) 1 (5) 61 (67) 24 (26) 6 (7) 
Timing of measurement 
comparable* 
20 (100) 0 0 84 (92) 6 (7) 1 (1) 
Intention to treat analysis 14 (70) 4 (20) 2 (10) 55 (60) 16 (18) 20 (22) 
       
Median score per trial 7 1 2 4 3 3 
       
*Timing of measurement of outcomes was comparable across all subgroups in the trial 
 
 
 
There was no difference in the number of criteria on which information was 
missing (scored ‘don’t know’) between trials on non-pharmacological treatments 
(233 out of a total of 910, 26%) and trials on pharmacological treatments (44 out 
of a total of 200, 22%) (Pearson chi-square < df = 1 > = 0.696, p= 0.286,) (Tables 
5.5 and 5.6). One exception was information on care-provider blinding which was 
lacking more often among trials on pharmacological treatments compared with 
non-pharmacological treatments trials (7 out of 20, 35% vs 5 out of 91, 6% 
respectively). 
 
There was a larger number of high quality trials on pharmacological treatments 
compared with trials on non-pharmacological treatments (16/20, 80% vs 34/91, 
37% respectively) (Pearson chi-square <df = 1> = 12.041, p=0.001). Among trials 
that provided information on care provider blinding, all trials on pharmacological 
treatments were given positive scores while none of the non-pharmacological 
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trials was given positive scores. For patient blinding, 80% of pharmacological 
trials were given positive scores compared with 12% of non-pharmacological 
trials. There was no significant difference between trials on the two types of 
treatments regarding positive scores on the remaining criteria.  
 
5.4.5.c Trials’ quality and year of publication (Figure 5.2)  
Trials included in this review were published during a period of 14 years (1993-
2007) with a median number of seven trials published per year (range 1, 20). The 
majority of included trials were published in the years 2002-2007 (80/118, 68%). 
15 trials were published during 1993-1995, 102 during 1997-2007 and one trial in 
1996.  
 
Out of 15 trials published before the publication of the CONSORT statement 
in1996, 14 trials were scored ‘don’t know’ for at least one quality criterion (93%) 
(median of 4 ‘don’t know’ scores per trial, range 0,6), compared with 83 out of the 
102 trials published after 1996 (81%) (median of 2 ‘don’t know’ scores per trial, 
range 0,8). This would suggest a positive trend regarding adequate reporting of 
information, although the difference was not statistically significant (Fisher exact 
test, p = 0.226). The single trial that was published in 1996 was scored ‘don’t 
know’ for two criteria. 
 
The number of positive scores did not differ among trials published before and 
after 1996 (median of five positive scores per trial published before 1996, range  
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Figure 5.2  Quality scores for all included trials for each publication year  
Number above bars refers to the number of trials.  Year 2007: not shown as only included trials published before April 2007 (incomplete year), refer to main 
text on trials’ inclusion.  
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1,8; compared with a median of five positive scores per trial published after 1996, 
range 1,8). The single trial published in 1996 was scored positive for four criteria.  
 
Although it seems that more high quality trials were published after 1996 
compared with before 1996 (52 out of 102, 51% vs 4 out of 15, 27% respectively), 
the difference between the two groups was not statistically significant (Pearson 
chi-square <df=1> =3.098 p=0.078). The single trial published in 1996 was 
considered to be of a low quality.  
 
 
5.5 Discussion 
 
Further to assessing the quality of trials as part of a systematic review, the aim 
was to particularly focus on the interpretation and analysis of quality data using 
the summary score analysis, describing individual quality criteria and inadequate 
reporting.  
 
Just under a half of the trials included in this study were considered to be of high 
quality with the majority falling below the expected standards. This echoes the 
findings of a study published in 2005 (Koes et al 2005) which specifically 
assessed the quality of back pain RCTs using the same quality assessment tool. 
In that review, Koes et al assessed the quality of 269 trials included in 15 
Cochrane systematic reviews of conservative treatments for low back pain over 
the period 1961-2004. They concluded that many of the RCTs did not meet the 
quality standards with a wide variation in their quality. Furthermore, and which is 
perhaps even more significant, they did not find evidence for improvement in 
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methodological quality of trials over the time from 1960 to 2004. The potential 
impact of the findings related to the quality of the RCTs included in the systematic 
review presented in Chapter Four is important to consider. This impact, or the 
association between quality and symptom progressions, will be formally tested in 
Chapter Six.  
 
For the broader implication of the findings in this thesis, it is important to note that 
trials’ inclusion criteria for Koes et al study (2005) are different from those of this 
review (Chapter Four) where RCTs were included to meet a specific objective 
which was to examine responses to treatments. Therefore, many trials were 
excluded from this review as they were concerned with either ineligible 
populations, treatments, outcomes or setting and their quality was not assessed. 
Caution therefore needs to be exercised regarding generalising the findings 
regarding trials quality to all back pain trials.  
 
The methods used and quality of subgroups of trials according to setting, type of 
treatment and publication date are discussed below. 
 
5.5.1 The summary score analysis 
One potentially major flaw with the summary score analysis is that the cut-off point 
is arbitrary with equal weights given to the individual criteria. The attraction of this 
analysis is obvious in that it offers an easy and communicable way to describe 
trials as poor or high quality that could also be used to examine the association 
between quality and trials outcomes or other characteristics.  
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The summary score analysis does not have the ability to discriminate between 
individual criteria according to their importance or relevance. Criteria such as 
adequacy of random sequence generation, selective drop-out, and concealment 
of allocation to treatment could probably be considered as more relevant and 
indicative of trial quality and unbiased outcome than, for example, comparability of 
timing of follow up across trial groups. The CBRG checklist did not assign weights 
to the criteria while some quality assessment lists such as the Maastricht List did 
(Verhagen et al 1998), even though the weights were arbitrary and not based on 
universally agreed consensus.  
 
After finishing writing the findings from this study the Cochrane Collaboration 
announced that they adopted a new quality assessment tool across all review 
groups which is the ‘risk of bias’ tool (Furlan et al 2009). This came as part of the 
Collaboration revising their whole reviewing process. The new tool addresses six 
specific domains: ‘sequence generation’, ‘allocation concealment’, ‘blinding 
(patients and practitioners)’, ‘incomplete outcome data’,’ selective outcome 
reporting’ and ‘other issues’. Each of these domains is scored ‘yes’, ‘no’ or 
‘unclear’, similar to the tool used in this thesis. The domains of sequence 
generation, allocation concealment and selective outcome reporting, are to be 
addressed for the whole trial. Other domains could be considered separately for 
separate outcome measures. The emphasis in the new tool is on encouraging 
reviewers to make judgement when drawing conclusions about the overall risk of 
bias. This indicates that the new tool addresses some of the caveats associated 
with the previous tool by trying to put different weights on various domains. More 
significantly, the recommendation is to keep the assessment for each domain 
separate and not to combine them into an overall summary score.  
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5.5.2 Analysis of individual quality criteria 
The criteria most frequently scored negative were related to blinding of patients 
and care providers and also managing co-interventions (prevention or 
standardisation). On the other hand, in a large number of trials randomisation was 
considered adequate as well as concealment of allocation to treatment and 
reporting of drop-out rates.  
 
This type of data provides insight into the particular weaknesses and strengths of 
aspects of trials’ quality, compared with merely providing an overall description of 
the trial as high or poor quality or the overall proportion of high quality trials. 
Identifying particular areas in which trials are consistently inadequate, such as 
blinding, can be explored further to identify causes and possible solutions. Data 
on individual quality criteria can also help assess the impact of particularly 
relevant criteria on outcomes and conclusions for particular types of treatments or 
types of trials.  
 
5.5.3 Quality of reporting 
The decision in this study was to assess the trials through assessing their 
published reports. To this extent, the assessment could arguably be described as 
quality assessment of reporting of trials rather than of the trials themselves. 
Assessment of trial quality is inherently linked with the quality of their reports 
(Moher et al 1995) and the incomplete reporting of important aspects of trials 
methods is a common problem (Mostellier et al 1980, Der Simonian et al 1982, 
Schulz et al 1994). The question is whether poor reporting is considered as equal 
to poor conduct. Studies have shown that the lack of information on 
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methodological aspects of trials in their published reports did not always reflect 
real flaws in their conduct, rather a reporting flaw (Hill et al 2002), although some 
studies contradicted this by implying that lack of information in the report of a trial 
was associated with inadequate conduct (Schulz et al 1995). One possible 
solution is to approach authors and seek the missing information. However, in 
addition to the obvious practical and logistic burden this would entail, this would 
not guarantee complete or accurate information. It was decided to rely on 
published reports to assess trials quality as the argument was that systematic 
reviews usually rely on published reports of RCTs in compiling their evidence and 
it is the published reports that are linked with the trials outcomes and conclusions. 
Using this approach, it is important to closely examine the missing information as 
a distinct part of assessing the quality of trials. Nevertheless, there are strong 
arguments and justifications for both approaches of either relying only on 
published reports or contacting authors, neither of which is perfect. The perfect 
solution would be for trialists to publish complete information on their trials.  
 
In 1996 the Consolidation of Standards for Reporting Trials (CONSORT) 
statement was published (Begg et al 1996) and revised in 2001 and 2010 (Moher 
et al 2001, Consort statement website). It has been endorsed by the World 
Association of Medical Editors, the International Committee of Medical Journal 
Editors (ICMJE), and the Council of Science Editors. One aim of the statement 
was to provide authors and publishers with guidelines on the information that 
should be included in RCT reports to enable readers to accurately appraise the 
findings of the trial within the context of the robustness of its methodology. It 
would also allow accurate identification of trials with the highest level of evidence 
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to compare and combine their outcomes in systematic reviews and meta-analyses 
(Turpin et al 2005).  
 
A number of studies, however, suggested that the introduction of CONSORT did 
not improve reporting of RCTs (Hill et al 2002, Moher et al 2001, Montori et al 
2002, Mills et al 2005). These findings seem to be consistent and seem to be 
shown over a period of time after the publication of CONSORT. The findings 
come in tandem with the fact that an increasing number of journals declare their 
endorsement of the CONSORT statement (Moher et al 2001). Mills et al (2005) 
examined 200 RCTs published in 2003 in five general and 10 specialty journals 
endorsing CONSORT in order to determine the extent to which these journals 
implement their recommendations. This study concluded that those journals, 
although adopted CONSORT, did not seem to enforce it consistently.  
 
In the attempt to explore the impact of CONSORT on reporting the trials included 
in this review, the focus was on the issue of the lack of information. There is, 
albeit not significant, evidence that trials published after 1996 seem to have more 
information on quality criteria and a larger number of positively scored items 
compared with trials published earlier which seems to point to some positive 
impact from CONSORT. Koes et al (2005) in their assessment of back pain RCTs 
found no evidence of improvement in trials quality between 1960 and 2004, 
however it is not clear how the ‘don’t know’ scores (lack of information) were 
analysed. 
 
The lack of information can be considered a sign of poor actual conduct and ‘don’t 
know’ scores, therefore, merged with negative scores (Schulz et al 1995). This 
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method was tested in this analysis and was found to change judgment of the 
quality of some individual criteria across trials from positive to negative (or vice 
versa). The problem with this approach is the obvious risk of describing a well 
conducted but poorly reported trial as a poor quality trial which could invalidate a 
valid outcome.  
 
5.5.4 The association between trials’ quality and other characteristics 
The majority of trials included in this review were on non-pharmacological 
treatments (91 trials, 77%), which reflects the role of these types of treatments in 
the primary care management of LBP (van Tulder 1997). One of the main findings 
is the distinctly high proportion of negative scores for blinding of care providers 
and patients for a large number of trials in the occupational healthcare and 
physiotherapy settings. Blinding of patients and care providers is considered, 
rightly, as an integral part of conducting a high quality RCTs to provide an 
important safeguard against potential bias (Montori et al 2002) and the explicit 
reporting of which has been called for in the CONSORT statement (Begg et al 
1996). More importantly, perhaps, empirical evidence suggests that 
methodological flaws in trial design such as inadequate patient and care provider 
blinding are associated with overestimated treatment effect (Schulz wet al 1995). 
The fact that the majority of trials included in the review have inadequately blinded 
care providers and participants would understandably raise concerns about the 
validity of their outcomes. 
 
However, it could be argued that this study’s findings might be expected 
considering the known difficulty in adequately blinding participants and care 
providers in trials on non-pharmacological treatments (Black 1996, Boutron et al 
108 
 
2003, 2004), such as education, exercises programmes, manual therapy or 
psychological treatments. Perhaps a quality assessment checklist such as the one 
used here is not suitable for trials on non-pharmacological treatments. Trials on 
these types of treatments might require a particular way to assess their quality to 
take into account particular aspects of their methodology such as difficulty in 
blinding. The argument could be extended to involve trials on other treatments 
such as some complementary and alternative treatments.  
 
The relevance of blinding, however, might also be related to the type of trial as 
well as the type of treatment. As mentioned earlier, it might be crucially relevant in 
an explanatory trial that aims to test the efficacy (specific effects) of a treatment 
(regardless of the type being pharmacological or non-pharmacological), compared 
with a pragmatic trial which aims to assess the overall effects of a treatment as 
used in clinical practice, including both its specific effect and the effects of non-
specific factors.  
 
For these reasons it could be argued that the high proportions of negative scores 
for blinding patient and care provider blinding were expected for the large 
proportion of non-pharmacological trials included. What was not expected and 
harder to explain, however, were the findings of high negative scores for criteria 
such as adequacy of random sequence generation, managing co-interventions 
and reporting drop-out rate in these same trials. There does not seem to be an 
obvious reason why trials should have unsatisfactory conduct in these important 
areas.  
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Trials on pharmacological treatments were more satisfactory in adequacy of 
random sequence generation, concealment of allocation to treatment arms, 
blinding and managing co-interventions. However, almost a third of these trials 
were still not satisfactory in controlling for co-interventions. Also, information was 
not available on each of the criteria in an average of a third of the trials. An 
interesting finding was the scale of lack of information on care provider blinding, 
which was missing in about six times the proportion of pharmacological trials as 
those on non-pharmacological treatments. The number of these types of trials, 
however, was small and therefore caution is required before generalising these 
results.  
 
 
5.6 Limitations 
 
The trials that were assessed for quality were included according to specific 
inclusion criteria in the original systematic review conducted to examine 
responses to primary care treatments. Many trials were excluded because they 
included either ineligible populations, treatments, outcomes or settings. However, 
the study satisfied the specific objectives. Findings in this thesis although provided 
important insight, might not be generalisable to all RCTs in back pain.  
 
Assessors of trials’ quality in this study were not blinded. Although some studies 
have suggested that blinded assessment would be associated with reduced 
reviewer and selection bias and provide a better consistency in the final quality 
scores (Jadad et al 1996) other studies did not find the same association 
(Verhagen et al 1998). Furthermore, blinding would not have been consistently 
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successful when the trials are from the field of interest and expertise of the 
reviewers.  
 
 
 
 
5.7 Summary  
 
Only about half of back pain trials included in this study were of high quality with a 
wide variation among trials. Information on important quality criteria was missing 
in many trials. Further to the previous repeated calls for authors to adhere to the 
CONSORT statement in reporting, this study shows that further efforts to address 
this situation are needed. The findings also confirm the importance of describing 
the extent of the missing information on quality criteria separately rather than 
simply adding them to the positive or negative scores.  
 
 
It seems that a quality assessment tool with the flexibility that provides the 
potential to allow it to be used with differing types of trials (exploratory or 
pragmatic) or treatments (pharmacological or non-pharmacological) might go a 
long way in addressing  some of the main issues outlined in this review, such as 
those around patient  and care-provider blinding. It seems that the new Cochrane 
Risk of Bias tool might represent an example of such a tool.  
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Not all back pain trials were assessed for their quality in this study, but only RCTs 
that were included in the systematic review. It is, therefore, important not to 
generalise the findings to all back pain trials. Another objective was to examine 
the association between quality and responses to treatments and this is the 
subject of the next chapter, Chapter Six.  
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Chapter Six  
 
 
Factors associated with responses to 
treatments for low back pain: 
a meta-regression analysis of randomised 
clinical trials 
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6.1 Introduction 
 
In Chapter Four responses to a wide range of primary care treatments in clinical 
trials for non-specific low back pain were studied. Further to the common pattern 
these responses appeared to follow, the review also showed a wide variation in 
the size of those responses which is the focus of this chapter.  
 
Variation in ‘treatment effects’ (heterogeneity) is common in systematic reviews 
(Higgins & Green 2008). It is defined as the amount in which the ‘effect’ in each 
trial deviates from the pooled ‘effect’ (Thompson & Higgins 2002). Exploring 
possible sources of heterogeneity is important (Egger et al 2009, Thompson 
1994) as they would represent factors that would be associated with or influence 
‘treatment effects’ (Thompson 2009). The aim in this chapter was to study 
possible sources of heterogeneity in overall responses to treatments.  
 
The principles and features of heterogeneity and its assessment for treatment 
effects should be the same when investigating heterogeneity in overall symptom 
progression. A possible difference, and arguably an advantage of studying 
sources of heterogeneity in overall responses to treatments, is that these 
responses represent the effects of all factors, specific and non-specific, and 
therefore include all possible sources of heterogeneity between responses.  
 
Clinical as well as methodological diversity among trials contribute to 
heterogeneity in responses to treatments. The type of treatments used (for 
example, pharmacological or non-pharmacological), intensity and duration of 
symptoms, patients’ socio-demographic characteristics as well as quality and 
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setting of the trials are examples of trial aspects that might influence response 
treatment. These trial characteristics represent, by definition, non-specific factors 
hence the interest in this thesis in studying them and their association with 
responses to treatments. Further, in Chapter Five, the findings showed that many 
(over a half) of the RCTs included in the systematic review were of low quality and 
information on a number of quality criteria was missing. In this chapter, the 
potential of the influence of trials overall quality, as well as individual aspects of 
quality, on responses to treatments will be explored.  
 
 
6.2 Objectives 
 
The main objective was to evaluate the extent to which heterogeneity in the size 
of responses to treatments for NSLBP described in Chapter Four is explained by 
the variation in the following trial characteristics: 1) patients’ sociodemographics; 
2) pain characteristics; 3) trial setting and quality. The observation in Chapter Four 
that the effect of non-specific factors was unrelated to the type of treatment and 
could in fact be stronger than the effect of the type of treatment was also tested by 
examining the association between type of treatment and symptom progression.  
 
 
6.3 Methods 
 
6.3.1 Criteria for trials’ inclusion 
Data from randomised clinical trials included in the systematic review (Chapter 
Four, Methods section) were used.  
115 
 
6.3.2 Outcomes 
The main outcome was overall symptom progression within each trial arm. 
Although data on symptom progression were collected for pain intensity (VAS for 
pain and its equivalents) and functional disability (RMDQ and ODI), pain intensity 
was the outcome measure that was used by the largest number of trials and was, 
therefore, the focus of analyses reported here. Similar analyses were performed 
for functional disability and reference to and comparison with the results for pain 
intensity will be made.  
 
Symptom progression was represented by the standardised mean change (SMC) 
calculated as the difference between mean outcome at baseline and follow up 
divided by the standard deviation (SD) at baseline (Morris 2000). Where means 
and standard deviations were not provided, these were calculated from the 
available data (see Chapter Four). Three common follow up time points were 
used for analyses, 13, 27 and 52 weeks. 
 
6.3.3 Characteristics  
These were pre-selected trial characteristics that are commonly identified in the 
literature as potential non-specific factors that could be associated with responses 
to treatments in clinical trials (Evers et al 2009, Macedo et al 2008, Pitz et al 2005, 
Wasan et al 2010). They were related to participants (age and gender), symptoms 
(duration) and methods (trial setting and trial quality). The quality assessment 
criteria checklist of the Cochrane Back Review Group (van Tulder et al 2003) was 
used to assess the internal validity of the included trials as described in Chapter 
Five. To examine whether the size of overall responses to treatments varied 
according to the type of treatment, the association between treatment type and 
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responses was examined using the two types of classification of treatment types: 
index, active comparator, placebo, usual care or waiting list and pharmacological 
or non-pharmacological.  
 
The available evidence on the influence of these characteristics or factors vary 
greatly and mainly comes from fields other than back pain, such as osteoarthritis 
(OA) (Zhang et al 2008), migraine headache (Evers et al 2009, Macedo et al 
2008) and irritable bowel syndrome (IBS) (Pitz et al 2005, Dorn et al 2007). This 
also applies to the evidence related to the association between trials quality and 
symptom progressions, as was discussed in Chapter Five. Furthermore, in the 
majority of the studies, these factors were studied for their association with 
treatment effect rather than overall symptom progressions. The exploration of the 
association of these factors on responses to treatments in this study, therefore, 
was not based on any a priori assumptions or hypothesis related to any of the 
selected characteristics. 
 
To facilitate the interpretation of analysis, data on some characteristics were 
dichotomised. Trials were dichotomised around the overall mean age for the 
included trials’ populations of 43 years and the mean percentage of females of 
52%. For pain duration, trials were dichotomised as ‘chronic’ pain trials and 
‘acute/subacute’ trials and the latter group was referred to as acute. This relied on 
the description provided by authors and inclusion criteria. This particular 
distinction between subacute and chronic (usually around a cut-off point of 12 
weeks, which is an accepted minimum duration for chronic pain), was used to 
avoid the potential problems associated with the diversity in defining ‘subacute’ 
back pain in trials (Pengel et al 2002).  
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Two types of classifications were used to subgroup trial arms according to type of 
treatment. The first was whether they were placebo, index, active comparator, 
usual care or waiting list (i.e. five groups). The second classification was 
according to whether the treatments were pharmacological or non-
pharmacological.  
 
Trials’ settings were split into general practice, occupational healthcare units, 
physiotherapy departments, general population, mixed setting and other in which 
the setting was not clear (i.e. six groups). Trial quality involved assessment of 
each individual quality criteria (‘yes’, ‘no’ and ‘not clear’). Results of these 
assessments were then summarised for each trial and the overall summary score 
dichotomised into high or low quality, defined according to at least 50% of the 
quality criteria being satisfied, i.e. five or more positive scores, as described in 
detail in Chapter Five. Studies with the ‘not clear’ category for individual quality 
criteria were dropped from analyses for those individual criteria to follow the 
argument for not adding ‘don’t know’ to the negative scores. Also, there was no 
logical justification to study the association between symptom progression and the 
‘not clear’ scores, which are related to reporting of the trial rather than the conduct 
of the trial itself. 
 
6.3.4 Analysis 
Meta-regression analyses (Thompson & Higgins 2002) were conducted to explore 
whether selected trial characteristics were associated with within-arm symptom 
progression. All arms of all included trials were included for the main analysis. 
Sensitivity analyses were conducted to evaluate the association in one randomly 
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selected arm from each trial, to overcome any potential cluster effect of within-arm 
responses in trials.  
 
A random effects model meta-regression analysis was used (Lau 1998, van 
Houwelingen et al 2002) using STATA IC11 software. The significance level was 
set at 5% (p = 0.05) to test the significance of the association between 
determinant and outcome. The weight for each trial arm was equal to the inverse 
of its variance. Larger size trial arms, which have smaller variance, were hence 
given larger weight than smaller arms. The measure of variability between 
responses in trial arms (squared tau) was calculated.                                                              
 
The concept of random effects model is not exclusive to meta-regression analysis, 
but applicable to meta-analysis in a broader sense, as was explained in Chapter 
Four, Analysis section. To explain the concept briefly, a random-effects model 
assumes that there is variation between trial arms in the association of 
characteristic and outcome. Hence this analysis leads to an estimate of the 
“average” association between characteristic and outcome across trial arms (Lau 
et al 1998).  
 
First, univariable analyses were performed to examine the unadjusted association 
between each of the selected trial characteristics and the SMCs. Multivariable 
analyses were then conducted to adjust for potential confounding. For these 
analyses pain intensity at baseline was selected as a potential confounder for the 
influence of pain duration as well as for the influence of gender.  
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The association of pain duration with symptom progression was expected to be 
potentially confounded by baseline pain severity. In other words, patients with 
longer duration LBP might have higher (or lower) pain severity than those of 
shorter LBP duration, which may explain part of the association between pain 
duration and outcome. Such a possible confounding was therefore explored. 
There is some evidence from the literature that women are more likely to report 
more severe pain and baseline pain intensity was therefore explored as a 
potential confounder for the association between gender and symptom 
progressions. Type of treatment was also assessed as a potential confounder for 
the association between response and some individual quality criteria that would 
be relevant to the type of treatment, such as patient blinding, practitioner blinding, 
drop out, concealment of allocation and compliance. However, only associations 
that were found to be significant in the unadjusted analyses were adjusted for 
potential confounding.   
 
 
6.4 Results 
 
Forty-four trials (Appendix 6) provided data for pain intensity outcome for 58 arms 
at 13 weeks, 59 arms at 27 weeks and 48 arms at 52 weeks. Thirty five trials 
provided data on the RMDQ, for 44 arms at 13 weeks, 24 at 27 weeks and 22 at 
52 weeks. Twenty six trials provided data on the ODI, for 24 arms at 13 weeks, 20 
at 27 weeks and 24 at 52 weeks. The results will be presented primarily for pain 
intensity outcome. The results on the RMDQ and the ODI will be presented 
separately and comparison made with pain.  
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6.4.1 Trial characteristics and symptom progression: Univariable analyses 
Table 6.1 shows the unadjusted associations of trial characteristics with symptom 
progression for pain intensity.  
 
6.4.1.a Socio-demographic variables: age, gender 
Data on age were not available in 11 arms. 53% of trial arms included participants 
younger than 43 years old. The association with age was only statistically 
significant at 13 weeks, showing that trial arms with mean age younger than 43 
years old was associated with larger symptom progression compared with mean 
age more than 43 years. Mean difference in pooled SMC was 0.37 (95% CI 0.05, 
0.68).  
 
Of the 44 trials providing data on pain intensity, three did not provide data on 
gender (eight arms). The mean percentage of females among trial arms providing 
data on pain intensity was 52%, which was not different from the mean for all the 
included trials (53%). There was a statistically significant association between the 
percentage of females in the trial arms and symptom progression at 27 and 52 
weeks. Trial arms with lower percentage of females showed larger responses: at 
27 weeks the difference in pooled SMC was 0.31 (95% CI 0.02, 0.59) and at 52 
weeks, 0.38 (95% CI 0.05, 0.70). The association was not significant at 13 weeks 
but the size and direction were similar. 
 
6.4.1.b Duration of pain 
40% of trial arms included participants of whom the majority had an acute back 
pain episode at inclusion. At 27 weeks, arms from trials of participants with mainly  
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Table 6.1  Results of univariable meta-regression analyses showing mean difference in pooled SMC between trial arms for the selected characteristics for 
pain intensity, mean (95% confidence interval). 
 
 
Trial characteristic 
 13 weeks  27 weeks  52 weeks 
 
n 
 
Coeff (95% CI) 
Tau2 
0.30 
   
n 
 
Coeff (95% CI) 
Tau2 
0.26 
 
n 
 
Coeff (95% CI) 
Tau2 
0.28 
          
Mean age, <43 years  38:24 0.37 (0.05, 0.68) 0.28 32:22 0.19 (-0.10, 0.49) 0.24 28:19 0.26 (-0.08, 0.60) 0.27 
Female, <52%  32:31 0.30 (-0.02, 0.61) 0.29 28:27 0.31 (0.02, 0.59) 0.23 18:34 0.38 (0.05, 0.70) 0.27 
Pain duration, acute  34:33 0.20 (-0.10, 0.50) 0.29 30:29 0.39 (0.12, 0.65) 0.22 20:35 0.49 (0.19, 0.78) 0.23 
          
Treatment type (reference: usual care) 8  0.28 7  0.26 7  0.29 
     Index 29 -0.38 (-0.87, 0.11)  25 -0.35 (-0.81, 0.11)  23 -.039 (-0.90, 0.11)  
     Active comparator 25 -0.39 (-0.89, 0.11)  23 -0.34 (-0.81, 0.12)  21 -0.34 (-0.85, 0.17)  
     Waiting list 3 0.06 (-0.81, 0.92)  4 -0.17 (-0.87, 0.52)  3 -0.56 (-1.37, 0.25)  
     Placebo 2 0.31 (-0.63, 1.26)  0 -  1 -0.35 (-1.62, 0.92)  
Treatment type, Non-pharmacological  53:4 0.24 ( -0.37, 0.86) 0.29 49:2 0.48 (-0.25, 1.22) 0.23 46:0 - - 
          
Setting (reference: general practice) 19  0.31 15  0.25 15  0.27 
     Occupational health care 18 -0.08 (-0.50, 0.33)  16 0.-22 (-0.61, 0.16)  13 -0.35 (-0.78, 0.08)  
     Physiotherapy departments 8 0.21 (-0.34, 0.76)  6 0.08 (-0.45, 0.60)  4 0.17 (-0.49, 0.83)  
     General population 9 -0.07 (-0.46, 0.60)  11 -0.35 (-0.77, 0.07)  5 -0.21 (-0.79, 0.36)  
     Mixed setting 11 -0.12 (-0.59, 0.37)  11 -0.36 (-0.78, 0.06)  18 -0.34 (-0.74, 0.05)  
     Other 2 0.48 (-0.44, 1.40)  0 -  0 -  
          
Quality: Overall trial quality, low 25:34 -0.02 (-0.33, 0.30) 0.31 28:27 -0.25 (-0.53, 0.03) 0.24  -0.45 (-0.73, -0.16) 0.23 
Individual quality criteria: not adequate          
     Randomisation 9:53 0.27 (-0.22, 0.76) 0.32 7:46 -0.33 (-0.79, 0.14) 0.27 5:33 -0.43 (-0.99, 0.14) 0.27 
     Concealment of allocation to treatment arms 0:41 -  0:37 -  2:24 -0.70 (-1.60, 0.20) 0.31 
     Patient blinding 54:13 -0.35 (-0.72, 0.02) 0.27 48:7 -0.43 (-0.85, 0.00) 0.24 46:9 -0.64 (-1.02, -0.26) 0.23 
     Care provider blinding 58:7 -0.05 (-0.54, 0.45) 0.31 54:5 0.05 (-0.46, 0.55) 0.26 46:9 -0.09 (-0.51, 0.33) 0.29 
     Co-interventions prevented 37:9 -0.07 (-0.60, 0.45) 0.38 27:9 -0.01 (-0.47, 0.44) 0.30 25:6 -0.08 (-0.61, 0.44) 0.27 
     Co-interventions standardised 31:6 0.08 (-0.61, 0.76) 0.47 25:2 0.63 (-0.25, 1.50) 0.31 25:0 - - 
     Compliance 5:29 -0.56 (-1.13, 0.02) 0.30 2:31 -0.68 (-1.24, -0.12) 0.28 7:24 -0.68 (-1.16, -0.20) 0.25 
     Drop out 25:42 -0.02 (-0.33, 0.30) 0.31 19:40 -0.01 (-0.31, 0.30) 0.26 17:36 0.01 (-0.32, 0.35) 0.27 
     Measurement comparable** 2:65 0.34 (-0.56, 1.23) 0.30 0:59 -  0:55 -  
     Intention to treat analysis 8:50 0.03 (-0.48, 0.55) 0.33 6:42 -0.46 (-0.93, 0.01) 0.23 2:39 -0.63 (-1.40, 0.13) 0.25 
          
Pooled SMC at 13 weeks: 0.99 (0.86, 1.11), 27 weeks:1.07 (0.93, 1.20) and 52 weeks: 0.91 (0.76, 1.05),  Coeff = coefficient from meta-regression. Positive (negative) coefficient indicates larger 
(smaller) response between baseline and follow-up compared to reference group. Underlined indicates significant (p<0.05). n: represent number of arms in the selected group compared with 
reference group. **Timing of measurement of outcomes comparable across groups. 
122 
 
acute back pain episode showed a significantly higher pooled response estimate 
compared with those with chronic episodes. However, this was statistically 
significant only at 27 and 52 weeks with mean difference in pooled SMCs of 0.39 
(95% CI. 0.12, 0.65) and 0.49 (95% CI 0.19, 0.78) at these times respectively. 
This suggests that symptom progression was larger among acute and subacute 
LBP patients compared with chronic LBP patients. At 13 weeks, the association 
was not statistically significant. However, the direction of difference at this time 
was the same. It is also noted that the size of the difference in response increased 
with follow up time.  
 
6.4.1.c Type of treatment 
Using both classifications for type of treatment, there was no significant 
association between types of treatments and symptom progressions at any follow 
up times. However, there were very small numbers of arms using placebo and 
pharmacological treatments. Caution is therefore warranted interpreting the 
related results.  
 
6.4.1.d Trial methods: Setting and quality 
There was no significant association between setting of trials and symptom 
progressions at any follow up time. 
 
Of the 44 included trials, 20 (46%) were considered high quality trials using the 
quality overall summary score (Chapter Five). Trial quality was associated with 
symptom progression, with low quality trials being associated with smaller within-
arm responses to treatments, but this was statistically significant only at 52 weeks 
(mean difference of pooled SMC was -0.45 (95% CI -0.73, -0.16). At 13 & 27 
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weeks, the associations were not significant. However, the size of the difference 
in response between high and low quality trials was smaller but the direction was 
similar at 27 weeks to that at 52 weeks. 
 
Of the individual quality criteria, the criteria of adequacy of patient blinding and 
compliance were statistically significantly associated with responses to treatments 
at 27 & 52 week follow up. When these two criteria were not satisfied, this was 
associated with smaller symptom progression. At 13 weeks, although these 
associations were not statistically significant, the size and direction of the 
associations were similar to those at 27 & 52 weeks. There was not sufficient 
number of arms to analyse the associations of the criteria related to concealment 
of allocation to treatments at 13 weeks, timing of outcome measurements at all 
follow up times and for the criterion of standardisation of co-interventions at 52 
weeks. Apart from a small number of exceptions, in general the associations 
suggest that inadequate satisfaction of quality criteria was associated with smaller 
responses to treatments.  
 
6.4.1.e Residual heterogeneity 
At 13 week follow up, between-arm variance represented by squared tau without 
any independent variable included in the analysis was 0.30. Introducing the 
selected independent variables into the analyses did not further explain the 
variation to a large extent.  
 
At 27 week follow up, squared tau without any independent variable included in 
the analysis was 0.26. The smallest residual variance was 0.22 following the 
inclusion of duration of pain in the model. This means that duration of pain 
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explained 15% of the between-arm variation in responses to treatment at 27 
weeks. Variance was reduced to a lesser extent (0.23) when the gender was 
introduced, thus explaining 12% of heterogeneity.  
 
At 52 weeks, between-arm residual variance without the introduction of any 
independent variable was 0.28. The largest reduction in between arms variation or 
heterogeneity was to 0.23, achieved with the introduction of duration of pain, 
overall trial quality and adequacy of patient blinding. This indicates that each of 
these determinants explained 18% of the variation in responses at this time point. 
Squared tau was reduced to a lesser extent with the introduction of compliance, to 
0.25, i.e. compliance explained 11% of variation in responses at 52 weeks.  
 
6.4.2 Multi-variable analyses (Table 6.2) 
4.6.2.a Influence of gender adjusted for baseline pain intensity 
Adjusting the association between gender and symptom progression for pain 
intensity at baseline resulted in similar estimates for gender as for the unadjusted 
analysis which were statistically significant at 27 and 52 weeks. Squared tau, 
reflecting the amount of variation in responses left unexplained, did not change at 
13 weeks and only marginally fell at 27 weeks from 0.23 to 0.22 and at 52 weeks 
from 0.27 to 0.24. This suggests that the association between gender and 
symptom progression was not confounded by differences in pain severity at 
baseline. 
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Table 6.2 Mean difference in SMC between trial arms for the selected characteristics for pain intensity, adjusted for selected potential confounders.  
 
 13 week  27week  52week  
Subgroups of trial characteristics Unadjusted Adjusted Tau2 Unadjusted Adjusted Tau2 Unadjusted Adjusted Tau2 
Model 1:  
Gender adjusted for baseline pain intensity 
Female < 52% 
         
0.30 (- 0.02, 0.61) 0.29 (-0.02, 0.60) 0.29 0.31 (0.02, 0.59) 0.31 (0.04, 0.59) 0.22 0.38 (0.05, 0.70) 0.41 (0.09, 0.72) 0.24 
          
Model 2:  
Pain duration adjusted for baseline pain intensity 
Pain type, <12w 
         
0.20 (-0.10, 0.50) 0.17 (-0.13, 0.48) 0.28 0.39 (0.12, 0.65) 0.35 (0.08, 0.61) 0.22 0.48 (0.19, 0.78) 0.43 (0.14, 0.73) 0.22 
          
Model 3:  
Patient blinding adjusted for type of treatment A a 
Patient blinding-Not adequate 
         
-0.35 (-0.72, 0.02) -0.26 (-0.67, 0.15) 0.27 -0.43 (-0.85, 0.00) -0.37 (-0.83, 0.09) 0.25 -0.64 (-1.02, -0.26) -0.60 (-1.01, -0.19) 0.24 
          
Model 4:  
Patient blinding adjusted for type of treatment B b 
Patient blinding-Not adequate 
         
-0.35 (-0.72, 0.02) -0.33 (-0.72, 0.06) 0.27 -0.43 (-0.85,0.00) -0.19 (-0.65, 0.26) 0.23 - -  
          
Model 5:  
Compliance adjusted for type of treatment A a 
Compliance-Not adequate 
         
-0.56 (-1.13,0.02) -0.54(-1.16, 0.08) 0.28 -0.68 (-1.24, -0.12) -0.59 (-1.16, -0.02) 0.27 -0.68 (-1.16, -0.20) -0.58 (-1.07, -0.10) 0.24 
          
Model 6:  
Compliance adjusted for type of treatment B b 
Compliance-Not adequate 
         
-0.56 (-1.13, 0.02) -0.63(-1.53, 0.28) 0.31 -0.68 (-1.24, -0.12) -0.74 (-1.57, 0.08) 0.25 - -  
          
a: according to classification of usual care, index, active comparator, waiting list and placebo. b: according to classification of pharmacological and non-pharmacological. 
Positive (negative) coefficient indicates larger (smaller) response between baseline and follow-up compared to reference group. Highlighted indicates significant (p<0.05) 
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6.4.2.b Influence of duration of back pain episode adjusted for baseline pain 
intensity 
Trials among chronic back pain patients had higher average pain intensity scores 
at baseline compared with trials among acute and sub-acute pain patients. 
Baseline pain intensity scores for chronic LBP trials were: mean 53, median 53, 
range: 19-79.7 and for acute LBP trials: mean 37, median 44.4, range: 20-61.  
 
The association between pain duration and symptom progression remained 
significant and of similar magnitude after adjustment for baseline pain intensity. 
Squared tau fell only marginally at 13 weeks and 52 weeks, from 0.29 to 0.28 and 
from 0.23 to 0.22 respectively, and remained the same at 27 weeks.  
 
6.4.2.c Influence of individual quality criteria adjusted for type of treatment 
The association between symptom progression and the criteria of adequacy of 
patient blinding and compliance was adjusted for type of treatments. The number 
of pharmacological treatment arms was too small at 52 week follow up to allow for 
these analyses. The association between these two criteria and responses 
remained significant after adjusting for the type of treatments, except for patient 
blinding at 27 weeks.  
 
The change in squared tau was marginal and not in a consistent direction after 
adjustment indicating insignificant effect of adjustment. The largest decrease in 
squared tau was at 13 weeks for compliance (from 0.30 to 0.28). 
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6.4.3 Functional disability  
The results of univariable analyses with the RMDQ as the outcome are presented 
in Table 6.3. Sufficient data were not available to undertake the adjusted 
analyses. 
 
Using the available data, pain duration (at all follow up times), gender (only at 52 
weeks) and patient blinding (at 27 and 52 weeks) were statistically associated 
with responses to treatment on the RMDQ as they were for the pain intensity 
outcome. The differences between these two outcomes were for age, overall trial 
quality and compliance (not significantly associated with responses on the 
RMDQ), setting (significantly associated with responses to treatments on the 
RMDQ) and drop-out rate (significant for RMDQ at 13 weeks only). The 
associations with setting were significant at all follow up times for occupational 
health care and mixed setting trials, and only at 13 & 27 weeks for the general 
population setting trials. The direction in all these associations suggests that, in 
relation to the reference category which was general practice setting, they all were 
associated with smaller responses to treatments, with the largest difference in 
response being at 27 weeks for occupational healthcare setting (-1.54, 95% CI -
2.35, -0.74). 
There was a fewer trial arms that used ODI and provided data for the various 
types of treatments at 27 and 52 week follow up. At 27 weeks, no arm used 
placebo or usual care, 10 arms used index or active comparator treatments and 
two arms used waiting list control. At 52 weeks, no arms used placebo or waiting 
list control, 12 used index treatment, 13 active comparator treatment and two 
usual care. Because of the insufficient data, characteristics were not analysed in 
trials using this outcome.  
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Table 6.3  Results of univariable meta-regression analyses showing mean difference in pooled SMC between trial arms for the selected characteristics for 
RMDQ, mean (95% confidence interval) 
  13 weeks   27 weeks   52 weeks  
 
Trial characteristic 
 
n 
Coeff (95% CI) Tau2  
0.35 
 
n 
Coeff (95% CI) Tau2  
0.43 
 
n 
Coeff (95% CI) Tau2  
0.39 
          
Mean age, <43 year 23:22 0.06 (-0.29, 0.42) 0.32 13:17 -0.35 (-0.85, 0.16) 0.41 11:11 -0.04 (-0.64, 0.56) 0.41 
Female, <49% 17:18 0.15 (-0.26, 0.57) 0.33 21:7 0.42 (-0.14, 0.98) 0.42 9:9 0.73 (0.15, 1.31) 0.28 
Pain duration, <12w 18:27 0.75 (0.47, 1.03) 0.18 14:16 1.02 (0.69, 1.35) 0.17 10:12 0.70 (0.20, 1.20) 0.27 
          
Treatment type (ref: usual care) 6  0.31 3  0.45 4  0.39 
     Index 20 0.05 (-0.50, 0.60)  12 -0.41 (-1.32, 0.50)  11 -0.31 (-1.12, 0.51)  
     Active comparator 16 -0.01 (-0.58, 0.56)  15 -0.37 (-1.26, 0.53)  7 -0.56 (-1.43, 0.30)  
     Waiting list 0 -  0 -  0 -  
     Placebo 3 -0.56 (-1.39, 0.27)  0 -  0 -  
Treatment type, Non-pharmacological     34:4 0.22 (-0.38, 0.82) 0.30 25:0 -  14:0 -  
          
Setting (reference: general practice) 11  0.22 2  0.21 8  0.22 
     Occupational health care  9 -0.88 (-1.32, -0.43)  7 -1.54 (-2.35, -0.74)  2 -0.96 (-1.78, -0.15)   
     Physiotherapy departments 0 -  2 -0.25 (-1.28, 0.79)  2 0.75 (-0.13, 1.62)  
     General population 5 -0.92 (-1.47, -0.37)  7 -1.45 (-2.26, -0.64)  3 -0.92 (-1.63, -0.21)  
     Mixed setting 9 -0.60 (-1.05, -0.14)  6 -1.42 (-2.25, -0.59)  5 -0.25 (-0.88, 0.39)  
     Other 11 -0.57 (-0.99, -0.14)  6 -0.73 (-1.55, 0.09)  2 -0.32 (-1.16, 0.53)  
          
Quality: Overall trial quality, low 31:14 0.32 (-0.05, 0.70) 0.30 21:9 0.15 (-0.41, 0.71) 0.44 9:13 0.11 (-0.50, 0.71) 0.41 
Individual quality criteria, quality not adequate          
     Adequacy of randomisation 3:34 -0.43 (-1.20, 0.35) 0.32 1:29 -0.75 (-2.27, 0.77) 0.43 1:17 -0.81 (-2.38, 0.76) 0.42 
     Concealment of allocation to treatment arms 0:30 - - 0:17 - - 0:8 - - 
     Patient blinding 28:13 -0.41 (-0.79, -0.03) 0.29 28:2 -1.23 (-2.14, -0.32) 0.34 16:6 -0.61 (-1.21, -0.02) 0.32 
     Care provider blinding 39:4 -0.13 (-0.75, 0.49) 0.32 30:0 - - 20:2 -0.19 (-1.22, 0.83) 0.41 
     Co-interventions prevented 29:12 0.18 (-0.24, 0.61) 0.34 17:9 0.44 (-0.12, 1.00) 0.41 14:4 -0.06 (-0.85, 0.73) 0.40 
     Co-interventions standardised 20:6 0.44 (-0.13, 1.01) 0.32 17:0 - - 14:0 - - 
     Compliance 2:35 -0.30 (-1.21, 0.60) 0.34 2:22 -0.33 (-1.42, 0.75) 0.47 2:12 -0.01 (-1.10, 1.08) 0.39 
     Drop out 24:21 -0.43 (-0.76, -0.10) 0.26 10:20 -0.39 (-0.91, 0.14) 0.41 13:9 -0.01 (-0.61, 0.60) 0.41 
     Comparable measurements* 3:42 0.47 (-0.28, 1.22) 0.31 1:29 0.75 (-0.77, 2.27) 0.43 1:21 0.82 (-0.66, 2.30) 0.39 
     Intention to treat analysis 4:34 -0.54 (-1.17, 0.10) 0.34 2:26 -0.62 (-1.64, 0.41) 0.45 4:14 -0.70 (-1.50, 0.11) 0.42 
          
Pooled SMC at 13 weeks: 0.79 (0.61, 0.97), 27 weeks: 0.97 (0.73, 1.21) and 52 weeks: 0.98 (0.73, 1.23). Coeff = coefficient from meta-regression. Positive (negative) coefficient indicates larger 
(smaller) response between baseline and follow-up compared to reference group. Underlined indicates significant (p<0.05). n: number of arms in the selected group compared with ref group. 
*Timing of measurement of outcomes comparable across groups. 
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6.5 Discussion  
 
The aim was to assess the extent to which trial characteristics explain the 
variation in responses to primary care treatments for non-specific low back pain in 
clinical trials.  
 
The findings suggest that age, gender, pain episode duration and trial quality 
could explain some of the heterogeneity of responses. A large proportion of 
variation still remained unexplained suggesting that other factors are contributing 
to the variation in responses that were not examined here. For this analysis 
factors were preselected for which sufficient data were available in the included 
trials. An important finding was that the type of treatment did not seem to be 
responsible for variation in responses in the trials studied, although the numbers 
were small for some treatments e.g. pharmacological treatments. This is in line 
with the proposed hypothesis of a similar pattern of responses regardless of the 
treatments used.  
 
Studies have been conducted to explore the association between certain trial 
characteristics and ‘effect’ of treatments for various medical conditions (Schulz et 
al 1995, Moher et al 1998, Kunz & Oxman 1998, Balk et al 2002) including low 
back pain (Wasan et al 2010).The study in this thesis is different in that the overall 
responses to treatments were studied rather than treatment effect. This would 
provide the opportunity to study factors that are usually controlled for and 
neutralised when treatment effects are studied.  
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The findings will be discussed in detail below and compared with evidence from 
the literature.  
 
6.5.1 Heterogeneity in systematic reviews 
A degree of variation in treatment effects or responses to treatments is expected 
in systematic reviews of clinical trials. In fact, some even argue that it is 
unreasonable to expect complete homogeneity among a group of trials in any 
systematic review (Hardy & Thompson 1998). Trials are likely to differ in 
population type, their socio-demographic characteristics, setting, types of 
treatments and their dosage, nature and severity of symptoms and methods of 
symptom assessment or outcome measures and trial protocol and conduct.  
 
6.5.2 Sources of variation in symptom progression   
6.5.2.a Gender 
Trial arms with larger percentages of females showed generally smaller size of 
response. The association between gender and musculoskeletal pain has been 
explored (Elliott et al 1999, Smith et al 1999, Wijnhoven et al 2006 & 2007). In 
these studies, women were found to be more likely to report pain and consult their 
general practitioners with pain than men and more likely to report higher pain 
severity and higher expressed needs. These differences, however, were not 
always statistically significant and varied according to site of pain. Furthermore, 
the implication of these results on responses to treatments and how these 
responses differ in the two gender groups is not clear. Observational studies have 
explored gender as a possible prognostic factor (Hestbaek et al 2003) however no 
conclusive evidence was found for its association with the course of back pain. 
Chenot et al (2008) conducted a secondary analysis of data of a cohort of 1342 
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(58% females) participants of an RCT and specifically examined sex differences 
in presentation, course and management of low back pain. They used the 
Hannover functional ability questionnaire to assess what they described as 
functional capacity. They concluded that women in their cohort tended to have 
lower functional capacity at baseline and after 12 months, however the differences 
between the gender groups were small and not statistically significant (scores for 
women at baseline 65 (95% CI 63.5, 66.5) and at 12 months 69.3 (95% CI 67.6, 
71.1) vs men at baseline 70.7 (95% CI 68.9, 72.6) and at 12 months 78.2 (95% CI 
76.3, 80.1)), p=0.886.  
 
Evidence for the association between gender and treatment effect for back pain 
comes from a study conducted by George et al (2006) who concluded that for 
patients with acute low back pain, there was no difference in pain and disability 
outcomes between males and females assessed four weeks after starting 
physical therapy treatments. I am not aware of a study that assessed the direct 
association between gender and symptom progression for NSLBP. 
 
6.5.2.b Duration of LBP  
The finding that trial arms with patients with shorter duration back pain show 
larger symptom progressions than patients with longer duration was not 
unexpected. The historical classification of back pain according to its duration 
remains in use in clinical guidelines on management options, indicating varying 
prognosis depending on its duration. Observational studies also showed the 
important role of pain duration in the clinical course of back pain (Hestbaek et al 
2003, Pengel et al 2003). These studies show that patients with shorter duration, 
132 
 
more recent or acute LBP, are more likely to show improvement in symptoms 
compared with patients with longer duration or chronic LBP. 
 
6.5.2.c Type of treatment 
The finding that responses in trial arms were not associated with type of treatment 
(index, active comparator, placebo, usual care, waiting list and pharmacological or 
non-pharmacological) confirms the observation in the systematic review 
presented in Chapter Four that the pattern of responses in trial arms was similar 
regardless of the type of treatment.  
 
However, the number of trial arms in some groups was small which might have 
compromised the ability to detect any association between types of treatment and 
response. Also, treatments were classified according to general types rather than 
to particular types of treatments such as acupuncture, manual therapies, NSAIDs 
or exercise. As within-arm responses studied here represent both the specific 
effects of the treatment and the context effect, variation between the overall 
responses might have been explained, partly, by effects of specific types of 
treatments such as those mentioned above, however small or modest they might 
be. However, two important points needs to be stated here to address this issue. 
Firstly the objectives of the study were not intended to prove the lack of specific 
effect of treatments for NSLBP. In fact one of the main intentions for this study 
and the whole thesis was the supposition that RCTs do not seem to be able to 
provide a clear evidence for the specific effects of treatments not necessarily 
because of the lack of such an effect but because of the large size of the context 
effect. Secondly, this study was not designed to study a particular treatment. As 
will be mentioned later in this chapter, and is pointed out in Chapter Six and 
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Chapter Seven, studying the effects of non-specific factors in groups of trials on 
particular treatments, adopting a similar approach to this thesis’, would address 
the issue discussed here but with objectives that would be different from those of 
this thesis.  
 
Beyond the significance of the associations with types of treatments, it is 
interesting to note that responses in usual care and waiting list arms were (albeit 
not significantly) larger than those in index and active comparator arms. This 
seems to be counterintuitive as the expectation would be that response to the 
index treatment should be larger as a result of the specific treatment effects. 
However, usual care and waiting list participants, although not provided with the 
trial treatment (no-treatment arm), are in fact free to use and have access to any 
active treatment available. Although the types of treatments used by participants 
in the ‘usual care’ arm are rarely recorded, some of these treatments might be 
similar in effect or even superior to some of the index treatments used in the trials 
(Somerville et al 2008). This might explain the findings related to the size of 
response in these treatment arms. However, this is an indirect comparison 
between different types of treatments, directed more towards specific effects of 
treatment, which of course is not the objective of this thesis.  
 
6.5.2.d Trials’ quality 
It has been suggested that treatment ‘effects’ estimated in poor quality trials could 
be an under or over-estimation of the ‘true’ treatment effect and some studies 
have shown that trial’s quality can influence treatment ‘effect’ size (Schulz et al 
1995, Elliott et al 1999, Smith et al 1999), although this has been contradicted by 
others (Moher et al 1998, Kunz & Oxman 1998, Balk et al 2002, Verhagen et al 
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2001). I am not aware of any study that examined the association between quality 
and within-arm symptom progression in back pain trials.  
 
It is important for any comparison between these findings and findings of other 
studies to be interpreted within the context of the quality assessment process that 
was used in this thesis which might be different from the assessment used in 
other studies. The evidence from this study for the association between overall 
trial quality and within-arm responses to treatment was limited. The problems and 
caveats associated with using the quality summary score approach were 
addressed and discussed in Chapter Five. It is therefore difficult to draw solid 
conclusions on the association between response and trial overall quality.  
 
6.5.2.e Individual quality criteria 
In this thesis, adequacy of patient blinding (for pain and RMDQ), compliance (for 
pain) and drop-out rate (for RMDQ) were found to be associated with responses 
to treatments. It is interesting to also note that although the association with the 
other criteria were not significant, the direction was similar. When these criteria 
were satisfied this was associated with larger within-arm responses to treatments.  
 
Some studies have found that treatment ‘effect’ was larger when patient blinding, 
as well as other quality criteria, was inadequate (Schulz et al 1995, 1996, Moher 
et al 1998). The explanation for those findings was assumed that when 
participants knew whether they received active or ‘inactive’ treatment they 
responded accordingly and the difference between the two groups was large 
(large effect size on a trial level). However, this is different in this thesis where 
within-arm responses to treatments were studied. Adjusting patient blinding for 
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type of treatment did not change the significant association, suggesting that it was 
independent of the type of treatment.  
 
The issue of patient blinding is about patient’s ‘knowing’ (or not) what type of 
treatment he is receiving. To correctly interpret the influence of this ‘knowing’ on 
symptom progression, it would be important to understand patients expectations 
from that treatment, any prior preference to a particular treatment, beliefs 
regarding the treatment and previous use of or experience with the treatment. 
Data on these factors were not available from a sufficient number of included trials 
to explore their influence. 
 
The majority of the trials included non-pharmacological treatments (e.g. exercise, 
manipulation, osteopathy, psychotherapy, heat wraps) in which it is widely argued 
that it is very difficult and might be impossible to successfully blind patients or 
practitioners (Black 1996, Boutron et al 2003, 2004). However it has been 
recommended that even if blinding is not feasible, inadequate blinding can be a 
source of potential bias in a trial (van Tulder 2003). In the results presented in 
Chapter Five, patient blinding was judged adequate in 80% of trials on 
pharmacological interventions and in 12% of non-pharmacological trials. This 
indicates that in the majority of trials included in the review the treatments were 
mostly active, non-pharmacological and blinding was mostly inadequate and 
factors such as expectations, preference and previous use of treatment may have 
influenced responses in these arms. 
 
Adequacy of compliance was also associated with larger symptom progression. 
Adjusted for the type of treatment, the significance of the association did not 
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change suggesting that better compliance was associated with larger responses 
regardless of the type of treatment used. Again the attention needs to be drawn to 
the large difference in the number of arms in the comparison groups. As was 
mentioned in the previous chapter, information on this criterion was available in 
54% of the included trials and in the majority of the trials (45% of all included 
trials) this was satisfied. Assuming this is sufficient evidence, it might reflect a 
characteristic of compliant individuals showing larger symptom progressions. It 
might reflect their expectation regarding the treatment or their satisfaction with the 
treatment. On the other hand, compliance might in fact be a reflection of the 
participants experiencing (or not) benefit from the treatment i.e. those who 
experience benefit (large symptom progression) would of course continue using 
the treatment (positive compliance) and those who did not experience benefit 
(small symptom progression) would discontinue (poor compliance). Completing 
the missing information in trials published reports and having larger number of 
arms in the groups might help clarify some of these issues. Alternatively, it might 
also mean that better compliance actually leads to better (specific) effects of 
treatment. 
 
 
6.6 Limitations 
 
Some of the characteristics analysed in this chapter can be described as “true” 
trial characteristics (Schmid et al 2004) that apply equally to all participants within 
a trial or within a trial arm with no differences between participants, such as type 
of treatment or trial quality. Other characteristics although provided at trial level 
are in fact properties of individual participants and have different values among 
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participants, and are aggregated and presented at a trial level as a summary 
mean of the individual values. These patient level characteristics, such as age, 
gender, severity or duration of pain, are therefore not “true” trial characteristics. 
One caveat associated with using aggregated data is the lack of power to detect 
association of patients’ characteristics with outcome. What does this mean is that 
when a significant association is found through this analysis it is likely that it is an 
important and underestimated association. However, the fact that the findings 
might be biased is important to consider, as outlined below.   
 
The use of aggregated data may yield biased results when associations are 
detected that are not present within the individual study samples, or actual 
associations are missed in the aggregated data (ecology fallacy or aggregation 
bias (Thompson & Higgins 2002). However, Schmid et al (2004), in a study to 
assess the utility of meta-regression in exploring the association between effects 
of treatment and trials’ and patients’ characteristics, concluded that in the absence 
of individual patients data, aggregated data could be used for this purpose with 
proviso that results are interpreted with caution and not generalised or applied to 
all patients.  
 
It is important to pre-select or specify covariates or determinants based on a pre-
analysis plan. Trials’ characteristics were preselected for this analysis to explore 
their association with responses to treatment. Due to the small number of trials 
providing information on some characteristics, multivariable analyses were 
restricted to include only two potential confounders and selected only a limited 
number of determinants to prevent data dredging.  
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The choice of determinants depended on the available data from the included 
trials. Determinants that would have been of interest and on which data were not 
widely available from the trials in the review include whether the treatment was 
provided in a public or private sector, the skills and expertise of the practitioners, 
whether the treatment was provided individually or in a group (e.g. exercises), 
patients’ expectations and preferences to treatment.  
 
The number of trial arms was sufficiently large for duration of pain, age, gender 
and trials overall quality. However, it was small for the type of treatments and 
some of the individual quality criteria.  
 
To facilitate analysis, the continuous variables of age, percentage of females and 
duration of pain were dichotomised. It is suggested that the simplicity achieved 
through this is gained at the cost of loss of power and residual confounding 
(Royston et al 2006). It would be ideal for continuous variables to be entered in 
the analysis as continuous. However, it was judged for this thesis that the 
dichotomisation approach is adopted for the gain of being able to conduct more 
interpretable analyses. 
 
 
6.7 Summary 
 
There is evidence for significant associations between non-specific factors 
represented by trial characteristics and symptom progressions for non-specific low 
back pain such as age, gender, duration of pain, adequacy of patient blinding, 
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compliance and overall quality of the trial. The types of treatments did not 
contribute to the variation in responses. 
 
These findings would explain some of the variation found in Chapter Four in the 
size of responses to treatments in clinical trials. Most of the variation remained 
unexplained which suggests that other unidentified non-specific factors may 
influence overall symptom progression.  
 
To examine the association between responses to treatments and patient level 
characteristics, individual patient data (IPD) would be the basis for a more 
powerful analysis. This was conducted and the outcome is presented in Chapter 
Seven. 
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Chapter Seven 
 
 
Factors associated with responses to 
treatments for low back pain:   
analysis of individual patient data (IPD) 
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7.1 Introduction  
 
In Chapter Six trial characteristics were studied as possible source of 
heterogeneity in responses to treatments, using the aggregated data (AD). Some 
characteristics were characteristics of the participants (e.g. age, gender, duration 
of pain) aggregated at trial level. Using individual participant or patient data (IPD) 
analysis is the ideal method to confirm the association between such 
characteristics and responses to treatments (Lambert et al 2002). This was the 
first reason to carry out the analysis reported in this chapter.  
 
The opportunity of using IPD was also taken to examine patient characteristics for 
which sufficient information was not available in the published trials included in the 
systematic review. Examples of these include patient expectation regarding 
helpfulness of treatment and patient preference for treatments. The importance of 
these characteristics, among other non-specific factors, was identified in a 
consensus study (Chapter Three) conducted among researchers who participated 
in a workshop during the International Low Back Pain Forum X meeting, held in 
Boston, USA in 2009. Patient expectations and preference for treatments were 
among 30 non-specific factors considered to be most influential on symptom 
progressions for low back pain (Box 3 Chapter Three).  
 
Using IPD presents the potential for pooling data from multiple trials enabling 
more powerful statistical analyses. This is different from pooled analysis using AD 
as data at individual patient level are used to estimate the associations between 
non-specific factors and individual symptom progression within trials before 
pooled estimates are calculated.  
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IPD systematic reviews and meta-analyses were introduced in the nineties to 
satisfy the need for applying scientific evidence from clinical trials to individual 
patients. They are considered the gold standard source of data for collating and 
synthesizing evidence from clinical trials (Stewart & Clarke 1995, Simmonds et al 
2005), superior to AD although the latter constitutes the basis for the vast majority 
of systematic reviews. The reason for the rarity of IPD systematic reviews and 
meta-analyses is that, compared with using AD, the whole process of using IPD, 
from obtaining the data to statistical analysis, requires more time and resources 
(Lambert et al 2002, Simmonds et al 2005, Riley et al 2010).  
 
 
7.2 Objectives 
 
The objective was to use individual patient data from randomised clinical trials to 
explore the influence on within-arm symptom progression of the following patient 
characteristics in terms of changes in pain and disability: 
1. Age, gender, pain duration and history of back pain. 
2. Expectations regarding helpfulness of treatment and preference for 
treatment. 
 
7.3 Methods 
 
7.3.1 Searching and selecting datasets 
A systematic on-line search of Medline, EBSCO and the Cochrane CENTRAL 
database was conducted. This search was broader than the search conducted for 
the systematic review presented in Chapter Four, to enable the identification of 
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more recent trials and trials that could provide the data relevant for this IPD 
analysis.  
 
7.3.1.a Criteria for inclusion 
Included were randomised clinical trials among patients with non-specific low back 
pain published in the 10 years immediately prior to the year of the study, 2010. 
 
7.3.1.b Participants and setting 
Trials conducted among adult patients (aged 18 + years) consulting primary care 
services with non-specific low back pain that included data on the potential non-
specific factors of outcome expectation and/or preference for treatments.  
 
7.3.1.c Outcome measures 
Outcome measures of interest were pain intensity (on VAS or similar, converted to 
0-100 scale) and functional disability (RMDQ, ODI).  
 
7.3.1.d Contacting authors 
Clinical trials that met the inclusion criteria were identified and corresponding 
authors contacted, introducing the study and summarising the background, aims, 
objectives and the variables of interest. Authors who declared interest were sent 
the study protocol. Specific data request forms were completed and databases 
obtained either in SPSS, STATA or Excel format. Subsequent communications 
were made to clarify various issues in the obtained databases such as missing 
variables, definitions of variables and to clarify variable names and codes.  
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7.3.2 Analysis 
Obtained databases were processed, prepared and analysed using SPSS 18 and 
STATA IC 11 software for Windows.  
 
7.3.2.a Data preparation: 
Relevant variables were identified and definitions and measurement scales 
checked. Variables were re-coded for uniformity across trials (e.g. gender: 0 male, 
1 female). Some variables were dichotomised to facilitate analysis e.g. age was 
dichotomised around the mean age of all included trial populations.  
 
7.3.2.b Factors influencing responses to treatments 
Factors selected to assess their influence on symptom progressions included 
factors that had been shown to be of importance based on the analysis of AD 
presented in Chapter Six (i.e. patients socio-demographic characteristics e.g. age, 
gender, duration of current episode and treatment allocation). Also included were 
factors of patients’ expectations regarding treatment and preference for treatment 
and history of back pain for which available AD was not sufficient to include in the 
meta-regression analysis.  
 
For duration of current episode of back pain, data from all trials were 
dichotomised around 12 weeks. This is the commonly accepted cut off to 
distinguish between acute/subacute and chronic back pain and was adopted for 
the meta-regression analyses in the previous chapter. For history of back pain, 
participants were dichotomised into those with presence or absence of history of 
back pain.  
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7.3.2.c Expectations and preferences  
Data on expectations regarding helpfulness of treatments were prepared to 
enable studying the influence of these characteristics on symptom progression. 
Expectation data were dichotomised into low and high expectation. Low 
expectation represented the low or negative half of the scale, e.g. 0-5 on 0-10 
VAS scale, 0-2 on 0-5 scale and ‘not helpful’ on the other scales. High expectation 
represented the high or positive half of the scale, e.g. 6-10 on 0-10 VAS, 3-5 on 0-
5 scale and ‘expect helpful’, ‘very helpful’ and ‘yes’ on the other scales. 
 
A new variable for expectation was then created: among those who received a 
particular treatment, those who had low expectation for it vs those who had high 
expectation. 
 
For the characteristic of preference for treatment, the influence of merely having a 
preference was studied. A new variable was created: those who did not have a 
preference (e.g. ‘did not know’, ‘did not mind’) versus those who did, regardless of 
the preference. A further new variable was created to study the influence on 
symptom progression of whether preference for a particular treatment was 
satisfied (by being allocated to the preferred treatment) or not. That is, among 
those who expressed a preference: those who were allocated to their preferred 
treatment vs those who were not. Those who did not have a preference were not 
included in this second variable. 
 
7.3.2.d Examining the influence of factors on responses to treatments 
The selected patient characteristics mentioned above were included in all 
analyses. Independent samples t-tests were performed to test the difference in 
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mean symptom progressions according to the selected non-specific factors. 
Associations were then adjusted for age, gender, duration of current episode of 
back pain and history of back pain using linear regression analyses. 
 
In line with the main objective of this thesis of examining associations with 
symptom progression within-arm rather than with between-arm treatment effect, 
the influence of non-specific factors was analysed at the level of treatment arm. 
The interest in these associations was regardless of the type of treatment, i.e. 
index, active comparator or control treatment. Therefore all analyses were 
performed separately for each treatment arm in each trial. 
 
7.3.2.e Pooling data from multiple trials 
IPD from the included trials was assessed for comparability of the dependent and 
independent variables and follow up times to assess the feasibility of pooled 
analyses. RMDQ was the outcome most commonly used in the trials and was 
therefore used for the pooled analyses. The follow up time points of 13, 27 and 52 
weeks were used as these were the most common follow-up periods across the 
trials and are similar to the time points used in the meta-regression analyses of 
the previous chapter.  
 
Adopting a two-stage approach (Simmonds et al 2005), within-arm differences in 
symptom progressions (mean difference, 95% confidence intervals), according to 
the selected patient characteristics, were computed for each individual trial arm 
(stage 1, using adjusted analyses described above) and then pooled and 
analysed using standard meta-analysis methods described in Chapter Four (stage 
2).  
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To assess the potential cluster effect of within-arm responses in each trial on the 
associations of factors with responses to treatments, sensitivity analyses were 
then performed. This was performed by extending stage 2 to a multivariable meta-
regression analysis with the trials as an independent variable 
 
 
7.4 Results  
 
Thirteen trials met the inclusion criteria. Three authors declined the invitation to 
provide data and responses were not received from four authors. IPD was 
successfully obtained for six trials published in the period 1999 – 2007 (Table 
7.1).  
 
Trial sample size ranged from 186 in the Moffett et al trial to 1334 in the UK BEAM 
trial with arm sample sizes ranging from 80 for usual GP care in the Thomas et al 
trial, to 353 for manipulation in the UKBEAM trial. Three trials included two arms 
(Hay et al, Johnson et al and Thomas et al), one included three arms (Heymans) 
whereas the UK BEAM trial investigated four types of treatments and also used 
two types of setting (private and NHS) for one of its treatments (manipulation).  
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Table 7.1  Descriptive summary of trials included in IPD analyses 
 
 
 
 
Trial 
 
 
 
Population type / 
setting 
 
 
 
 
Treatments 
 
 
Age, year 
Mean 
(SD) 
 
 
 
Female 
% 
 
Pain 
baseline 
VAS, 0-100 
Mean (SD) 
 
 
RMDQ 
baseline 
Mean (SD) 
 
Duration 
of LBP 
episode 
<1m (%) 
 
 
History of 
LBP 
Yes (%) 
 
 
 
Employment 
Yes (%) 
          
Hay et al, 
2005, UK 
Primary care 
consulters with LBP, 
UK 
-Manual physiotherapy 
-Brief pain management 
41 (11.8) 48 55.6 (23.1) 13.53 
(4.85) 
74 74 50 
Heymans et 
al, 2006, 
Netherlands 
Workers sick-listed for 
LBP and who visited 
occupational 
physician, The 
Netherlands 
 -High intensity back school 
-Low intensity back school 
-Usual occupational therapy 
40 (9.8) 21 65.8 (18.0) 8.62 (4.42) 33 81 100 
Johnson et 
al, 2007, UK 
Primary care 
consulters with LBP, 
UK 
-Community-based treatment 
program, consisting of eight 
2-hour group sessions over a 
6-week period. Each group 
comprised between 4 and 10 
participants and was led by 2 
physiotherapists.  
-Back pain educational 
booklet and usual GP care. 
48 (11.2) 60 48.3 (20.9) 10.76 
(3.93) 
46 - 77 
Moffett et al, 
1999, UK 
Primary care 
consulters with LBP, 
UK 
-Exercise program 
-Routine GP care 
42 (8.9) 43 - 6.08 (4.00) 9 78 85 
Thomas et 
al, 2006, UK 
Primary care 
consulters with LBP, 
UK 
-Acupuncture 
-Usual care a 
42 (10.7) 61 - 32.93b 
(15.03) 
- 84 79 
UK BEAM 
team, 2004 
Primary care 
consulters with LBP, 
UK 
-Best GP care 
-Exercise 
-Manipulation 
-Combined exercise & 
manipulation 
43 (11.2) 56 - 9.02 (4.02) 7 68 73 
          
 a Comprised a mixture of interventions including physiotherapy, manipulation, drugs and back exercises. b: ODI outcome 
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Age of participants ranged from a mean of 40 years (SD 9.8) in the Heymans et al 
trial, to 48 years (SD 11.2) in the Johnson et al trial, mean age across all trials 
was 43 years. Percentage of females ranged from 21% in the Heymans et al trial 
to 61% in the Thomas et al trial. 
 
7.4.1 Symptom progression  
Five trials used the RMDQ, three of these also used pain intensity outcome 
(VAS). One trial (Thomas et al.) used the ODI only. Mean responses to treatment 
on the RMDQ were calculated for the five trials within each trial arm (Appendix 
7.1).  
 
7.4.2 The influence of non-specific factors on symptom progression  
Table 7.2 shows patients’ characteristics that were selected to assess their 
influence on symptom progression. Data on age and gender were available from 
all trials; on history of LBP and duration of present episode of back pain from five 
trials; on expectation of helpfulness of treatment from four trials and on treatment 
preference from three trials.  
 
The results of unadjusted and adjusted within-arms analyses of the associations 
between pre-selected characteristics and responses to treatments are outlined 
below. These findings will now be described in detail. For each selected 
characteristic, the results of within-arm analyses will be outlined followed by the 
results of the pooled analyses. Appendix 7.2 shows the results for the Thomas et 
al trial using ODI.  
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Table 7.2  Characteristics included in analyses to assess their influence on 
responses to treatment 
 
UKBEAM 
 
Hay et al 
Heymans et 
al 
 
Johnson et al 
 
Moffett et al 
 
Thomas et al 
      
Age Age Age Age Age Age 
Gender Gender Gender Gender Gender Gender 
History of 
LBP 
History of LBP History of LBP  History of LBP History of LBP 
Duration of 
LBP 
Duration of 
LBP 
Duration of 
LBP 
Duration of 
LBP 
Duration of 
LBP 
 
   Presence of 
preference for 
treatment 
Presence of 
preference for 
treatment 
Presence of 
preference for 
treatment 
   Satisfaction of 
preference for 
treatment 
  
Helpfulness of 
treatments 
 Helpfulness of 
treatments 
 Belief in 
effectiveness 
of index 
treatment 
Expectation 
re- 
acupuncture 
      
 
 
 
 
7.4.2.a Gender 
Within-arm adjusted analyses showed that for pain and RMDQ (Table 7.3a, b) the 
evidence for the associations was weak and not consistent and the direction 
varied even within one trial (Heymans et al). The association was significant in 
three arms of two trials for RMDQ and only one arm for pain.  
 
The results of the pooled analyses (Table 7.12) (13 arms, 2455 patients) did not 
show significant association between gender and symptom progressions for 
RMDQ for the selected follow up times. However, the direction of the associations 
(not statistically significant) suggests that men were more likely to have larger 
symptom progressions than women. The size of the difference in response 
ranged from 0.26 (95% CI -0.31, 0.84) at 13 weeks to 0.57 (95% CI -0.66, 1.81) at 
27 weeks. 
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Table 7.3a  Within-arm difference in the change in outcome scores (mean, 95% CI) according to gender (males compared with females) for pain intensity (0-100 VAS). Positive results indicate  
larger improvement in pain. 
 
  13weeks  27weeks  52weeks 
 n Unadjusted Adjusted n Unadjusted Adjusted n Unadjusted Adjusted 
          
Hay et al 2005          
   -Manual physiotherapy 82:66 -3.53 (-12.50, 5.43) -4.44 (-13.42, 4.55)     91:70 3.02 (-6.06, 12.09)  3.70 (-5.55, 12.87)  
   -Brief pain management 79:68 -3.84 (-13.45, 5.76)  -3.76 (-13.51,10.0)     88:72 1.81 (-7.99, 11.61)  2.16 (-7.74, 12.06)  
Heymans et al 2006          
   -Occupational health care 62:15 -3.0 (-14.2, 13.6)  -3.8 (-17.2, 9.6) 61:12 -0.9 (-17.9, 16.0)  -3.1 (-20.9, 14.8) 67:17 -1.9 (-16.6, 12.8) -1.0 (-18.3, 14.3)  
   -Low intensity back school 52:15 -9.2 (-25.1, 6.8)  -8.5 (-24.7, 7.7)  49:16 -2.8 (-18.7, 13.0) -2.4 (-17.6, 12.8)  64:19 -14.3 (-28.8, 0.2) -15.0 (-29.2, -0.8)  
   -High intensity back school 50:18 7.0 (-3.2, 24.5)  10.2 (-0.41, 24.4)  45:17 -1.7 (-18.5, 15.1)  -3.1 (-20.3, 14.1)  52:16 -0.0.2 (-2.0.3, 1.9.9)  0.1.2 (-1.6.8, 1.9.3) 
Johnson et al 2007          
   -Physiotherapist led community- 
    based treatment program 
41:69 0.57 (-8.79, 9.93)  0.47 (-9.01, 9.95)  41:64 6.91 (-2.39, 16.02)  6.20 (-3.19, 15.59)  38:64 0.51 (-10.47, 11.49)  -0.11 (-11.23,11.44)  
   -Back pain educational booklet  
    and usual GP care 
47:66 1.63 (-7.86, 11.12)  1.38 (-8.24, 10.99)  40:58 10.36 (-0.84, 21.56)  10.40 (-0.86, 21.66)  37:57 9.56 (-1.60, 20.72)  9.41 (-1.78, 20.60)  
          
n number of males versus females. Underlined indicates significant p<0.05 
 
 
 
 
 
 
Table 7.3b  Within-arm difference in the change in outcome scores (mean, 95% CI) according to gender (males compared with females) for RMDQ. Positive results indicate larger improvement in function. 
 
  13weeks  27weeks  52weeks 
 n Unadjusted Adjusted n Unadjusted Adjusted n Unadjusted Adjusted 
          
Hay et al 2005          
   -Manual physiotherapy 89:73 -0.27 (-2.16, 1.61) -0.44 (-2.20, 1.41)    93:72 0.55 (-1.35, 2.44)  0.77 (-1.13, 2.68)  
   -Brief pain management 33:74 0.53 (-1.57, 2.63) 0.49 (-1.62, 2.60)     88:76 1.96 (0.00, 3.91)  1.87 (-0.06, 3.81)  
Heymans et al 2006          
   -Occupational health care 62:15 1.97 (-3.91, 7.85)  1.28 (-4.52, 7.08)  59:12 2.24 (-3.80, 8.28)  2.03 (-3.86, 7.93)     67:17 4.25 (-0.69, 9.20)  4.74 (-0.36, 9.84)  
   -Low intensity back school 55:15 -6.19 (-10.75,-1.63) -5.56 (-10.04,-1.07)  51:17 -3.55 (-8.28, 1.18)  -3.40 (-8.13, 1.33)  65:19 -3.56 (-8.05, 0.93)  -3.31 (-7.81, 1.19)  
   -High intensity back school 51:17 3.61 (-1.13, 8.35)  3.92 (-0.94, 8.77)  46:16 1.72 (-2.61, 6.05)  1.62 (-2.89, 6.14)  53:15 4.02 (-0.67, 8.72)  4.01 (-0.79, 8.81)  
Johnson et al 2007          
   -Physiotherapist led community-  
    based treatment program 
41:69 2.09 (0.31, 3.86)  1.92 (0.11, 3.72)  41:64 2.02 (0.29, 3.75)  1.74 (0.00, 3.47)  39:63 1.95 (-0.25, 4.14)  1.56 (-.68, 3.80)  
   -Back pain educational booklet   
    and usual GP care 
47:66 -1.09 (-2.84, 0.65)  -1.07 (-2.85, 0.70)  40:58 0.15 (-1.80, 2.11)  0.16 (-1.80, 2.13)  37:57 0.38 (-1.64, 2.40)  0.33 (-1.67, 2.34)  
Moffett et al 1999          
   -Exercise program 50:35 1.09 (-0.47, 2.64)  1.11 (-.47, 2.70)  46:31 1.99 (-0.14, 4.11)  1.97 (-0.19, 4.13)  50:33 1.97 (0.05, 3.88)  1.95 (-0.02, 3.91)  
   -Routine GP care 53:41 -0.14 (-1.71, 1.43)  -0.14 (-1.74, 1.46)  50:36 -.85 (-1.84, 1.13)  -1.04 (-3.03, 0.95)  51:37 -0.34 (-2.18, 1.49)  -0.36 (-222, 1.50) 
UKBEAM 2004          
   -Best GP care 114:142 0.64 (-0.44, 1.73)  0.61 (-0.51, 1.72)     105:142 -0.57 (-1.74, 0.61)  -0.57 (-1.80,0.66)  
   -Exercise 93:132 0.01 (-1.09, 1.12)  0.10 (-1.10, 1.30)     92:124 -0.46 (-1.63, 0.71)  -0.75 (-1.98, 0.47)  
   -Manipulation 108:179 0.18 (-0.97, 1.33)  0.11 (-1.16, 1.38)     104:169 -0.49 (-1.73, 0.75)  -0.60 (-1.96, 0.75)  
   -Combined exercise &  
    manipulation 
111:147 0.41 (-0.65, 1.46)  0.33 (-0.86, 1.52)     109:148 0.10 (-1.04, 1.24)  -0.26 (-1.51, 1.00)  
          
n number of males versus females. Underlined indicates significant p< 0.05 
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The conclusion with regard to gender is that the evidence, weak and inconsistent 
as it is, seems to suggest a larger improvement in function (RMDQ) for men 
compared with women. 
 
7.4.2.b Age 
Within-arm adjusted analyses for both pain intensity and RMDQ (Table 7.4a&b) 
did not show evidence for a significant influence of age on symptom progressions 
apart from one treatment arm and at one follow up point (occupational healthcare 
arm, RMDQ at 27 weeks). The direction of the associations between age and 
responses to treatments was not consistent across treatment arms and trials. 
 
When data for RMDQ from the five RCTs (13 arms, 2455 patients) were pooled, 
there was similarly no evidence for a significant influence of age on the pooled 
symptom progressions of included trials at the selected follow up times (Table 
7.12) However, the direction of the non-significant differences in responses was 
the same in all follow up points in favour of younger patients suggesting that 
patients younger than 43 year old were more likely to show larger improvement in 
function (RMDQ) than older patients. The differences ranged from 0.17 (95% CI -
0.28, 0.61) at 13 weeks to 0.45 (95% CI -0.80, 1.70) at 27 weeks.  
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Table 7.4a  Within-arm difference in the change in outcome scores (mean, 95% CI) according to age (younger compared with older than 43 years) for pain intensity (0-100 VAS).  
Positive results indicate larger improvement in pain.  
 
  13weeks  27weeks  52weeks 
 n Unadjusted Adjusted n Unadjusted Adjusted n Unadjusted Adjusted 
          
Hay et al 2005          
   -Manual physiotherapy 86:62 1.40 (-7.65, 10.45) -0.51 (-9.79, 8.78)  -  92:69 -4.96 (-14.03, 4.10) -4.83 (-14.19, 4.53) 
   -Brief pain management 80:67 -0.24 (-9.88, 9.40) -0.22 (-9.94, 9.51)  -  88:72 -2.41 (-12.21, 7.39) -2.22 (-12.09, 7.65) 
Heymans et al 2006          
   -Occupational health care 37:40 -2.3 (-13.3, 8.7) -5.3 (-15.9, 5.4) 32:41 -1.0 (-13.7, 11.6) -2.9 (-15.8, 10.1) 41:43 -0.3 (-12.1, 11.5) -0.6 (-13.0, 11.8)  
   -Low intensity back school 39:28 2.9 (-10.7, 16.5) 1.5 (-12.9, 15.9) 35:30 9.1 (-4.5, 22.6) 8.5 (-4.7, 21.7) 45:38 7.8 (-4.5, 20.2) 8.3 (-3.9, 20.6)  
   -High intensity back school 39:29 -1.3 (-13.9, 11.3) -1.6 (-14.8, 11.6) 33:29 -9.1 (-23.9, 5.8) -11.3 (-27.4, 4.8) 37:31 1.8 (-12.8, 16.4) 1.0 (-14.6, 16.7)  
Johnson et al 2007          
   -Physiotherapist led community- 
    based treatment program 
41:69 -7.29 (-16.54, 1.97) -7.29 (-16.67, 2.09) 40:65 -3.80 (-13.11, 5.52) -3.86(-13.19,5.46) 37:65 -2.35 (-13.38, 8.69) -2.57 (-13.86, 8.71)  
   -Back pain booklet & usual GP care 35:78 3.99 (-6.11, 14.08) 3.78 (-6.43, 13.99) 27:71 7.37 (-5.08, 19.81) 7.45 (-5.0, 19.88) 26:69 6.02 (-6.30, 18.33) 5.38 (-6.95, 17.71)  
          
          
n number in the younger versus older groups 
 
 
 
 
 
Table 7.4b  Within-arm difference in the change in outcome scores (mean, 95% CI) according to age (younger compared with older than 43 years) for RMDQ. Positive results indicate larger  
improvement in function.  
 
 
  13weeks  27weeks  52weeks 
 n Unadjusted Adjusted n Unadjusted Adjusted n Unadjusted Adjusted 
          
Hay et al 2005          
   -Manual physiotherapy 96:66 0.38 (-1.53, 2.28) 0.01 (-1.87, 2.07)  -  93:72 0.30 (-1.59, 2.19)  0.37 (-1.58, 2.32)  
   -Brief pain management 86:71 0.78 (-1.32, 2.88) 0.72 (-1.40, 2.84)  -  90:74 0.18 (-1.80, 2.15)  0.47 (-1.47, 2.42)  
Heymans et al 2006          
   -Occupational health care 37:40 3.06 (-1.56, 7.68) 2.77 (-1.83, 7.36) 32:39 5.36 (0.98, 9.74)  5.01 (0.65, 9.37)  42:42 3.07 (-0.92, 7.06)  3.37 (-0.75, 7.48)  
   -Low intensity back school 41:29 -4.97 (-8.78, -1.15)  -3.99 (-7.91, 0.07) 35:33 -2.49 (-6.61, 1.63)  -2.01 (-6.16, 2.14)  45:39 -3.39 (-7.14, 0.36)  -2.98 (-6.83,0.87)  
   -High intensity back school 37:31 1.81 (-2.36, 5.98)  2.26 (-2.12, 6.64) 32:30 -0.77 (-4.58, 3.04)  -0.58 (-4.74, 3.58)  36:32 -1.28 (-5.25, 2.69)  -1.29 (-5.40, 2.82)  
Johnson et al 2007          
   -Physiotherapist led community-  
    based treatment program 
41:69 -0.71 (-2.53, 1.10)  -0.78 (-2.56, 1.01) 40:65 -1.11 (-2.88, 0.66)  -1.18 (-2.90, 0.55)   36:65 -0.53 (-2.78, 1.72)  -0.74 (-2.98 1.50)  
   -Back pain educational booklet and     
    usual GP care 
34:78 0.56 (-1.32, 2.43)  0.54 (-1.35, 2.42)  27:71 1.29 (-0.85, 3.42)  1.30 (-0.87, 3.47)  26:68 1.16 (-1.03, 3.36)  0.94 (-1.27, 3.15)  
Moffett et al 1999          
   -Exercise program 45:40 0.40 (-1.15, 1.95)  0.42 (-1.17, 2.00)  41:36 0.90 (-1.23, 3.02)  0.73 (-1.43, 2.88)  42:41 0.11 (-1.82, 2.03) -0.16 (-2.10, 1.69) 
   -Routine GP care 44:50 0.62 (-0.94, 2.17)  0.58 (-1.04, 2.19)  40:46 0.89 ( -1.07, 2.86) 0.93 (-1.08, 2.94)  42:43 -0.11 (-1.92, 1.71) 0.04 (-1.84, 1.92)  
UKBEAM 2004          
   -Best GP care 112:130 0.93 (-0.15, 2.0)  0.65 (-0.46, 1.76)  -  111:123 1.05 (-0.10, 2.21)  0.86 (-0.36, 2.07)  
   -Exercise 91:125 -0.40 (-1.50, 0.69)  -0.44 (-1.63, 0.75)   -  81:125 -0.25 (-1.42, 0.93)  0.02 (-1.22, 1.26)  
   -Manipulation 127:158 -0.20 (-1.32, 0.92)  -0.31 (-1.55, 0.94)   -  114:157 -0.15 (-1.36, 1.06)  -0.13 (-1.47, 1.21) 
   -Combined exercise + manipulation 111:142 0.24 (-0.82, 1.29) 0.44 (-0.73, 1.61)   -  112:141 0.71 (-0.41, 1.84) 1.24 (-0.01, 2.47)  
          
n number in the younger versus older groups. Underlined indicates significant p<0.05 
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7.4.2.c Duration of current episode of back pain  
Measurements of duration of current episode of LBP varied across the five trials 
that provided data on this characteristic (Hay et al, Heymans et al, Johnson et al, 
Moffett et al & UKBEAM trials). The Hay et al trial was conducted among patients 
all with NSLBP of less than 12 weeks duration and therefore could not be included 
in this analysis.  
 
For pain intensity (Table 7.5a), the adjusted within-arm analyses based on the two 
trials that provided data on this outcome (Heymans et al & Johnson et al trials) 
showed significant influence of duration of current episode of back pain on 
symptom progressions in two arms (both from the Heymans et al trial) only and at 
single follow up times (Occupational healthcare treatment arm at 13 weeks, and 
low intensity back school at 52 weeks). The direction of these significant 
associations, similar to that of the majority of the non-significant associations, 
suggests that shorter duration was associated with larger symptom progression. 
 
For RMDQ (Table 7.5b), the adjusted association between duration and within-
arm response was significant in three separate arms from two trials: occupational 
healthcare arm in the Heymans et al trial, at 13 weeks and exercise and combined 
treatment arms of the UK BEAM trial at 52 weeks. The direction of these 
significant associations, similar to that of the vast majority of the other non-
significant associations, suggested that shorter duration was associated with 
larger responses to treatment.  
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Table 7.5a  Within-arm difference in the change in outcome scores (mean, 95% CI) according to duration of current episode of back pain (12 weeks or shorter compared with longer than  
12 weeks) for pain intensity (0-100 VAS). Positive results indicate larger improvement in pain. 
 
  13week  27week  52week 
 n Unadjusted Adjusted n Unadjusted Adjusted n Unadjusted Adjusted 
          
Heymans et al 2006          
   -Occupational health care 63:13 16.9 (2.9, 30.9) 16.4 (2.3, 30.4)  61:11 4.3 (-13.2, 21.8) 4.9 (-13.3, 23.2)  71:12 -7.4 (-24.3, 9.5) -7.2 (-24.6,10.2)  
   -Low intensity back school 60:7 17.1 (-4.5, 38.6) 17.0 (-5.4, 39.3)  56:9 22.6 (3.6, 41.6) 24.1 (5.0, 43.1) 74:9 19.7 (0.1, 39.2) 20.1 (0.9, 39.4)  
   -High intensity back school 60:8 3.8 (-15.5, 23.2) 2.7 (-17.7, 23.2)  52:10 6.7 (-13.7, 27.0) 13.1 (-8.9, 35.1)  56:11 9.0 (-10.9, 28.8) 11.8 (-9.8, 33.4)  
Johnson et al 2007          
   -Physiotherapist led community- 
    based treatment program 
72:38 -0.43 (-9.94,9.09) 0.13 (-9.55, 9.80)  69:36 3.97 (-5.56,13.50) 3.19 (-6.49,12.86)  68:34 1.27 (-9.99, 12.53) 1.63 (-10.11,13.37)  
   -Back pain educational booklet and  
    usual GP care 
64:49 3.14 (-6.29,12.56) 2.67 (-6.92,12.27)  53:45 0.76 (-10.48,12.0) 0.56 (-11.73,10.61)  51:43 5.92 (-5.13, 16.97) 4.88 (-6.21, 15.96)  
          
n number of those with duration of 12 weeks or less versus longer duration back pain. Underlined indicates significant p<0.05 
 
 
 
 
 
 
 
 
 
Table 7.5b  Within-arm difference in the change in outcome scores (mean, 95% CI) according to duration of current episode of back pain (12 weeks or shorter compared with longer than  
12 weeks) for RMDQ. Positive results indicate larger improvement in function. 
 
  13week  27week  52week 
 n Unadjusted Adjusted n Unadjusted Adjusted n Unadjusted Adjusted 
          
Heymans et al 2006          
   -Occupational health care 63:13 8.40 (2.43, 14.37) 7.97 (1.90, 14.04)  60:10 6.60 (0.30, 12.90) 5.91 (-0.31,12.13)  71:12 2.05 (-3.74, 7.84) 0.93 (-4.84, 6.71) 
   -Low intensity back school 63:7 2.43 (-4.11, 8.97) 2.22 (-3.99, 8.43)  59:9 3.81 (-2.26, 9.88) 3.36 (-2.71, 9.43)  75:9 0.62 (-5.55, 6.78) 0.36 (-5.75, 6.46)  
   -High intensity back school 60:8 0.77 (-5.71, 7.25) 0.15 (-6.71, 7.01)  52:10 -0.47 (-5.65, 4.70) -0.51 (-5.23, 5.21)  56:11 3.59 (-1.74, 8.93) 4.08 (-1.64, 9.81)  
Johnson et al 2007          
   -Physiotherapist led community-  
    based treatment program 
72:38 1.24 (-0.60, 3.08)  0.99 (-0.85, 2.83) 69:36 1.80 (0.01, 3.59) 1.59 (-0.20, 3.38)  67:34 1.13 (-0.18, 4.31) 1.84 (-0.48, 4.16)  
   -Back pain educational booklet and     
    usual GP care 
64:49 -0.16 (-1.91, 1.59) -0.70 (-1.84, 1.70)  53:45 0.00 (-1.93, 1.93) -0.14 (-2.09, 1.82)  51:43 1.60 (-3.53, 3.56) 1.47 (-0.52, 3.46)  
Moffett et al 1999          
   -Exercise program 53:32 0.29 (-1.31, 1.89) 0.35 ( -1.26, 1.96) 48:29 0.60 (-1.59, 2.79) -0.61 (-1.58, 2.79)  52:31 0.35 (-1.63, 2.33) 0.47 (-1.50, 2.44)  
   -Routine GP care 56:38 0.21 (-1.37, 1.80) 0.21 (-1.40, 1.83)  53:33 -1.60 (-3.59, 0.40) -1.71 ( -3.72,0.31)  53:35 -0.57 (-2.42, 1.27) -0.61 (-2.49, 1.27) 
UKBEAM 2004          
   -Best GP care 101:144 1.24 (0.15, 2.34) 1.10 (-0.04, 2.23)     98:140 0.87 (-.35, 2.08) 0.71 (-0.54, 1.95) 
   -Exercise 92:125 1.24 (0.12, 2.36) 1.20 (-0.01, 2.41)     86:122 2.46 (1.29, 3.63) 2.06 (0.82, 3.29) 
   -Manipulation 113:161 0.61 (-0.57, 1.78) 0.42 (-0.84, 1.68)     102:157 0.72 (-0.55, 1.99) 0.37 (-0.98, 1.72) 
   -Combined exercise + manipulation 97:145 1.17 (0.06, 2.28) 1.08 (-0.21, 2.22)     94:147 1.51 (0.33, 2.70) 1.36 (0.06, 2.66)  
          
n number of those with duration of 12 weeks or less versus longer duration back pain. Underlined indicates significant p<0.05 
156 
 
The results of the pooled analyses (Table 7.12) showed statistically significant 
influence of duration on symptom progression at 13 weeks (mean difference 0.76, 
95% CI 0.25, 1.27) and at 52 weeks (1.03, 95% CI 0.49, 1.57). Although the 
association was not significant at 27 weeks its direction was similar.  
 
The conclusion that could be drawn regarding duration of pain is that patients with 
back pain of 12 weeks or shorter duration were more likely to have larger 
improvement in function over time compared with patients with longer LBP 
duration.  
 
7.4.2.d History of back pain  
Information on history of back pain was available from five trials (only the Johnson 
et al trial did not provide such information). The scales used varied among trials 
(Table 7.6). In two trials (Hay et al & Heymans et al trials) information was 
provided on presence or absence of history of back pain (yes or no), in the other 
two trials (Thomas et al and UK BEAM trials) patients were asked to choose from 
the scale: ‘none’, ‘1-5’ or ‘>5’ episodes and in the Thomas et al trial, a choice of 
‘my pain never went away’ was included in a similar scale. In the Moffett et al trial, 
patients were given an open question about the number of previous back pain 
episodes they had.  
 
In spite of the variation in the scales, the data generally suggest that the vast 
majority of patients had a history of back pain (Table 7.6). In the three trials that 
provided data on the number of previous episodes (Thomas et al & UK BEAM 
trials), more than half of the patients had six or more previous episodes.  
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Table 7.6  Description of data on presence of history of back pain in included trials 
 
Trial Variable and scale n (%) 
    
Hay et al 2005 Previous history of LBP Yes  296 (74) 
No 106 (26) 
Missing 0 
Heymans et al 2006 Previous episodes of LBP 
 
Yes 243 (81) 
No 46 (16) 
Missing 10 (3) 
Moffett et al 1999 Number of previous episodes 
of LBP 
Open question Range 0-9, mean 2 
Thomas et al 2006 Previous history of LBP 1=None 38 (16) 
2=1-5 episodes 80 (34) 
3=More than 5 
episodes 
121 (51) 
4=My pain never 
went away 
0 
UKBEAM 2004 Number of previous episodes 
of LBP 
0=None 174 (13) 
1=1-5 episodes 346 (26) 
2=6-10 episodes 185 (14) 
3=More than 10 
episodes 
510 (38) 
  Missing 119 (9) 
    
 
 
Within-arm adjusted analyses for pain and RMDQ (Table 7.7a, b) showed that the 
association was significant only in one arm (best GP care, control arm, of the UK 
BEAM et al trial) for RMDQ and only at 52 week follow up. Patients of this trial 
who had no history of back pain showed smaller response to the best GP care 
than those who had history of back pain (mean difference in response on RMDQ 
1.92 (95% CI 0.19, 3.66)). The direction of the associations was inconsistent in 
the other arms for pain and RMDQ.  
 
 
The results of the pooled analyses (Table 7.12) showed significant association 
between presence of history of back pain and symptom progression only at 52 
weeks. Absence of history of back pain was associated with smaller symptom 
progression for RMDQ at this follow up time.  
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Table 7.7a  Within-arm difference in the change in outcome scores (mean, 95% CI) according to the presence of a history of back pain (presence compared with absence of a history of back pain)  
for pain intensity (0-100 VAS). Positive results indicate larger improvement in pain. 
 
  13week  27week  52week 
 n Unadjusted Adjusted n Unadjusted Adjusted n Unadjusted Adjusted 
          
Hay et al 2005          
   -Manual physiotherapy 49:99 8.11 (-1.29, 17.50) 8.76 (-1.03, 18.55)     50:111 -2.50 (-12.22, 7.23)  -1.93 (-12.03, 8.18)  
   -Brief pain management 32:115 -2.05 (-13.67, 9.58) -1.76 (-13.51, 1.00)     34:126 -3.68 (-15.59, 8.23)  -3.76 (-15.82, 8.31) 
Heymans et al 2006          
   -Occupational health care 11:65 14.9 (-0.3, 30.0)  14.7 (-0.4, 29.9)  9:63 9.2 (-9.7, 28.1)  9.9 (-9.7, 29.6)  10:73 0.4 (-17.9, 18.7)  1.0 (-16.3, 19.9)  
   -Low intensity back school 17:50 3.8 (-11.6, 19.1)  4.8 (-11.5, 21.0)  14:51 9.0 (-7.5, 25.6)  10.1 (-6.1, 26.2)  18:65 3.9 (-11.2, 19.0)  3.6 (-11.2, 18.4)  
   -High intensity back school 9:59 -7.7 (-26.0, 10.6)  -6.7 (-26.0, 12.6)  10:52 6.5 (-13.9, 26.8)  6.6 (-15.1, 28.3)  9:59 7.2 (-14.2, 28.7)  11.8 (-9.8, 33.4)  
          
    n number in the group with no history of back pain versus the group with history of back pain. 
 
 
 
 
 
 
 
 
 
 
 
Table 7.7b  Within-arm difference in the change in outcome scores (mean, 95% CI) according to the presence of a history of back pain (presence compared with absence of a history of back pain)  
for RMDQ. Positive results indicate larger improvement in pain. 
 
  13week  27week  52week 
 n Unadjusted Adjusted n Unadjusted Adjusted n Unadjusted Adjusted 
          
Hay et al 2005          
   -Manual physiotherapy 52:110 1.19 (-0.81, 3.19)  1.24 (-0.86, 3.33)    51:114 -1.29 (-3.31, 0.73)  -1.19 (-3.33, 0.95)  
   -Brief pain management 32:125 1.07 (-1.52, 3.67)  0.96 (-1.66, 3.58)    34:130 0.55 (-1.88, 2.98)  0.86 (-1.56, 3.28)  
Heymans et al 2006          
   -Occupational health care 11:65 3.58 (-3.09, 1-.24)  2.19 (-4.35, 8.73)  8:62 3.86 (-3.23, 10.95)  3.10 (-3.86, 9.97)  10:73 2.57 (-3.88, 8.82)  1.22 (-5.05, 7.48)  
   -Low intensity back school 17:53 -3.58 (-8.09, 0.94)  -2.25 (-6.75,2.24)  15:53 -2.50 (-7.48, 2.48)  -1.89 (-6.91, 3.13)  18:66 -2.12 (-6.74, 2.51)  -1.37 (-6.05, 3.32)  
   -High intensity back school 8:60 -0.34 (-6.82, 6.14)  0.45 (-6.41, 7.31)  9:53 -0.34 (-5.78, 5.07)  -0.57 (-6.49, 5.36)  8:60 -0.54 (-6.71, 5.63)  1.16 (-5.41, 7.72)  
Moffett et al 1999          
   -Exercise program 15:70 -0.10 (-2.13, 1.94) -0.29 (-2.38, 1.79) 14:63 -0.81 (-1.94, 3.57) 0.53 (-2.25, 3.31) 14:69 1.04 (-1.52, 3.59) 0.81 (-1.79, 3.40) 
   -Routine GP care 8:86 -0.55 (-3.34, 2.24) -0.35 (-3.24, 2.54) 8:78 -0.49 (-3.88, 2.89) -0.22 (-3.67, 3.23) 8:80 1.14 (-2.0, 4.27) 1.14 (-2.13, 4.41) 
UKBEAM 2004          
   -Best GP care 35:201 -0.59 (-2.14, 0.96) -0.66 (-2.20, 0.87)    33:197 -2.02 (-3.71, -0.33) -1.92 (-3.66, -0.19) 
   -Exercise 31:179 -0.70 (-2.28, 0.88) -0.46 (-2.14, 1.23)    30:171 -1.59 (3.24, 0.06) -1.41 (-3.11, 0.29) 
   -Manipulation 29:229 0.27 (-1.63, 2.17) 0.28 (-1.66,  2.21)    25:215 -0.14 (-2.25, 1.97) -0.19 (-2.33, 1.94) 
   -Combined exercise + 
manipulation 
24:210 -1.73 (-3.57, 0.12) -1.45 (-3.39, 0.50)    31:202 -2.11 (-3.88, -0.34) -1.82 (-3.66, 0.03) 
          
    n number in the group with no history of back pain versus the group with history of back pain. Underlined indicates significant (p<0.05). 
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7.4.2.e Expectation of helpfulness of treatment 
Four trials provided data on expectation (UKBEAM, Heymans et al, Moffett et al 
and Thomas et al). The various scales used to measure expectation in these trials 
are shown in Table 7.8. The majority of patients seem to have high expectation of 
helpfulness of treatments. The ratio of high to low expectation ranged from 23:1 
for combined exercise-manipulation treatment in the UK BEAM trial to 1.2:1 for 
low intensity back school treatment in Heymans et al trial. In the Thomas et al 
trial, only two patients reported low expectation of help from acupuncture and 75 
(31%) said they didn’t know. The only exception was in the Moffett et al trial, 
where a larger number of patients had low expectation of helpfulness of class 
exercise treatment than those who had high expectation (123 (65.8%) vs 64 
(34.2%)). 
 
Within-arm adjusted analyses (Table 7.9) did not show the association between 
expectation and symptom progression to be statistically significant in any trial arm 
for the outcomes of interest and at any follow up point. The direction of the 
associations was inconsistent across trial arms.  
 
The results of the pooled analyses (Table 7.12) did not show the association 
between expectation and symptom progression to be significant for RMDQ at any 
follow up point. The direction of the associations also varied at different follow up 
points.  
 
7.4.2.f Preference for treatment  
Three trials provided data on pre-randomisation patients’ preference for 
treatments (Moffett et al trial, scale: prefer active treatment or ‘indifferent’,  
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Table 7.8  Descriptive summary of expectation of helpfulness of treatments  
 
 
Trial 
 
 
Expectation scale 
 
 
Trial treatments 
Expectation, n (%)  
 
High 
 
Low 
 
Missing 
Don’t 
know 
       
UKBEAM 
2004 
Helpfulness of each 
treatment: 
Very helpful, Helpful, 
Not helpful 
Exercise alone 958 (71.8) 146 (10.9) 230 (17.2)  
Manipulation alone 1037 (77.7) 66 (4.9) 231 (17.3)  
Combined exercise and 
manipulation 
1057 (79.2) 47 (3.5) 230 (17.2)  
GP care 650 (48.7) 454 (34) 230 (17.2)  
       
Moffett et 
al 1999 
Belief in effectiveness of 
exercise classes:  
0-5 
Exercises classes 64 (34.2) 123 (65.8) 0  
Control (Routine GP care) - - -  
       
Heymans 
et al 2006 
Helpfulness of each 
treatment: 
VAS 0-10 
High intensity back school 175 (55) 128 (40.2) 15 (4.8)  
Low intensity back school 156 (52.2) 128 (42.8) 15 (4.8)  
Usual occupational care treatment 161 (53.8) 122 (40.8) 16 (5.4)  
       
Thomas et 
al 2006 
Expectation of help from 
acupuncture: 
Yes, No, Don’t know 
Acupuncture 162 (67) 2 (0.8) 0 75 (31) 
Usual GP care - - -  
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Table 7.9  Within-arm differences in the change of outcome scores (mean, 95% CI) according to 
expectation of helpfulness of treatment (low compared with high expectation) for the 
outcomes of interest. Positive results indicate larger improvement in symptoms. 
 
  
Outcome 
Time, 
weeks 
Low expectation 
Trials treatment arms Unadjusted Adjusted 
     
Heymans et al 2006     
-Usual occupational care  RMDQ 13 -0.46 (-5.20, 4.28) -1.13 (-5.90, 3.64) 
  27 0.90 (-3.77, 5.58) -1.23 (-5.93, 3.46) 
  52 -1.29 (-5.43, 2.85) -1.82 (-5.98, 2.34) 
-Low intensity back school  13 -0.09 (-4.24, 4.06) 1.52 (-2.48, 5.52) 
  27 -0.99 (-5.26, 3.29) -0.04 (-4.56, 4.47) 
  52 0.41 (-3.53, 4.35) 1.45 (-2.52, 5.42) 
-High intensity back school  13 1.77 (-2.62, 6.16) 2.17 (-2.38, 6.70) 
  27 -0.18 (-4.20, 3.85) 0.22 (-4.03, 4.47) 
  52 -2.35 (-6.43, 1.74) -2.01 (-6.15, 2.14) 
     
-Usual occupational care  Pain 0-100 13 -0.7 (-11.8, 10.5) -0.2 (-11.4, 11.0) 
  27 2.0 (-10.9, 15.0) 2.2 (-11.5, 15.9) 
  52 -3.8 (-15.8, 8.2) -3.4 (-16.0, 9.3) 
-Low intensity back school  13 -7.0 (-20.8, 6.8) -4.8 (-20.1, 10.5) 
  27 -8.1 (-22.0, 5.7) -8.2 (-23.2, 6.8) 
  52 -10.8 (-23.2, 1.6) -8.1 (-21.1, 4.9) 
-High intensity back school  13 6.7 (-6.4, 19.8) 7.7 (-5.8, 21.1) 
  27 -7.5 (-23.1, 8.0) -9.2 (-25.2, 6.9) 
  52 -7.0 (-22.1, 8.0) -6.7 (-22.6, 9.2) 
Moffett     
-Exercise programme RMDQ 13 0.85 (-0.78, 2.47) 0.71 (-0.98, 2.40) 
  27 -0.24 (-2.47, 2.0) -0.60 (-2.88, 1.68) 
  52 1.0 (-1.04, 3.04) 0.89 (-1.21, 2.98) 
Thomas     
-Acupuncture ODI 13 0.44 (-4.71, 5.59) 1.12 (-4.03, 6.27) 
  52 -1.70 (-7.78, 4.38) -1.17 (-7.23, 4.90) 
UKBEAM     
-Best GP care RMDQ 13 -0.34 (-1.51, 0.83) -0.02 (-1.25, 1.21) 
  52 -0.26 (-1.55, 1.03) 0.56 (-0.77, 1.88) 
-Exercise  13 -0.28 (-1.99, 1.43) 0.10 (-1.72, 1.92) 
  52 0.04 (-1.80, 1.88) 0.56 (-1.32, 2.44) 
-Manipulation  13 0.08 (-2.23, 2.38) 0.09 (-2.54, 2.72) 
  52 0.59 (-2.02, 3.20) 1.23 (-1.63, 4.08) 
-Combined exercise & manipulation  13 -1.46 (-4.54, 1.63) -1.55 (-4.72, 1.64) 
  52 -2.70 (-5.79, 0.41) -2.70 (-5.84, 0.45) 
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Johnson et al trial, scale: ‘prefer active treatment’, ‘prefer control’ or ‘indifferent’ 
and Thomas et al trial, scale: ‘prefer acupuncture’, ‘prefer control treatment’ or ‘do 
not mind’). In the Moffett et al trial118 participants (63%) preferred the trial index 
treatment, class exercise, and the remaining 69 (37%) were ‘indifferent’. Of those 
who had a preference, 53 (45%) had their preference satisfied. In the Johnson et 
al trial, 134 participants (57%) had a preference and 100 (43%) were ‘indifferent’. 
114 participants (48.7% of all trial participants) preferred active treatment and a 
much smaller number (20, 8.5% of all trial participants) the control treatment. Of 
those who had a preference (134), 71 (53%) had their preference satisfied. In the 
Thomas et al trial 194 (97%) preferred acupuncture, only one (0.5%) usual care, 
five (2.5%) ‘did not mind’ and data were not available for 39 participants (16%).  
 
Sufficient data were available from these trials to analyse the influence of 
presence of preference on symptom progression. However, because of the large 
difference in numbers in groups in the Thomas et al trial, the related results 
require caution. Within-arm adjusted analyses (Table 7.10) showed that merely 
having a preference for a treatment (regardless of the type of treatment and 
whether or not the preferred treatment was received) did not influence symptom 
progression in the three trials for the selected outcome measures and at any 
follow up point. The direction of the associations was also not consistent for the 
two main outcome measures and across all follow up time points.  
 
Studying the influence on symptom progression of preference satisfaction 
(allocation to the preferred treatment) among participants who expressed a 
preference, the number of participants in the groups in the Thomas et al trial was  
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Table 7.10  Within-arm differences in change of outcome scores (mean, 95% CI) according to the presence of preference (preference not present 
compared with preference present) for the outcomes of interest. Positive results indicate larger improvement in symptoms. 
 
 
Trials treatment arms 
 
Outcome 
Follow up 
weeks 
 
n* 
Preference not present 
Unadjusted Adjusted 
      
Johnson et al 2007 RMDQ     
   -Physiotherapist led community-          
    based treatment program 
 13 53:57 -0.74 (-2.49, 1.02) -0.72 (-2.44, 1.01)  
 27 50:55 0.38 (-1.35, 2.11) 0.41 (-1.31, 2.12)  
 52 48:53 -0.59 (-2.75, 1.57) -0.61 (-2.80, 1.59)  
   -Back pain educational booklet  
    and usual GP care 
 13 43:70 0.04 (-1.74, 1.83) -0.03 (-1.82, 1.77)  
 27 39:59 0.23 (-1.74, 2.19) -0.01 (-2.01, 1.99)  
 52 39:55 1.46 (-0.52, 3.44) 1.18 (-0.86, 3.22)  
   -Physiotherapist led community- 
    based treatment program 
Pain 0-100 13 53:57 -2.59 (-11.63, 6.46) -1.79 (-11.00, 7.42)  
 27 50:55 -4.85 (-13.89, 4.18) -5.18 (-14.37, 4.01)  
 52 49:53 -7.77 (-18.28, 2.75) -7.62 (-18.55, 3.31)  
   -Back pain educational booklet  
    and usual GP care 
 13 43:70 0.42 (-9.22, 10.06) -0.61 (-10.42, 9.20)  
 27 39:59 3.86 (-7.56, 15.28) 1.80 (-9.71, 13.31)  
 52 39:55 2.93 (-8.29, 14.16) 0.64 (-10.90, 12.17)  
Moffett et al 1999 RMDQ     
   -Exercise programme  6 35:50 -0.94 (-2.50, 0.62) -0.90 (-2.50, 0.71)  
 27 31:46 -0.80 (-2.96, 1.37) -0.69 (-2.85, 1.46)  
 52 34:49 -0.63 (-2.58, 1.31) -0.64 (-2.58, 1.30)  
   -Usual GP care  6 31:63 -.02 (-1.68, 1.64) 0.17 (-1.55, 1.89) 
  27 29:57 -0.40 (-2.48, 1.68) 0.10 (-2.0, -2.20) 
  52 30:58 -0.77 (-2.67, 1.13) -0.38 (-2.32, 1.56) 
Thomas et al 2006 ODI     
  27 3:120 -12.37 (-29.55, 4.80) -11.69 (-29.03, 5.65) 
   -Acupuncture  52 3:110 -8.12 (-27.18, 10.94) -9.31 (-28.83, 10.21) 
  104 2:92 -5.00 (-24.86, 14.84) -5.78 (-26.43, 14.86) 
   -Usual care  27 2:58 -9.56 (-30.72, 11. -9.71 (-31.54, 12.11) 
  52 0:48 - - 
  104 1:40 -22.59 (-56.08, 10.89) -21.99 (-57.37, 13.39) 
      
*number of participants whose treatment preference was not satisfied compared with that of those whose preference was satisfied. 
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too small to allow analyses and therefore data from this trial were not included in 
this analysis. The Moffett et al trial provided data only for preference for the active 
treatment and not for the control treatment and therefore also could not be 
included in this analysis. Only the Johnson et al trial provided sufficient data on 
preference for both treatments of the trial. For this reason, the influence of 
preference satisfaction among participants who expressed a preference 
(‘indifferent’ group not included) on symptom progression was only studied in the 
Johnson et al trial. A sensitivity analysis was carried out to investigate whether 
including the ‘indifferent’ group in the comparison group, would influence the 
results of the analyses, for the Johnson et al and the Moffett et al trial (Table 
7.11).  
 
The results of adjusted within-arm analyses showed that the influence of 
satisfaction of preference for treatment was only statistically significant in one arm 
(back pain educational booklet, control arm of the Johnson et al trial), and only for 
RMDQ at 27 weeks. The direction of this significant association, similar to that of 
the majority of the other non-significant associations, was consistent suggesting 
that patients whose preference for treatment was not satisfied were more likely to 
show smaller responses to treatments.  
 
Including data for the ‘indifferent’ group, there was no significant association 
between preference satisfaction and symptom progression in any arm of the two 
trials. However, apart from one trial arm at only one follow up point, the direction 
of associations (statistically insignificant) was the same, suggesting that those 
who were allocated to the treatment they did not prefer or those who didn’t have a  
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Table 7.11  Within-arm differences in change in outcome scores (mean, 95% CI) for the outcomes of interest according to preference satisfaction 
(not allocated to the preferred treatment compared with being allocated to it). Comparison is presented where the ‘indifferent’ groups 
were included and not included in the variable. Positive results indicate larger improvement in symptoms. 
 
 
 
Trials treatment arms 
 
 
Outcome 
Follow 
up 
Weeks 
 
 
n* 
‘Indifferent’ group not included  ‘Indifferent’ group included 
 
Unadjusted 
 
Adjusted 
 
n* 
 
Unadjusted 
 
Adjusted 
         
Johnson et al 2007 
   -Physiotherapist led community-          
    based treatment program 
RMDQ 13 5:52 -1.22 (-5.64, 3.21) -1.61 (-6.0, 2.78)  58:52 -0.87 (-2.63, 0.88)  -1.02 (-2.75, 0.71)  
 27 5:50 -2.40 (-6.48, 1.68) -2.88 (-6.91, 1.12) 55:50 -0.07 (-1.81, 1.66) -0.18 (-1.90, 1.55)  
 52 5:48 -2.98 (-7.69, 1.74) -3.46 (-8.35, 1.43) 53:48 -1.07 (-3.23, 1.08) -1.26 (-3.45, 0.93) 
   -Back pain educational booklet  
    and usual GP care 
 13 55:15 -1.39 (-4.11, 1.32) -1.62 (-4.38, 1.13) 58:55 -1.24 (-3.79, 1.30)  -1.07 (-3.61, 1.47)  
 27 46:13 -4.11 (-7.18, -1.03) -4.10 (-7.26, -0.93) 52:46 -3.59 (-6.33, -0.85) -3.40 (-6.19, 0.62)  
 52 45:10 -3.36 (-6.59, -0.12) -3.21 (-6.53, 0.11) 49:45 -2.40 (-5.56, 0.77) -2.16 (-5.38, 1.06)  
   -Physiotherapist led community- 
    based treatment program 
Pain 0-100 13 5:52 -14.33 (-36.95, 8.46) -11.55(-34.34, 11.23) 58:52 -4.73 (-13.76, 4.29) -4.02 (-13.24, 5.20)  
 27 5:50 -13.61 (-36.12, 8.90) -14.68 (-38.10, 8.75) 55:50 -6.77 (-15.76, 2.22) -7.50 (-16.65, 1.66)  
 52 5:48 -12.18 (-36.49,12.14) -12.82 (-38.52, 12.87) 54:48 -9.22 (-19.70, 1.26) -9.29 (-20.22, 1.64)  
   -Back pain educational booklet  
    and usual GP care 
 13 55:15 3.94 (-11.58, 19.46) 4.32 (-11.67, 20.31) 58:55 3.75 (-10.02, 17.53)  5.00 (-8.88, 18.88)  
 27 46:13 -16.10 (-33.84, 1.64) -15.12 (-33.28, 3.05) 52:46 -12.70 (-29.01,3.61) -11.26 (-27.61,5.08)  
 52 45:10 -12.07 (-30.13, 6.00) -11.82 (-30.03, 6.39) 49:45 -9.69 (-27.54, 8.17) -11.19 (-29.27,6.88)  
Moffett et al 1999 
   -Exercise programme 
RMDQ 6    35:50 -0.94 (-2.50, 0.62) -0.90 (-2.50, 0.71)  
 27    31:46 -0.80 (-2.96, 1.37) -0.70 (-2.85, 1.46)  
 52    
 
34:49 -0.63 (-2.58, 1.31) -0.64 (-2.58, 1.30)  
         
*number of participants whose treatment preference was not satisfied compared with that of those whose preference was satisfied. Underlined indicates significant (p<0.05). 
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preference, showed smaller symptom progression compared with those whose 
preference was satisfied.  
 
Pooled analyses were only possible for data on the presence of a preference. The 
results of these analyses (Table 7.12) showed that the associations were not 
statistically significant between having a preference and symptom progressions. 
However, the direction of these non-significant associations was similar across all 
follow up time points, suggesting that participants who expressed a preference for 
a treatment were more likely to report larger improvement in function compared 
with those who did not have a preference.  
 
7.4.3 Pooled analysis 
The outcome of the pooled analyses shows low heterogeneity between included 
treatment arms as shown in Table 7.12. As an example, a forest plot of the 
association of episode duration and symptom progression at 52 weeks is shown 
in (Figure 7).  
 
The results of the sensitivity analyses that were conducted to assess the influence 
of clustering of responses within trials on the associations between the non-
specific factors and responses to treatment are presented in Table 7.13. The 
results showed that the associations did not significantly vary by trial.    
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Table 7.12  Pooled mean differences (random effects model) in the change in outcome scores (mean, 95% CI) for RMDQ, according to gender, age, 
duration of current episode of back pain, history of back pain, expectation of helpfulness of treatment and preference for treatment.   
 
 
 13weeksb 27weeksc 52weeks 
  I2  I2  I2 
Gender, male 0.26 (-0.31, 0.84)  31% 0.57 (-0.66, 1.81) 37% 0.48 (-0.42, 1.0) 45% 
Age, <43 years 0.17 (-0.28, 0.61) 0% 0.45 (-0.80, 1.70) 41% 0.35 (-0.13, 0.83) 0% 
Duration of LBP, <12 weeks 0.76( 0.25, 1.27) 7% 0.27 (-1.15,1.68) 46% 1.03 (0.49, 1.57) 0% 
History of LBP, absent -0.05 (-0.81, 0.71) 15% 0.02 (-1.76, 1.80) 0% -0.84 (-1.56, -0.13) 0% 
Expectation of the received treatment a, low 
(Heymans et al, Moffett et al, UK BEAM) 
0.16 (-0.60, 0.92) 0% -0.47 (-2.14, 1.20) 0% 0.28 (-0.55, 1.11)  2% 
Preference for treatment, absent 
(Johnson et al, Moffett et al) 
-0.40 (-1.24, 0.44) 0% -0.01 (-0.20, 0.18) 0% -0.12 (-1.12, 0.87)  0% 
       
a Expectation of helpfulness of the received treatment dichotomised as low and high. b In Moffett et al trial a 6 week follow up time was used to represent a 13 week  follow up. c Data for 27 
weeks analysis was provided only in three trials, Heymans et al, Johnson et al and Moffett et al.  
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Figure 7  Mean difference in standardised mean change in RMDQ at 52 weeks 
between patients who had back pain episode duration of 12 weeks or 
less versus longer than 12 weeks. Positive indicates change associated 
with shorter episode duration.  
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Table 7.13 Pooled mean differences in change in RMDQ outcome scores according to gender, age, duration of current episode of back pain, 
history of back pain, outcome expectation and preference for treatment, adjusted for trial. The Moffett et al trial is the reference trial. 
 
 13weeks 27weeksa 52weeks 
  Tau2  Tau2  Tau2 
       
Gender, male       
Unadjusted 0.28 (-0.32, 0.88) 0.00 0.57 (-0.98, 2.12) 0.97 0.25 (-0.58, 1.07) 0.46 
Adjusted                   Hay et al 2005 -0.54b (-3.50, 2.43) 0.01   0.58 (-2.11, 3.27) 0.00 
                                 Heymans et al 2006 -1.21 (-6.31, 3.89)  -0.56 (-6.44, 5.33) 2.01 0.62 (-3.72, 4.95)  
                                 Johnson et al 1999 -0.12 (-2.94, 2.70)  0.54 (-4.32, 5.41)  0.13 (-2.71, 2.97)  
                                 UK BEAM 2004 -0.19 (-2.32, 1.94)    -1.28 (-3.35, 0.79)  
Age <43 years       
Unadjusted 0.17 (-0.32, 0.66) 0.00 0.43 (-1.17, 2.02) 0.70 0.35 (-0.18, 0.89) 0.00 
Adjusted                   Hay et al 2005 -0.14 (-2.58, 2.31) 0.00   0.48 (-1.94, 2.89) 0.00 
                                 Heymans et al 2006 -0.47 (-4.03, 3.10)  -0.13 (-6.18, 5.93) 1.89 -0.31 (-3.68, 3.07)  
                                 Johnson et al 1999 -0.65 (-2.88, 1.59)  -0.86 (-6.29, 4.57)  0.18 (-2.42, 2.79)  
                                 UK BEAM 2004 -0.38 (-2.02, 1.26)    0.58 (-1.26, 2.41)  
Duration of LBP <12 weeks       
Unadjusted 0.76 (0.19, 1.33) 0.00 0.24 (-1.57, 2.05) 1.25 1.01 (0.30, 1.73) 0.19 
Adjusted                   Heymans et al 2006 3.48 (-1.12, 8.08) 0.00 3.92 (-1.54, 9.39) 0.19 1.86 (-2.62, 6.34) 0.13 
                                 Johnson et al 1999 -0.17 (-2.21, 1.86)  1.98 (-1.10, 5.05)  1.68 (-1.07, 4.42)  
                                 UK BEAM 2004 0.69 (-0.85, 2.22)    1.29 (-0.64, 3.22)  
History of LBP, no history       
Unadjusted -0.05 (-0.94, 0.84) 0.32 -  -0.82 (-1.66, 0.03) 0.09 
Adjusted                   Hay et al 2005 2.26 (-0.52, 5.04) 0.00 -  -1.23 (-4.30, 1.85) 0.00 
                                 Heymans et al 2006 -0.41 (-4.68, 3.86)    -1.39 (-5.86, 3.08)  
                                 UK BEAM 2004 -0.26 (-2.53, 2.01)    -2.36 (-5.01, 0.28)  
Expectation, low       
Unadjusted 0.16 (-0.75, 1.07) 0.00 -  0.29 (-0.70, 1.27) 0.00 
Adjusted                   Heymans et al 2006 0.22 (-3.71, 4.16) 0.00 -  -1.62 (-6.09, 2.85) 0.00 
                                 Johnson et al 1999 -0.81 (-3.30, 1.67)    -0.56 (-3.83, 2.71)  
       
a Data for 27 weeks analyses was provided only in three trials, Heymans et al, Johnson et al and Moffett et al trials. b As an example, this value means that Hay et al trial showed 
mean difference in response between genders 0.54 smaller than the reference trial Moffett et al, but not statistically significant. 
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7.5 Discussion 
 
In this chapter, IPD analysis was used to study the influence of patient 
characteristics on within-arm symptom progression for back pain. Evidence was 
found for the influence of the duration of pain episode at inclusion in clinical trials 
on symptom progression. A favourable trend, although not statistically significant, 
was found for the influence of gender, age and presence and satisfaction of 
preference for treatment and symptom progression. Men, patients younger than 
43 year old, patients who reported a preference and patients who were allocated 
to the preferred treatment seemed to be more likely to report larger responses to 
treatments, based on pain and functional disability. These findings will be 
discussed in detail.  
 
7.5.1 Duration of back pain  
Analysing pooled data from five IPD sets provided evidence for the influence of 
duration on symptom progression. Participants with duration of back pain of 12 
weeks or less had on average up to 1 point more improvement on the RMDQ 
compared with those with longer duration.  
 
It is relevant to point out that the evidence for the influence of episode duration on 
symptom progression within arms of each included trial was limited to a small 
number of arms. The advantages and disadvantages of using cut off points in 
analyses have been mentioned earlier in the thesis. One caveat is that the 
meaning of the difference between groups immediately on the two sides of the cut 
off point might be unclear. Also, and as has been touched on in the previous 
chapter, there is a growing challenge to the traditional classification of back pain 
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symptoms simply based on duration (Dunn et al 2008, von Korff & Dunn 2008), 
with the alternative proposition being that almost all back pain is a ‘chronic 
problem with an untidy pattern of grumbling symptoms’ (Croft et al 1998).  
 
However, there is empirical evidence from observational studies for duration of 
back pain as an important prognostic factor (Henschke et al 2008, da Costa et al 
2009). It is also recognised that patients who suffered from back pain for a longer 
duration tend to have additional associated features and characteristics that would 
negatively influence their symptom progressions (BenDebba et al 1997, Groth-
Marnat et al 2000). Longer duration back pain has been suggested to be 
associated with psychological distress (Waxman et al 1998, 2000), poorer 
prognosis (van den Hooger et al 1997), extensive care seeking behaviour 
(Boutron et al 2004), more time off work and more likelihood of depression (Dunn 
et al 2008). For these reasons, traditional classification of back pain into acute 
and chronic based on duration of symptoms is still used to guide treatment 
recommendations in clinical guidelines, which gives utility to using it in research. 
 
7.5.2 History of back pain 
The evidence in this thesis for the influence of history of back pain on symptom 
progression was limited to the pooled analysis of data from a number of trials and 
only at 52 week follow up time.  
 
There is evidence from the literature that the presence of a history of back pain is 
an important predictor of the development of a new episode (Papageorgiou et al 
1996, Hestbaek et al 2003) and may also be associated with the severity of 
prevalent back pain. In a population survey, Hincapie et al found that a history of 
172 
 
occupational back pain was associated with high severity low back pain (Hincapie 
et al 2008). Another survey among factory workers found that previous history of 
back pain was associated with reduced functioning at work (Ratzon et al 2007). I 
am not aware, however, of any evidence for history of back pain as a predictor of 
symptom progression in clinical trials.  
 
Although data on the history of episodes of low back pain were collected in five of 
the six included trials, this data either were not provided in trial publications 
(Moffett et al trial), only published as part of baseline characteristics that were 
used to adjust effect estimates (Hay et al, Heymans et al & Thomas et al trials) or 
studied among other factors as treatment effect modifiers (Underwood et al 2007). 
In none of the trials was the influence of history of back pain on symptom 
progression explored directly.  
 
It is important to note that scales used to assess this variable in the trials varied 
which might have compromised the analyses. Another issue is that with the 
current understanding of back pain being a condition of ongoing symptoms that 
run a course with fluctuations, relapses and remissions in the majority of cases 
(Dunn et al 2006, 2008, 2010, von Korff & Dunn 2008), the distinction between 
‘duration of current episode’ and ‘previous episodes of back pain’ as if they were 
exclusive features becomes less convincing. The validity of questions related to 
these features is not clear, nor is patients’ understanding and interpretation of 
these questions and how they answer them. All these reasons, in addition to the 
small number of datasets that was available for this study, might explain the 
failure of finding a clear evidence for the influence of history of back pain on 
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symptom progression, assuming it has such an influence. A clear conclusion, 
therefore, could not be drawn from these findings.  
 
7.5.3 Expectations and preferences 
No clear evidence was shown for the influence of expectation of helpfulness of 
treatment or preference for treatment on symptom progression. It is important to 
note the small number of trials providing data on these outcomes which reduced 
the power of analyses, as well as the variation in the scales used which further 
compromised the ability to compare or pool data from trials. There seems to be a 
trend that suggests those who reported a preference and who received the 
treatment they preferred were more likely to report larger response to the 
treatment. A larger volume of data would have provided more statistical power 
and a better opportunity to establish clear evidence on the importance of 
treatment preferences.  
 
Heymans et al collected data on expectation. However, they published these data 
as part of baseline patients’ characteristics and did not explore its influence on 
symptom progression. Moffett et al collected data at baseline on participants’ level 
of belief in the effectiveness of the trial index treatment (class exercises), but 
similarly did not present assessment of the influence on treatment outcome in 
their published paper. In the UK BEAM trial, participants were asked pre-
randomisation about their expectation of helpfulness for each of the trial 
treatments. They reported a significant association between the expectation of 
helpfulness of the combined treatment (exercise and manipulation) and treatment 
outcome at 52 weeks (Underwood 2007). They were, however, not confident of 
this finding commenting that it could be a chance finding.   
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In their published paper, Moffett et al used baseline pre-randomisation preference 
for treatment to adjust the reported treatment effects. They compared change in 
RMDQ scores at 52 weeks within each arm between participants who preferred 
the treatment and those who were indifferent, and found no difference between 
the two preference groups in the change in RMDQ scores. Johnson et al, on the 
other hand, used a similar approach to that adopted in this thesis where 
improvement in symptoms was assessed among those who received the 
treatment they preferred and those who didn’t. They found that patients allocated 
to the intervention for which they had expressed a preference had clinically 
important reductions in pain and disability. There was no reference in the 
published paper of the Thomas et al trial of patient preference regarding 
treatment. 
 
Similar to preference for treatment, expectation of helpfulness of treatments has 
been widely studied to examine its association with treatment ‘effect’, in back pain 
as well as in other medical conditions (Crow et al 1999). Evidence was not found 
for an association between expectation and symptom progression in this thesis. 
Intuitively, patients who receive their preferred treatment and who have high 
expectations regarding treatment would be expected to show larger response to it 
compared with those who do not. The evidence for this, however, is conflicting, 
both for expectation and preference. Some trials did not find evidence for the 
association between preference and expectation and treatment ‘effect’ (Sherman 
et al 2010, Leykin et al 2007) while others did (Lutz et al 1999, Kalauokalani et al 
2001, Linde et al 2007, Myers et al 2008).  
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Preference and expectation are complex characteristics and it is plausible that the 
inconsistent evidence for their association with benefit of treatment might be 
related to the simple methods used to explore these characteristics and interpret 
their meaning. Various elements and factors need to be considered before simply 
interpreting patient’s expectation that a treatment is helpful to mean that they 
would show a large response to it. High expectation could also reflect patient’s 
desperation for a helpful treatment, which might represent a negative attitude with 
a potential negative influence on symptom progression. It has been suggested 
that merely having a preference indicates a level of articulation and health 
awareness that could be associated with higher symptom progression (Thomas et 
al 2006, Johnson 2007). This illustrates the complexity of investigating preference, 
when various explanations for conflicting findings related to various aspects of the 
concept of preference for treatments have been proposed.  
 
Interactions of expectation and preference with other concepts such as general 
beliefs, attitude, previous use of the treatment, duration and severity of symptoms, 
influences of friends and family, cultural background and educational level are 
possible. Although preference and expectation have been used interchangeably 
(Johnson et al 2007) and there is some evidence to suggest a positive correlation 
between the two concepts (Torgeussell 1996), they convey distinct meanings. 
Preferring a particular treatment might not always mean that the patient has high 
expectation of its helpfulness, but could be because the patient wanted to try a 
new treatment with an open mind, prefer a specific treatment for practical 
reasons, or disliked other alternative treatments. Studying the correlation between 
preference and expectation was beyond the scope of this thesis and empirical 
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evidence from in-depth exploration of the meaning and reasons for preference 
and expectations would be valuable.  
 
The inter-relation between patients’ preference for treatment and participants 
blinding to treatments is also important to explore. In the two trials that explored 
preference for treatments, participants were not blinded to allocation to treatments 
and, as stated in the published trials, the main reason for exploring preference 
was an attempt to ameliorate the possible influence of un-blinded allocation to 
treatment on outcome (Moffett et al and Johnson et al trials). The majority of 
randomised clinical trials among back pain patients do not or cannot blind 
participants to trial treatments, either because it is difficult for the nature of the 
treatment e.g. manual treatments or the trials are pragmatic by design and 
participants are intentionally not ‘blinded’. Trials included in this chapter were on 
non-pharmacological treatments, which is not unusual for primary care treatments 
used for non-specific low back pain (van Tulder et al 1997). The significance of 
this is that in trials where participants are not blinded, i.e. are able to see whether 
the treatment they receive is or is not their preferred, the influence of the 
satisfaction of their preference on symptom progressions would be most relevant. 
In other words, in pragmatic trials on back pain treatments in which blinding of 
patients is not enforced, part of the size of their symptom progression might be 
related to the fact that they have received their preferred treatment. This is one 
reason why it is worthwhile investigating the potential influence of non-specific 
factors in these trials in particular.  
 
Another issue is that there is a concern that patients with a strong preference for a 
particular treatment might self-select or self-exclude themselves from a clinical 
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trial if they felt their preference would not be satisfied (Fairhurst & Dowrick 1996). 
This would be particularly the case in unblinded trials, in which such preferences 
could also lead to drop out, poor compliance and attrition (Corrigan & Salzer 
2003). Although trials that explored the effect of ‘un-matched’ preference on drop-
out rate (Leykin et al 2007) found no evidence for such an effect, more robust 
evidence from larger trials is required. Furthermore, to examine the impact of 
preference on agreeing to enrol in a trial, rate of attrition, drop out or compliance 
with treatment, the strength of preference, not simply the presence of preference, 
might be useful to assess. This is not commonly done.  
 
7.5.4 IPD analysis 
Compared with the well-developed methods for the more commonly used meta-
analysis of aggregated data, there is a wide variation in the methods used for IPD 
meta-analysis (Simmonds et al 2005). A review conducted by Simmonds et al 
showed that two general methodological approaches were used in the majority of 
IPD reviews (Simmonds et al 2005), a one-stage and a two-stage analysis.  
 
In the one-stage analysis, IPD from multiple trials are combined and analysed 
retaining original trials’ identities that would be used in appropriate statistical 
analyses, such as a multilevel framework, to adjust for the cluster effect within 
each trial. In the two-stage approach data are analysed within each trial 
separately in the first stage and the summary statistics combined using standard 
summary data meta-analysis. The two-stage approach has been found to be used 
in the majority of IPD meta-analyses (Simmonds et al 2005). However, these two 
approaches were found to provide similar results (Riley et al 2010).  
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As the method of analysis presented in this thesis was to study responses to 
treatments within trial arms and not within-trial treatment effect, the 2-stage 
approach was adopted here. There was still the risk of the influence of cluster 
effect within each trial on the associations between variables and symptom 
progressions. To assess the potential effect of this in this thesis, the trials were 
included as independent variable in a meta-regression analysis as a sensitivity 
analysis. An alternative approach would have been to use multilevel analysis at 
the 2nd stage. However, given the small number of trials and small total number of 
arms, this was not feasible and the option that was adopted here was a less 
complicated and a valid alternative. 
 
Corroborating with the results of the meta-regression analyses using AD 
presented in Chapter Six, duration of current episode of pain was associated with 
responses to treatment both on trial level using aggregated data and on patients 
level using individual participants data. The evidence for the association of gender 
with symptom progressions using AD was not supported by a clear evidence 
using IPD. Age was not associated with symptom progression in either analysis 
strengthening the evidence for this characteristic.  
 
 
7.6 Limitations 
 
Using individual data from several trials, it was possible to study the influence of 
patients’ characteristics on symptom progressions for non-specific low back pain 
in more detail and a more powerful analytic approach compared with using 
aggregated data. Data from six trials were obtained to explore the association with 
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factors such as preference for treatments, expectation of helpfulness of treatment 
and history of back pain for which data were not available for the aggregated data 
analysis.  
 
The IPD analyses were secondary analyses which were not intended in the 
design of the original trials. Also, although similar variables were used by a 
number of trials, different scales were used such as those for history of back pain 
and expectation. The attempts to standardise data for comparison might have led 
to a degree of distortion of data and affected the outcome of analyses. Extra care 
and caution, therefore, was taken to dichotomise data in a clear and justified way. 
This, however, was at the cost of reduced statistical power, and a reduced ability 
to compare trials or pool data from various trials. An example was data on 
preference for treatment which could not be pooled as data for all trial arms was 
not provided by all trials.  
 
The number of datasets that could be obtained was small. This hindered 
conducting pooled data analysis and comparing results regarding similar variables 
from a large number of trials. The small number of available datasets also limited 
the opportunity to study the influence of patient characteristics on responses to 
similar types of treatments. This would have helped to understand whether factors 
such as expectations and preferences are generic or whether the size of their 
influence varies in relation to particular treatments. 
 
A further limitation is the large number of analyses which might have led to some 
spurious findings of significant associations due to chance (as pointed out by 
Underwood et al 2007) and which need to be highlighted here.   
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7.7 Summary  
 
Evidence was shown that improvement of back pain symptoms in clinical trials is 
influenced by duration of back pain and history of back pain episodes, regardless 
of the treatment received.  
 
The lack of evidence for the association of other factors with symptom 
progression, such as expectation of helpfulness of treatment does not necessarily 
mean that no association exists. Rather it might reflect the complexity of those 
factors and the various ways they may influence symptom progression. It might 
equally reflect a lack of sufficient or appropriate data. 
 
This study represents an attempt to utilise the value of using IPD of trials on back 
pain to study the influence of patients’ or symptoms’ characteristics on responses 
to treatments, which may be difficult and costly to explore in single trials. Beyond 
the findings and the associated limitations already pointed out, this study provides 
a framework and a basis for using IPD to study the influence of non-specific 
factors on within-arm responses to treatments.  
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Chapter Eight 
 
 
The effect of participating in randomised 
controlled trials on patient outcome: 
comparing the course of back pain 
symptoms in RCTs and cohort studies. 
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8.1 Introduction 
 
In the previous chapters, the course of back pain symptoms in clinical trials 
showed that the majority of participants show large improvement in their 
symptoms over time (Chapter Four). The findings in Chapter Six also showed that 
the variation in the size of response among trial arms was not explained by the 
type of treatment, according to the two classifications used. To explore sources of 
variation in the size of responses in these trials, the association between non-
specific factors and symptom progressions in clinical trials was studied (Chapter 
Six and Seven). Some of those factors were related to the trials themselves while 
others to the patients and their symptoms.  
 
Another non-specific factor that was suggested to influence the course of 
symptoms in clinical trials is the mere involvement in a trial. This is said to be 
related to the care and attention provided, often referred to as the ‘Hawthorne 
effect’, the ‘care effect’ or the ‘protocol effect’. These effects are assumed to 
contribute to improvement among participants in clinical trials that is in addition to 
the specific effects of the treatments (Braunholtz et al 2001) and have even been 
suggested to underline participants’ self-selection to trials (Emergency Care 
Research Institute website) as they seek to benefit from new treatments or 
treatments they perceive as effective.  
 
If participation in a trial has a unique effect (unrelated to the treatment) it would 
not be expected to contribute to the variation in responses to treatments between 
trial arms or between trials. Rather, it would contribute to the large size of the 
overall symptom progressions in clinical trials in general. In other words, to 
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identify such an effect and be able to relate it to enrolment in RCTs, the 
improvement in symptoms in RCTs need to be compared with that outside the 
RCTs and to demonstrate a difference in the size of improvement in favour of 
RCTs.  
 
The aim of this part of the study was to explore the evidence for an added 
improvement in back pain symptoms among RCT participants related to their 
participation in the trials.  
 
 
8.2 Objectives 
 
The main objective was to examine and compare the change in outcome scores 
over time between participants of RCTs (within-arm change of outcome scores 
from baseline to follow up) and those in observational cohort studies.  
 
 
8.3 Methods  
 
8.3.1 Searching and selection of studies 
For randomised clinical trials, the same pool of clinical trials included in the 
systematic review conducted in Chapter Four was used, which were RCTs 
identified from the CENTRAL Cochrane register of randomised clinical trials 
database, accessed in April 2007.  
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For cohort studies, a literature search was conducted for which the detailed 
strategy is shown in Appendix 8. In summary, the databases of AMED, EMBASE, 
MEDLINE and CINAHL were searched separately using the keywords ‘low back 
pain’, ‘back pain’, ‘spinal pain’, ‘primary care’, ‘general practice’, ‘population’, 
‘cohort’, ‘observational’, ‘prognosis’, predictor’ and ‘course’. The filters ‘human’ 
and ‘English language’ were used. The final search was conducted in April 2011. 
The results of separate searches on these databases were then combined to 
remove duplicates. References of relevant systematic reviews (e.g. Pengel et al 
2003, Hestbaek et al 2003) and included cohort studies were checked to identify 
additional potentially eligible studies. 
 
The criteria for inclusion of cohort studies were: 
1. Studies: cohort or observational studies conducted in primary care (and allied 
services) or among the general population. 
2. Participants: individuals aged 18 or over with non-specific low back pain. 
3. Outcome measures: pain intensity (VAS or equivalent) and / or functional 
disability (e.g. RMDQ, ODI). 
4. Treatments: (if any treatment used at all) primary care treatments (using similar 
criteria as used for RCTs). 
5. Language: only studies published in English. 
 
Excluded were studies conducted among patients with specific LBP of identifiable 
cause (e.g. cancer or arthritis), post-operative or post-traumatic back pain, or back 
pain associated with pregnancy or labour. 
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The result of the final combined searches was then screened and inclusion criteria 
applied. Full texts of potentially eligible articles were then retrieved and screened 
for inclusion criteria.  
 
The literature search was conducted by the author and selection of cohort studies 
was checked by the supervisors (DvdW & KPJ) based on the full text of potentially 
eligible studies. 
 
8.3.2 Data extraction  
Data extraction was managed by two researchers, the author extracted the data 
which were checked by DvdW.  
 
The extracted data included the following: 
1. Study characteristics (publication year, country of study, clinical setting, sample   
    size, drop-out rate).  
2. Participants’ characteristics (age; gender; duration of symptoms). 
3. Outcome measures: baseline and follow up mean scores (and baseline SD) of  
    pain intensity, RMDQ and ODI. 
 
8.3.3 Analysis 
The same three steps of analysis used in Chapter Four to study responses to 
treatments in RCTs were used here to study responses in RCTs and the course of 
symptoms in cohort studies. The steps include describing the pattern of the 
symptom progression in RCTs and cohort studies; assessing variation in the 
progression of symptoms and finally calculating pooled estimates of the change of 
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symptoms over time. Further to that, and for the specific objectives of this study, 
the change in symptoms in cohort studies was compared with that in RCT arms.  
 
Mean outcome scores of pain and disability over time within each RCT arm and 
cohort study were plotted to show the pattern of symptom course. Meta-analysis, 
using random effects model, was performed using STATA/IC 11 software to 
compute pooled mean pain scores (and SD) at baseline and follow up points 
separately for RCTs and for cohort studies. Commonly used follow up times of 13, 
27 & 52 weeks were selected for comparison. Data of other time points were 
considered to fall within the selected points if they were within a three-week 
range. 
 
To estimate and compare the size of change in outcome scores in RCTs and 
cohort studies, these changes were analysed by calculating the standardized 
mean change (SMC) (Morris 2000). SMC was calculated for each trial arm and 
each cohort study by subtracting the follow-up mean score of the outcome 
measure from the baseline mean score and dividing by SD at baseline. Pooled 
SMCs and mean scores of all RCT arms and all cohort studies were calculated 
using standard random effects model meta-analyses methods. The concepts of 
random and fixed effects models have been explained in Chapter Four. To 
compute the 95% Confidence Intervals for response sizes, the variance of 
response size was calculated using the formula given in Chapter Four Analysis 
section. The overall change in outcome scores were investigated for 
heterogeneity by computing I2 (Higgins et al 2003). Meta-regression analyses 
were conducted to assess the significance of the difference in the size of SMCs 
between RCTs and cohort studies at the selected three follow up points.  
187 
 
8.4 Results 
 
8.4.1 Included studies 
The search for cohort studies yielded a total of 964 citations including 31 from 
systematic reviews and cross references. Following exclusion of duplicates 653 
records were screened for inclusion and 592 were excluded. The full texts of the 
remaining 61 articles were assessed for eligibility for inclusion and 33 were 
excluded (Figure 8.1) leaving 28 articles that fulfilled the inclusion criteria. Twenty 
four studies collected data on pain intensity, 13 on RMDQ and eight on ODI. 
However, pain intensity data useful for this analysis, i.e. mean scores for baseline 
and follow up points, were provided in 15 studies only, for RMDQ in six and for 
ODI in only two studies. The other studies provided either only baseline data or 
follow up data stratified by characteristics such as gender or use of healthcare 
service. The analysis was therefore focused on studies providing data on pain 
intensity measured with VAS or NRS for their entire cohort. Nine authors from 
studies that used pain intensity but did not provide data relevant for the analyses 
used in this study in their articles were approached for the mean pain intensity 
scores at baseline and follow up points. Four authors provided the requested 
scores. The final number of cohort studies considered for analyses was therefore 
19. The number of RCTs included was 44 (104 treatment arms) that provided data 
on pain intensity as described in Chapter Four.  
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      Number of records identified     Number of additional records 
       through database searching             identified through other sources 
   933                 31 
 
 
 
 
         Number of records after duplicates removed 
       653 
 
 
 
 
 
          Number of records screened       
       653                 
 
             
             Number of records excluded 
          592 
 
           Number of full text articles        
                          assessed for eligibility           
        61                  
 
              Number of full-text articles 
              excluded, with reasons: 33 
              Not selected outcomes: 19 
              RCT: 3 
            Number of articles fulfilled        Not cohort study: 3 
  inclusion criteria: 28        Not primary care: 1 
     Pain intensity: 24         Specific treatment used: 1 
          RMDQ: 13        Age under 18 years old: 3 
             ODI: 8         Not exclusive to LBP: 3 
 
 
 
       Number of studies providing  
              data appropriate for  
                    analyses: 23 
    Pain intensity: 15 
           RMDQ: 6 
              ODI: 2 
         
 
 
         Total number of studies  
            for which data on pain  
            intensity was available  
          after contacting authors:  
  19 
 
Figure 8.1  Flow chart of identification and inclusion of cohort studies in the systematic  
       review  
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8.4.2 Population characteristics 
Population characteristics of the included studies and trials are presented in 
tables 8.1 and 8.2. The trials and cohort studies were comparable for age, gender 
composition, mean pain duration and baseline pain intensity. Although not directly 
contemporaneous, the trials and cohort studies were both conducted within a 
similar period of time, 1993-2010. 
 
The19 cohort studies included populations that were representative of back pain 
patients. They included direct cohorts from the general population as well as 
consulters in general practice (11 studies) and other allied primary care services 
such as chiropractic clinics, physiotherapy departments. All participants were 
described to be receiving ‘usual’ or ‘standard care’. They were conducted in 13 
countries including the USA and Australia, and European countries. There was no 
major difference in population characteristics between cohort studies that 
provided data included in the analyses and those that did not (Table 8.2).  
 
 
8.4.3 The pattern of pain scores over time 
Pain intensity scores were provided by the included cohort studies at baseline and 
various follow up time points including 1, 2, 4, 6, 8, 13, 27, 36 & 52 weeks. As 
mentioned in the Methods section, data from cohort studies and RCTs were used 
in the analyses if they were within a range of three weeks around the follow up 
times of 13, 27 and 52 weeks. This included nine cohort studies & 58 RCT arms 
at 13 weeks, 10 & 59 at 27 weeks and 13 & 40 at 52 weeks. Two cohort studies 
had a follow up of up to 2 and 6 weeks and were not included in the analyses.   
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Table 8.1  Characteristics of included cohort studies  
 
 
 
Author 
 
 
Country 
 
 
Sample 
Drop-
out rate 
% 
 
Duration of 
pain episode 
 
 
Study population 
Age, 
mean 
years 
 
Female 
% 
Baseline 
pain 0-100 
mean (SD) 
         
Bakker  et al 2007                                                                                                                                                                                                                                                    The Netherlands                                                                                                                                                                                                   97 9 Acute GP consulters                                                                                                                        41 48 60 (15)
BaRNS                                                                                                                                                                                                                                                      UK                                           206                                                                                                                                                                                                                                30 (28)
Bekkering et al 2005                                                                                                                                                                                                                                                  The Netherlands                                      500 4 Acute Physiotherapy consulters                                                                                                             45 52 64 (21) 
Carey et al 1995                                                                                                                                                                                                                                                      USA                                  1628 Acute GP and chiropractic consulters                                                                                                                                                      42 52 53 (24)
Coste et al 2009                                                                                                                                                                                                                                                      France                             103 11 Acute GP consulters                                                                                                                46 40 66 (18) 
Chenot et al 2008                                                                                                                                                                                                                                                     Germany                                                                                                                                                                                                                                                    1342 1 Chronic GP consulters                                                                                                                                         44 51 (21)
Demmelmeir et al 
2010                                                                                                                                                                                                                                                 
Sweden                                                                                                                                                                                                                                                    379 Chronic General population                                                                                                                    42 55 41 (16)
Grotle et al 2007                                                                                                                                                                                                                                                     Norway                                                                   123 9 Acute Primary care                                                                                                             38 55 67 (18)
Hass et al 2002                                                                                                                                                                                                                                                       USA                            2780 63 Acute Community chiropractic clinics                                                                                                                               43 53 51 (25)
Hoogan et al 1998                                                                                                                                                                                                                                                     The Netherlands                                       443 4 Acute GP consulters                                                                                                                        44 55 50 (25) 
Kovacs et al 2006                                                                                                                                                                                                                                                     Spain                                                                                                                                                                                                                                                      648 42 Acute GP consulters                                                                                                                 46 52 59 (22)
McGuirk et al 2001                                                                                                                                                                                                                                                    Australia                                                           83 Acute GP consulters                                                                                                               53 57 41 (27)
Miller et al 2002                                                                                                                                                                                                                                                     UK                                                                                                                                                                                211 6 Acute GP consulters                                                                                                                                     39 60 20 (12)
Nyiendo et al 2001                                                                                                                                                                                                                                                    USA                                                                                                                                                                                                                                                     835 43 Chronic Medical and chiropractic clinics                                                                                                                              51 (24)
Perreault  et al 2006                                                                                                                                                                                                                                                 Canada                                                             78 0 Acute Physiotherapy departments                                                                                                                                 51 45 (23)
Sefarlis et al 1998                                                                                                                                                                                                                                                   Sweden                                                                                                                                                                                                                 60 32 Acute GP consulters                                                                                                              39 51 (14)
Sharma  et al 2009                                                                                                                                                                                                                                                    USA                         2872  Chronic Medical and chiropractic clinics
consulters                                                                                                                                                                                                                
40 50 54 (24)
Tamcan et al 2010                                                                                                                                                                                                                                                     Switzerland                              340 13 Chronic General population                                                                                                                 42 50 30 (16)
van Tulder et al 1998                                                                                                                                                                                                                                                 The Netherlands                                  368 11 Chronic GP consulters                                                                                                                    41 49 56 (29) 
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Table 8.2  Comparison of population characteristics of included studies 
 
  Cohort studies RCTs a 
  Excluded e Included  
     
Number  9 19 44 trials (104 arms) 
Publication year  1996-2010 1994-2010 1993-2006 
Sample size, Median 
(range) 
 297 (39, 974) 368 (60, 2872) 123 (28, 681)b 
51 (12, 340)c 
Age, mean d (SD)  42 (2) 43 (4.1) 43 (5.8) 
Female mean %  44 (8.7) 52 (4.8) 52 (17.5) 
Type of pain n (%) Acute  4 (44) 8 (42) 18 (41) 
 Chronic 5 (56) 11(58) 26 (59) 
Baseline pain 
intensity, mean c (95% 
CI) 
  47.29 (38.62, 55.95) 46.78 (43.69, 49.88) 
     
a RCTs that provided data on pain intensity outcome. b Sample size of RCT. c Sample size of arm.  d Mean of 
all cohort/RCT means. e Studies excluded because they did not provide data appropriate for analysis in this 
study. 
 
 
 
 
The course of pain intensity scores in the cohort studies plotted in Figure 8.2 
shows a common pattern of large and rapid improvement of pain symptoms in the 
majority of studies within the first 13 weeks followed by very small further 
improvement over the period to 52 weeks. This appears to be similar to the 
pattern of responses to treatments in the included RCTs as shown in Chapter 
Four Figures 4.3a-c. 
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Figure 8.2  The course of pain symptoms in the included cohort studies. 
 
 
 
 
8.4.4 The size of change in pain scores 
Pooled mean pain intensity scores at baseline and follow up for cohort studies 
and RCTs are presented in Table 8.3 and Figure 8.3. The pooled estimates 
confirm the similar pattern of improvement in symptoms in both RCT arms and 
cohort studies.  
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Table 8.3  Pooled pain intensity scores on VAS 0-100, mean (95% CI), of included 
RCTs and cohort studies 
 
 Baseline 13weeks 27weeks 52weeks 
     
RCTs     
Pain 
intensity 
46.78 (43.69, 49.88) 29.78 (26.63, 32.94) 25.60 (22.94, 28.26) 28.79 (25.82, 31.76) 
Sample 
size* 
7225 4820 3719 2870 
     
Cohorts     
Pain 
intensity 
47.29 (38.62, 55.95) 29.10 (22.72, 35.49) 25.42 (12.34, 38.51) 25.69 (20.32, 31.06) 
Sample 
size* 
13096 10965 5580 6386 
     
*The sum of sample size of all included studies that provided data for the selected follow up times.  
 
 
 
 
 
Figure 8.3   Pooled mean pain intensity scores in included cohort studies and RCTs 
 
 
 
Change in symptoms is best represented by SMC values (Table 8.4, Figure 8.4) 
that take into account the distribution (standard deviation) of baseline scores. 
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Table 8.4  Pooled estimates of SMCs for pain intensity (baseline mean-follow up 
mean/baseline SD) (mean, 95% CI) of included cohorts and RCTs using 
random effects model meta-analysis. 
 
 Pooled SMCs (95% CI) 
 13weeks 27weeks 52weeks 
 n  I2 n  I2 n  I2 
          
RCTs 67 0.99 (0.86, 1.11) 91 62 1.07 (0.93, 1.20) 90 55 0.91 (0.76, 1.05) 89 
          
Cohorts 9 1.03 (0.79, 1.28) 99 10 1.27 (0.77, 1.77) 99 13 1.14 (0.81, 1.47) 99 
          
p  0.755   0.295   0.238  
          
 
 
 
 
 
Figure 8.4  Pooled SMCs for pain in included cohort studies and RCTs 
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Three observations can be made from these SMC values: firstly they show large 
size improvement in pain symptoms in both RCT arms and cohort studies, ranging 
from 0.91 for RCT arms at 52 weeks (55 arms) to 1.28 for cohort studies at 27 
weeks (8 studies). SMCs larger than 0.8 are considered large, 0.5 – 0.8 moderate 
and less than 0.5 small (Cohen 1997). Secondly, there is a large heterogeneity in 
the sizes of pain improvement in cohort studies (as represented by the high 
I2 values), slightly larger than the heterogeneity in the responses in RCT treatment 
arms. Thirdly, Meta-regression analysis revealed no statistically significant 
difference between the SMC values of RCTs and cohort studies at any follow up 
point.  
 
 
8.5 Discussion 
 
The aim was to examine the course of back pain symptoms in cohort studies and 
compare it with that in randomized clinical trials. The supposition was a large 
improvement of symptoms among RCT participants that would be attributed to 
their participation in the RCT.  
 
The results did not show evidence for the hypothesis that improvement in cohort 
studies was smaller than that in RCTs.  
 
One explanation for the findings would be that such an effect does not exist. 
Another explanation could be the fact that RCTs and cohort studies are not 
greatly different in the attention and care provided to their participants, or at least 
how the care and attention are perceived by the participants. In other words, it is 
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plausible to assume that cohort participants would still perceive participation in 
cohort studies to be beneficial. This, if true, would explain the inability of this study 
to find smaller size of symptom improvement in cohort studies compared with 
RCTs.      
 
The results also showed no significant difference in the course of symptoms and 
the size of change over time between RCTs and cohort studies. Similar to that in 
RCTs, this large improvement in symptoms over time common to the included 
cohort studies represents, at least in part, the effects of non-specific factors. 
These non-specific factors, which were discussed in Chapter Two, would explain 
much of the large variation that was found in the size of symptom improvement in 
the cohort studied. 
 
Studying their association with the course of symptoms in these cohort studies, 
similar to how this was studied in RCTs in Chapter Six, would have been 
informative but was not feasible for the small number of studies.    
 
To further understand the findings, a number of issues need to be discussed in 
more detail:  
 
8.5.1 The benefits from participating in an RCT 
It is not difficult to have a conjecture on the reasons why an RCT might have a 
beneficial effect on its participants. The invitation/recruitment process might have 
implicit positive assumptions or promises; the treatment offered might be a new 
treatment or the trial might be large and heavily publicized. Trial clinicians might 
assess patients more extensively, be better trained to deliver the treatments or 
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more careful and thorough in following and adhering to the trial protocol. The 
participants might have high expectations regarding the trial treatment or have 
particularly high perceived needs. However, such assumed beneficial trial effects 
have not been supported by solid unequivocal evidence.   
 
A reason for the lack of solid evidence may lie in the difficulty in capturing a trial 
effect assuming it exists. Various approaches have been adopted to examine 
such an effect (Braunholtz et al 2001, Stiller 1994, Vist et al 2005) each with its 
own caveats and shortcomings. No single approach was considered as gold 
standard. The crucial issue is the choice of the comparison population that would 
have no exposure to any ‘trial effect’. Various comparison populations have been 
suggested such as eligible patients who were not recruited for an RCT; eligible 
patients who refused to participate in an RCT; eligible patients from a 
geographical area other than that of the trial and eligible patients of practitioners 
who were not involved in the trial. Using RCTs nested in cohort studies is another 
example of a method that would provide an opportunity for a contemporaneous 
comparison of the two populations. The findings of attempts to examine the 
evidence for a ‘trial effect’ provided inconsistent results ranging from a positive 
trial effect (Braunholtz et al 2001) to a negative trial effect (Rochon et al 1999) 
through no-effect (Stiller 1994, Vist et al 2005). 
 
One review (Stiller 1994) examined the published literature for survival rates for 
cancer with relation to entry into clinical trials. The review included eight studies 
that examined cancer survival rates in patients selected to enter RCTs and in 
those who were not but were included in population-based cancer registries 
(Ward et al 1992, Davis et al 1985, Bertelsen 1991, Karjalainen & Palva 1989, 
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MRC 197, Stiller et al 1989, Lennox et al 1970). It found that the survival rate of 
cancer patients who were selected to enter into clinical trials was higher than that 
of concurrent non-trial patients who were on the cancer registries, in all of the 
eight studies. The review acknowledged that these outcomes should be 
considered within the context of varying criteria for patient selection for the studies 
and also for the different qualities and completeness of cancer registries in 
different countries. The review also reported results regarding cancer patients 
treated at major specialist centres and teaching hospitals compared with smaller 
centres or non-teaching hospitals, which showed that higher survival rates among 
the former groups were not conclusively found in all studies.  Studies varied in 
their inclusion criteria and in the meaning or relevance of the differences ascribed 
to the comparison centres and their populations.  
 
A second review (Braunholtz et al 2001) specifically aimed to examine the 
evidence for an added effect of participating in a randomized clinical trial, again 
through examining the published literature.  It included 14 articles, the majority of 
which were on cancer patients. This review nicely illustrates the wide variation in 
the choice of comparison group with potential significant impact on outcome. One 
of the 14 articles did not include a concurrent comparison or control group but 
simply compared outcome of RCT patients, who were asthmatics, with that 
forecast by the authors given the natural course of the disease. Two articles made 
indirect comparisons: between trial districts (where patients were entered into one 
of three trials) with control districts, and between treating physicians who were 
associated with Medical Research Council (MRC) trials and control physicians 
who were not. The remaining 11 articles compared the clinical outcomes of 
patients in one or more trials directly with those in at least one concurrent non-trial 
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control group. In three studies, the non-trial group was made up of people who 
had refused to participate in the trial; one study used refusers as well as eligible 
but non-recruited patients of recruiting clinicians; one study used all non-
randomized patients of recruiting clinicians. They found that six trials reported 
larger statistically significant overall improvement among RCT participants 
compared with non-participants and three reported a favourable trend that was 
not statistically significant. This review was updated in 2004 (Peppercorn et al 
2004), including seven of the earlier trials and adding a further 17, in an attempt to 
capture a larger data source and provide clearer evidence. Their conclusion was 
that sufficient data were still not available to confidently provide evidence for a trial 
effect.  
 
Vist et al conducted a systematic review to compare the outcomes of participants 
in RCTs with non-participants who received the same or similar treatments (Vist et 
al 2005). They included five RCTs and 50 cohort studies. Participants of the RCTs 
were randomised to whether they had the option to participate. Two RCTs 
randomised patients to “n of 1 trial” compared with standard practice—that is, 
randomised, double blind, multiple crossover comparisons of an active drug with a 
placebo in a single patient. One study was in patients who had or had not been 
informed that they were in an RCT. One study in patients randomised to an RCT 
compared results with patients randomised to a patient preference trial in which 
they had a choice of treatment. Another study was in patients randomised to an 
RCT compared with those who were not invited to participate. The outcomes and 
the questions asked varied, one study measured spontaneously self-reported side 
effects in patients who had or had not been informed that they were in an RCT, 
another reported satisfaction among patients randomised to an RCT compared 
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with patients randomised to a patient preference trial in which they had a choice of 
treatment, another reported pain reduction among patients randomised to an RCT 
compared with those who were not invited to participate. None of these studies 
found significant differences in outcomes between patients treated in or outside 
RCTs. Of the total of 73 comparisons in the cohort studies between patients 
participating in RCTs and patients treated outside RCTs, 59 comparisons reported 
no significant differences in outcome; 10 reported significantly better outcomes for 
patients treated in RCTs, and four reported significantly worse outcomes for 
patients treated in RCTs. 
 
The overwhelming majority of trials included in these reviews were among cancer 
patients. We are not aware of any work that examined the influence of 
participation in RCTs among back pain or other musculoskeletal patients. The 
nature of the medical condition or the symptoms, their prognosis and outcomes 
will arguably have an influence on any beneficial effect, or otherwise, from 
participating in a trial. Therefore, there might well be some unique features that 
enhance or diminish the trial effect among cancer patients compared with patients 
with other non-life threatening conditions such as back pain. Cancer patients, for 
instance, might have higher hopes and expectations from participating in a trial 
with potentially effective or new treatments that are often not available at the time. 
The results of the systematic reviews examining trial effect in cancer trials, 
however, did not seem to identify solid evidence for such a benefit. Other factors 
might confound the trial effect such as the type of cancer and its prognosis and 
the availability of effective treatment. Vist et al (2005) commented that the effects 
of such possible confounders were not explored in the included studies.  
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8.5.2 The ‘negative’ effects of RCTs  
Participation in clinical trials might have a negative impact on some participants. 
One relevant issue is the role of participants’ expectations regarding the treatment 
which might influence any preference they might have for the trial treatment. 
Some participants might have such strong views regarding a particular treatment 
that this would influence their decision whether or not to participate and consent to 
randomisation. In the previous chapter some evidence, albeit inconclusive, was 
found for a greater improvement among RCT participants who received their 
preferred treatment. If patients with strong preferences self-exclude themselves 
from RCTs, included participants might have no or weak preference regarding the 
treatment used and this might possibly lead to low estimates of response. If 
patients with strong preference participated hoping to receive the preferred 
treatment then were disappointed with the outcome of treatment allocation, they 
might either drop out or have a poorer outcome (‘resentful demoralisation’ 
(Berglund et al 1997)). This second scenario might in fact augment the difference 
between the RCT two treatment arms, i.e. increase the specific treatment effect. 
The implication of all these scenarios depend on the strength of participants views 
and preferences, the prevalence of those with strong preferences and more 
importantly the number of those who self-excluded themselves because of their 
strong views. Another factor to consider is blinding patients to treatments, which, 
as was discussed in Chapter Five, is not commonly performed adequately in 
RCTs on back pain, intentionally not performed in some pragmatic trials or not 
possible with some manual treatments. Preferences, expectations, allocation to 
treatments, randomization, patient blinding and other factors are complex and 
often interact with each other, hence the complexity of their positive or negative 
impact on participation in an RCT and subsequent patient outcomes.    
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8.5.3 Outcomes to measure the ‘trial effect’ 
Another issue that is important to address is the exact nature of the ‘trial effect’ if 
such an effect exists and whether the appropriate or correct tools are being used 
to assess it and measure it. Outcome measures used were to assess pain 
intensity and functional disability. The effects of the extra care and attention 
provided in clinical trials and the satisfaction or otherwise of receiving or not 
receiving the preferred treatment might be poorly captured by these measures. 
Other more global tools such as patient satisfaction might be better suited to 
measure these effects. This measure, however, does not have a universally 
agreed structure or definition and it is not designed specifically to measure the 
trial effect. Survival rate was an outcome that was commonly used in the studies 
and reviews that assessed the trial effect in cancer studies mentioned earlier. It is 
not clear whether the reported differences in survival rates reflected the trial effect 
or treatment effects, as most of these reviews did not adjust for type of cancer 
treatment. The review by Vist et al. (2005) was the only review that compared 
studies using the same or similar treatments, and did not identify strong evidence 
for a trial effect.  
 
 
8.6 Limitations 
 
A large pool of back pain RCTs with various types of treatments for back pain was 
accessed to explore the size of change in pain symptoms in their various arms 
and compare this with the change in pain intensity in cohort studies. The number 
of cohort studies from which relevant data were available was too small to provide 
similarly powerful analyses. Although the overall numbers were sufficient to 
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compare response sizes, the small number did not allow for useful subgroup 
analyses. An example of a subgroup analysis that would be useful in the context 
of examining a trial effect is the type of treatments used in the comparison groups.  
 
Excluding cohort studies that did not include data relevant to the analyses used in 
this study might have introduced potential selection bias. However, they were not 
different in their population characteristics from included studies. The populations 
of the included cohort studies seemed to be representative of non-specific back 
pain patients encountered in primary care.  
 
Although the number of cohort studies included was small, their population 
characteristics appear similar to those of included RCTs and also to those of the 
excluded cohort studies. This strengthens these analyses and subsequent 
conclusion.  
 
The method adopted in this study to examine the evidence for a trial effect might, 
arguably, not be the best approach. As was discussed earlier, various methods 
have been suggested with varying claimed accuracy in capturing this effect and 
these produced inconsistent results. However, it was decided to make use of the 
material available to attempt to achieve the study aims.  
 
 
8.7 Summary 
 
Progression of back pain symptoms in cohort studies follows a pattern that is 
similar to that in RCTs represented by large early improvement followed by a 
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smaller irrelevant further improvement. Evidence was not shown for an added 
effect of participating in RCTs compared with cohort studies. However, it could not 
be confidently concluded that this is evidence for the lack of such an effect. A 
better understanding of the meaning and nature of the effect of participating in a 
clinical trial, possibly through qualitative research, and careful design of methods 
to assess the effect and appropriate outcome measures that accurately capture it, 
are needed to provide robust evidence for or against it.  
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Chapter Nine 
 
 
Discussion and conclusions 
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In this chapter, the main findings from the various stages of the study will be 
summarised. This will be followed by a discussion of these findings within the 
context of the broad study aims. This will avoid repeating the detailed discussion 
points that were addressed in previous chapters and instead will focus on the 
main overarching points. The limitations of the research will be outlined and 
general conclusions will be drawn and recommendations for future research 
made.  
 
The overall aim of this thesis was to examine the association between non-
specific factors and within-arm response (symptom improvement) to treatments 
for non-specific low back pain (NSLBP). The specific objectives were:  
 
1. To examine within-arm overall responses to treatments in RCTs on non-specific 
low back pain to assess the pattern and the size of those responses and the 
extent of variation between them.  
2. To examine the sources of variation in responses to treatments by investigating 
the association of non-specific factors (represented by trial level characteristics 
including mean age and gender of participants, duration of low back pain and 
aspects of trial quality) with overall responses to treatments in RCTs. 
3. To examine the influence of patient characteristics (age, gender, duration of 
pain, previous history of back pain, expectation regarding helpfulness of treatment 
and preference for treatment) on responses to treatments using individual patient 
data from RCTs.  
4. To examine whether merely participating in RCTs contributes to the size of 
symptom progression (the ‘trial effect’).  
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9.1 Summary of findings 
 
9.1.1 The pattern of overall responses to treatments 
Based on the results from 118 trials the thesis (Chapter Four) showed evidence 
for a common pattern in responses to treatments for NSLBP in RCTs, represented 
by a rapid and large improvement in symptoms within the initial 13 weeks after 
inclusion followed by a plateau showing little change in symptoms over the next 6 
months. This pattern appeared to be common to most treatment arms and 
regardless of whether they were index or comparator treatments.  
 
9.1.2 The association between trial characteristics and responses to 
treatments using aggregated data (AD) 
The results of meta-regression analyses using AD of RCTs (Chapter Six) showed 
that male gender (for both outcome measures of pain intensity and RMDQ), short 
duration of low back pain episode (for pain and RMDQ), higher trial overall quality 
(for pain), better reported compliance (for pain), low drop-out rate (for RMDQ) and 
adequate patient blinding (for pain and RMDQ) were associated with larger within-
arm responses to treatments.  
 
9.1.3 The association between patient characteristics and responses to 
treatments using IPD 
The outcome of pooled IPD analyses (Chapter Seven) showed that duration of 
back pain episode and history of back pain influenced responses to treatments in 
the six RCTs included in the analysis. Evidence was not found for a significant 
influence of age, gender, patient expectation of helpfulness of treatment or 
preference for treatment on symptom progressions using RMDQ. However, the 
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direction of the association between these characteristics and symptom 
progression for RMDQ, using both within-arm and pooled analyses, suggested a 
similar trend for larger responses to treatment in favour of patients younger than 
43 years compared with older patients, men compared with women, and those 
who reported a preference for treatments compared with those who did not.  
 
9.1.4 The ‘trial effect’ 
The thesis (Chapter Eight) did not show evidence for a ‘trial effect’. The size of 
symptom improvement as measured by pain intensity and disability in 104 
treatment arms of 44 RCTs was similar to that in 19 cohort studies. Similar to 
RCTs there was a large variation in the size of the change in symptoms in cohort 
studies. However, the number of included cohort studies was too small to enable 
an assessment of non-specific factors as possible sources of that variation, as 
was performed with RCTs (Chapter Six). 
 
 
9.2 Discussion of findings 
 
9.2.1 Symptom progression 
In this section the following issues will be discussed: the overall pattern of 
symptom progression in RCTs on NSLBP; the size of improvement in back pain 
symptoms in RCTs, the case definition (NSLBP) and the choice of follow up time 
points and of outcome measures.  
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9.2.1.a The pattern of responses to treatments 
The findings in this thesis support the observation of a common pattern of within-
arm responses to treatments in RCTs for primary care treatments for NSLBP. This 
provides empirical evidence for what has hitherto only been an anecdotal 
observation of a common pattern of responses in trial arms. There was also a 
large variation in the sizes of those responses. Evidence was not found that the 
type of treatment (index, active comparator, placebo, usual care, waiting list, 
pharmacological or non-pharmacological) explained that variation.  
 
9.2.1.b The size of overall responses to treatments 
Estimating the specific effects of primary care treatments for back pain was 
outside the objectives of this thesis. However, cautious comparison will be made 
between effect size estimates from the literature of treatments commonly used for 
NSLBP and the size of effects of some non-specific factors estimated in this 
thesis, in order to get some understanding of the magnitude of the size of the 
context effect associated with the use of treatments relative to their specific 
effects.  
 
In a published systematic review which estimated the specific effects of 
treatments for NSLBP in RCTs (as the mean difference between response to 
active treatment and a placebo treatment), Machado et al (2009) reported that the 
treatment used in the largest number of trials was muscle relaxants and this had a 
pooled effect size of 12 points on a 0-100 pain intensity VAS (95% CI 7, 18) 
compared with placebo, from nine trials including 820 participants. Point estimates 
for effects of 16 treatments (half of the treatments included in the review) were no 
more than 10 points on a 0-100 scale for pain intensity. These treatments 
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included traction, physiotherapy, prolotherapy, exercise, anti-depressants, 
behavioural treatments, adenosine triphosphate, spinal manipulative therapy, 
NSAIDs, percutaneous thermo-coagulation intradiscal techniques, radiotherapy 
and magnets. The effect was not significantly larger than placebo for 15 of these 
treatments (NSAIDs being the exception).   
 
In this thesis, the size of differences in overall responses to treatments according 
to a particular non-specific factor was up to 8.99 points (95% CI -1.68, 19.66) (0-
100 VAS for pain) for compliance at 27 weeks using AD. Using IPD, the significant 
difference in within-arm symptom progression according to particular non-specific 
factors for pain intensity (0-100 VAS) was up to 20.1 points (95% CI 0.9, 39.4) for 
short versus long episode duration in the low intensity back school arm of the 
Heymans et al trial at 52 weeks. These values suggest that the size of effect of 
some non-specific factors is comparable to that of the specific effects of some 
treatments.  
 
The observed small size of treatment effects in RCTs on NSLBP has a number of 
possible explanations. Clearly, the treatments may indeed have small specific 
effects. Alternatively, the specific effect may not be captured completely due to 
using inadequate outcome measuring tools or some non-specific factors may 
have large effects on symptoms that might overshadow the specific effect of the 
treatment. In some cases such non-specific factors might be considered an 
integral part of the treatment itself, e.g. communication with patient in acupuncture 
treatment.  
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9.2.1.c The nature of non-specific low back pain  
A challenge in RCTs of NSLBP is the heterogeneity of the group of patients who 
are included in these trials as having ‘non-specific low back pain’. ‘Non-specific 
low back pain’ (NSLBP) is a name that has been increasingly used since its 
introduction in the early eighties to refer to low back pain that has no identifiable 
cause or pathology. The clearly appealing simplicity this definition might provide, 
however, has a number of problems. First, it is not known what proportion of 
NSLBP patients included in RCTs has in fact an underlying specific pathology that 
simply has not been identified. Second, accepting that a large proportion of 
patients do actually have NSLBP with no specific pathology, this description 
encompasses patients who are widely heterogeneous in their characteristics such 
as severity of symptoms, history of back pain, co-morbidities and co-pharmacies, 
previous use of treatments, expectations, beliefs regarding illness and treatments 
and healthcare services utilization. Viewing these patients as a single 
homogeneous group and expecting them to show uniform reactions and 
responses to treatments, therefore, might be inappropriate. This variation in 
patients’ characteristics is certainly not exclusive to back pain and is present 
among patients with other medical conditions. However, it is not clear whether the 
lack of an identifiable diagnosis for NSLBP might make the impact of variation in 
patients’ characteristics on symptom progression more prominent compared with 
other conditions with specific diagnoses such as diabetes or hypertension. This 
might be explained by the arguably large heterogeneity of NSLBP patients 
regarding the back pain diagnosis compared to those with hypertension or 
diabetes. Also, although RCTs use baseline characteristics of participants to 
assess comparability between treatment arms, these descriptions are often 
restricted to socio-demographic and disease specific characteristics and do not 
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include the other potentially important characteristics mentioned above. Dividing 
non-specific back pain patients into more homogeneous subgroups with common 
characteristics might be one way to assess whether certain treatments might be 
effective in certain groups. This was the drive and the basis for the proposal of 
using classification systems in non-specific low back pain trials (Hay et al 2008, 
Flynn et al 2002). In fact, results from such trials seem to show a better response 
when treatments are matched with patients groups’ characteristics compared with 
that among patients receiving unmatched treatments (Brennan et al 2006) or non-
stratified care (Hill et al 2011).  
 
9.2.1.d Follow up times in RCTs 
The findings in this thesis show that the large improvement in symptoms in RCTs 
occurred early after the end of treatment. Findings from systematic reviews on 
treatments for NSLBP show that evidence for effectiveness of treatments was 
mainly in the short term rather than the long term (van Tulder et al 2006). In fact, 
in one review, treatment effects were estimated with the primary endpoint of the 
first follow up time after end of treatment (Keller et al 2007), citing the ‘known’ 
observation that patients improve most early in the course of trials as the 
justification for selecting this time point.  
 
This raises the issue of the choice of follow up time points in RCTs. In this thesis, 
the follow up points of 13, 27 & 52 weeks were selected because they were the 
points most commonly selected by the included trials and because this allowed for 
a comparison of the pattern and size of response between trials. There were 
RCTs that provided data on earlier time points (from as early as one day after the 
end of treatment), however the number of such trials was too small to allow for a 
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useful comparison. Assessing responses to treatment in this early period is 
required in newly conducted trials to enable examination of the influence of non-
specific factors on responses in this period. 
 
9.2.1.e Selection of outcome measures  
The detailed analyses in this thesis were focused on the outcome measures most 
commonly used in the included trials, primarily pain intensity for AD analyses and 
RMDQ for IPD analyses The usefulness of using uniform outcome measures in 
RCTs is widely recognised in that, among other benefits, it allows comparison and 
pooling of studies’ findings (Jadad 1998, Jadad and Cepeda, 2000, Dworkin et al 
2005). 
 
It is relevant to discuss the issue of whether the outcome measures selected for 
analyses in this thesis were the ‘right’ outcomes that would be likely to capture the 
effects of non-specific factors. The two outcomes used (pain and disability) are 
subjective outcomes and as such would allow for and be expected to capture the 
effects of non-specific factors such as patient expectations and beliefs, and trial 
and practitioner factors. However, it could be argued that these outcome 
measures might not capture the totality of patient’s experience with treatment. A 
combination of outcomes including patient perceived global improvement, patient 
satisfaction with treatment, depression scales and quality of life measures would 
be appropriate to capture the whole experience of receiving the treatment as well 
as the influence of other non-specific factors. The initial plan in the systematic 
review presented in Chapter Four was to collect data on all these outcomes in the 
included trials. However, there were insufficient data for most outcomes, which 
meant they could not be included in the analyses. In addition, the lack of 
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uniformity in the scales used in trials was a further obstacle for any meaningful 
interpretation or attempt at pooling the results of these other outcome measures.  
 
Future researchers might consider using outcome measures that have been 
specifically developed based on the understanding of the complexity and 
interaction of non-specific factors with each other and with the treatments used. 
An example for the latter is a measure that incorporates expectation regarding 
helpfulness of treatments with reasons for these expectations (e.g. previous use 
of the treatment, desperation to try something new or recommendation by a friend 
or own practitioner) combined with preferences for treatment and reasons for the 
preferences. Such a tool has been developed (van Hartingsveld et al 2010) and 
could be used to explore the impact of patient expectations on responses to 
treatments.  
 
 
9.2.2 The association between non-specific factors and symptom 
progression 
 
AD and IPD were used to study the extent to which non-specific factors explain 
the variation in the size of responses to treatments. AD was used in meta-
regression analyses to study factors at a trial level (trial setting, quality, 
participants’ age and gender and duration of back pain episodes). Selection of 
these factors or characteristics was based on evidence for their importance from 
the literature and the availability of sufficient data for analyses in the included 
trials. IPD was used to study some of the same characteristics that were studied 
using AD but at the individual patient level (age, gender, pain duration). The IPD 
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analysis also addressed other characteristics that were considered to represent 
potentially important non-specific factors and for which available AD from RCTs 
was not sufficient for pooled analyses, such as history of back pain, patient 
expectation regarding helpfulness of treatment and preference for treatment.  
 
9.2.2.a AD vs IPD 
IPD meta-analysis is a lengthy and resource intensive exercise but has more 
statistical power compared with AD and so is more likely to detect a clinically 
relevant association with statistical significance. Also, as was pointed out in 
Chapter Six, using AD is associated with the risk of providing biased results when 
associations are detected that are not present within the individual study samples 
(aggregation bias).  
 
9.2.2.b The associations of non-specific factors with symptom progression 
Table 9.1 summarises the evidence for and the direction of the associations 
between the non-specific factors studied in this thesis and responses to 
treatments using AD and IPD analyses for the outcome measures for which data 
were available. Pain intensity was not used for the pooled IPD analyses because 
of the small number of trials that provided data for this outcome. 
 
The table shows that for the three non-specific factors used in both AD and IPD 
analyses (age, gender and duration of NSLBP episode), consistently strong 
evidence for an association with symptom progression on pain and RMDQ 
outcomes was found only for duration of the back pain episode at most follow up 
times. The direction and size of difference in response was also consistent at 
these points.  
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Table 9.1 Summary of the evidence for the statistical significance and the direction of  
the associations between the studied factors and responses to treatments 
based on outcomes of pooled analyses of AD and IPD.  
 
 AD IPD 
 Pain RMDQ RMDQ 
 13w 27w 52w 13w 27w 52w 13w 27w 52w 
Age, <43 years ●+ ○+ ○+ ○+ ○- ○- ○+ ○+ ○+ 
Gender, male ○+ ●+ ●+ ○+ ○+ ●+ ○+ ○+ ○+ 
Duration of NSLBP episode, 
acute 
○+ ●+ ●+ ●+ ●+ ●+ ●+ ○+ ●+ 
History of NSLBP, absent       ○- ○+ ●- 
Expectation of helpfulness of 
treatments, low 
       ○+ ○ ○+ 
Preference for treatments          
     Absent       ○- ○- ○- 
Treatment type (ref: usual care)          
     Index ○- ○- ○- ○+ ○- ○-    
     Active comparator ○- ○- ○- ○- ○- ○-    
     Waiting list  ○+ ○- ○-       
     Placebo ○-  ○- ○-      
     Non - pharmacological  ○+  ○+   ○+      
Setting (ref: general practice)          
     Occupational health care ○-  ○+ ○- ●- ●- ●-    
     Physiotherapy departments  ○+  ○+  ○+  ○- ○+    
     General population ○- ○- ○- ●- ●- ●-    
     Mixed setting ○- ○- ○- ●-                                      ●- ○-  
     Other  ○+   ○- ○- ○-    
Trial overall quality, low ○- ○- ●-   
○+ 
○+ ○+    
Individual quality criteria, not 
adequate 
         
     Adequacy of randomisation ○+ ○- ○- ○- ○- ○-    
     Concealment of allocation to   
     treatment arms 
  ○-       
     Patient blinding ○- ●- ●- ●- ●- ●-    
     Care provider blinding ○-  ○+ ○- ○-  ○-    
     Co-interventions prevented ○- ○- ○-  ○+ ○+ ○-    
     Co-interventions standardised  ○+  ○+  ○-      
     Compliance ○- ●- ●-  ○+ ○- ○-    
     Drop out ○- ○-  ○+       
     Measurements comparable  ○+    ○+ ○+ ○+    
    Intention to treat analysis  ○+ ○- ○- ○- ○- ○-    
          
● Indicates statistically significant association. ○ Indicates statistically non-significant association. + Indicates 
higher response for given category of factor. – indicates lower response for given category of factor. Lack of a 
sign indicates lack of sufficient data for analysis. 
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An issue discussed in Chapter Seven is whether episode duration is a non-
specific factor in the context studied in this thesis or whether it simply represents 
the natural history of back pain symptoms, with long baseline duration of 
symptoms reflecting chronic, persistent back pain. However, as the definition of 
non-specific factors adopted in this thesis covers factors that could influence 
symptom progressions (contributing to the clinical course of back pain symptoms) 
and be related to the patient, symptoms, practitioner, treatment or setting, it is 
reasonable to consider symptom duration a non-specific factor.  
 
There was no conclusive evidence for the association between age and symptom 
progression, which was only significant using AD and only at 13 weeks. The 
direction of associations between age and outcome measures was also not 
consistent. This would suggest that responses to treatments in RCTs on non-
specific low back pain do not systematically vary depending on age. This is in 
contrast to evidence available from some observational studies that suggest older 
age has a negative effect on recovery from back pain symptoms (van Doorn 1995, 
Bakker et al 2007). 
 
For gender, the significant association with symptom progressions based on AD 
analyses for the RMDQ and pain intensity outcomes was not supported by 
evidence from IPD analyses. However, the direction of association was similar for 
both types of analyses, for both outcome measures and at all follow up time 
points. This would suggest a trend of larger symptom progression among men 
compared with women. Evidence from the literature for an association between 
gender and symptom progression is limited, although it suggests that female 
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gender is associated with higher reported pain severity and functional disability 
(Chenot et al 2008). 
 
Aggregated data on history of back pain were not available from a sufficient 
number of RCTs to assess its association with symptom progression. Using IPD 
analysis, the evidence for the association between history of back pain and 
symptom progression was limited to the pooled IPD analysis on RMDQ at 52 
week follow up. This suggests that patients with no history of back pain showed 
smaller responses to treatments on RMDQ only at 52 weeks. As was already 
discussed in Chapter Seven, the variations in the scales used in trials to collect 
data on this characteristic as well as the possible overlap between history of back 
pain and duration of back pain episode might explain the inability to arrive at a 
clear evidence for the association between history of back pain and symptom 
progression. 
 
9.2.2.c The large unexplained heterogeneity in the size of responses 
The non-specific factors studied in this thesis explained only a small proportion of 
the heterogeneity in symptom progression with the larger proportion remaining 
unexplained. This may be due to the lack of sufficient information from the 
published reports on important trial characteristics, as was the case for a number 
of the individual quality criteria or on other important factors that were not studied, 
such as practitioner skills, patient-practitioner interaction, patient beliefs, patient 
previous relevant experiences and concomitant use of other treatments.  
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9.2.2.d The effects of the non-specific factors in a broad context 
One issue that has been discussed in Chapter Three and merits further 
discussion here is whether the influence of non-specific factors on symptom 
progression is generic and fixed across all types of patients, practitioners, 
treatments and settings or whether it is variable and related to the individual 
patient, the particular disease, symptoms or practitioner. It is plausible to expect 
that at least part of the effects of non-specific factors is related to or dependent on 
other factors.  
 
An example of a non-specific factor that has been studied for interaction with 
other factors is patients’ expectation regarding the treatment. Studies have 
suggested that expectation regarding the outcome of treatment can be influenced 
by patient beliefs (Kincheloe et al 1991, MacDonald et al 1980) and by verbal 
suggestions (Kirsch et al 1988, Benedetti et al 1999, Pollo et al 2001, Benedetti et 
al 2002). Treatment expectations could be positively influenced, for example, by 
explaining to the patient the mechanism of action of a particular treatment or by 
suggesting that the treatment is effective as supported by evidence. Negative 
expectations could be triggered by suggesting to the patient that it is not known 
whether the treatment offered is effective. This might be one explanation for the 
contradictory findings from trials that attempted to explore the effect of patient 
expectation on treatment outcome. 
 
Related to this is the broad issue of the utility of identifying influential non-specific 
factors for research and clinical practice. Factors that influence patient outcomes 
have been structured around three broad categories in research terms: 1) 
predictors or prognostic factors, 2) treatment effect modifiers or moderators, and 
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3) treatment mediators (Hill & Fritz 2011). Prognostic factors are those factors that 
are said to influence patient outcome regardless of the treatment used. Examples 
include symptom duration or presence or severity of depression symptoms. 
Treatment effect modifiers are factors that are measured at baseline and are 
associated with response to a specific treatment. These include factors such as 
patient expectations regarding the treatment or educational level in the case of 
cognitive therapy. Prognostic factors and effect modifiers do not have to be 
causally associated with symptom progression, but can be used to identify high 
risk patients who may need further treatment (prognostic factors) or to select 
patients who may benefit from specific treatments (modifiers). ‘Treatment 
mediators’ is the name given to factors that influence or mediate the effect of a 
particular treatment on outcome and explain why treatments may or may not work 
in individual patients. Examples of such factors include self-efficacy, which may 
become a specific target for a treatment with the aim of increasing the effect of the 
treatment in particular individuals.    
 
This is perhaps a simplified representation of a rather complex area where some 
factors could belong to more than one category (e.g. self-efficacy can be a 
prognostic factor, modifier and mediator when investigating the effects of cognitive 
behavioural treatment for NSLBP). Some factors could be considered as integral 
part of the treatment, as was mentioned earlier (e.g. reassurance or 
communication in acupuncture), yet may be seen as mediators, partly explaining 
the effect of the treatment.  
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9.3 Strengths and limitations 
 
9.3.1 Strengths 
3.3.1.a Multi-method approach 
A strength of this thesis is the fact that its findings are based on adopting a multi-
method approach in studying the data. This included systematic reviewing, meta-
analyses and meta-regression analyses, using aggregated as well as individual 
patient data, from randomised clinical trials and cohort studies in addition to a 
semi-Delphi approach in a consensus study. Such approach allowed the use of a 
triangulating method in testing the evidence from one source of data using one 
approach to be corroborated with evidence from another source or another 
approach. On a personal educational and experience development level, which is 
relevant as this research project was undertaken in the context of a training 
fellowship, this provided me with the experience of using these various methods 
and sources of data and learning about their advantages and challenges.  
 
9.3.1.b The number of included studies 
Notwithstanding the fact that obtaining a larger number of studies would have 
provided more powerful analyses, the findings in this thesis was based on 
studying a large volume of data, including 118 randomised clinical trials for 
NSLBP in the aggregated data analysis.  
 
9.3.1.c studying responses to a wide range of treatments 
The approach in this thesis went beyond studying responses to a specific 
treatment, to studying responses to treatments as a generic entity, i.e. studying 
responses to a wide variety of treatments rather than to a particular treatment. I 
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am not aware of a study that adopted a similar approach in which the effects of 
non-specific factors on responses to treatments were studied regardless of the 
type of treatment.  
 
 
9.3.2 Limitations 
 
Some limitations have been referred to earlier in this chapter and in the various 
chapters of the thesis. Further to those, some general limitations will be outlined 
here: 
 
9.3.2.a Selection of studies 
Confining the source of RCTs to the CENTRAL database satisfied the specific 
objectives for this study in providing a sufficient pool of RCTs with a wide range of 
primary care treatments for NSLBP. The small number of trials that used placebo 
or sham treatments and trials that used pharmacological treatments is not unusual 
for back pain trials in primary care. Some eligible RCTs might not have been 
included because they were not included in the database. However, this  is 
unlikely to have affected the outcome of the study in that there was no systematic 
exclusion of certain types of trials on certain primary care treatments or in certain 
primary care settings.  
 
A number of limitations have already been mentioned with regard to the 
investigation of the trial effect (Chapter Eight). Related to the issue of selection, 
the choice of cohort studies as the comparator population might not be ideal to 
study the effect of participating in RCTs. A better method would be a comparison 
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of IPD of cohort studies with IPD of RCTs. More superior still would be an 
observational study with a nested RCT, designed specifically to examine the 
effect of participating in RCT.  
 
9.3.2.b Studying single factors 
The influences of non-specific factors on symptom progression are possibly more 
complex than is assumed when investigating the influence of single factors in 
isolation. Studying the factors in various combinations or incorporating the 
interaction between them might provide a clearer insight into their role in the 
clinical course of symptoms. In this thesis, studying multiple factors 
simultaneously was undertaken, but only in the context of adjusting for potential 
confounding. Further interaction analyses or including other combinations of 
factors were beyond the objectives of this thesis and might not be appropriate 
using the data available. Secondary analyses of published data carry the risk of 
analysing data from studies not designed for these secondary analyses. The IPD 
sets that were obtained for this thesis were limited, both in terms of numbers and 
also the non-specific factors studied, and would not have provided sufficient data 
for these analyses.  
 
Novel approaches need to be developed that allow for an assessment of the 
interaction of these factors with each other and with the type of treatment (e.g. the 
influence of expectation regarding acupuncture might be different from that 
regarding joint injection).  
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9.3.2.c Other non-specific factors 
Although a large number of non-specific factors were identified from the literature 
and from the semi-Delphi survey presented in Chapter Three, only a limited 
number of non-specific factors were actually studied. This is one of the possible 
reasons for the large remaining heterogeneity in responses to treatments that 
could not be explained by the effects of the studied factors. The limited data 
available for other important factors in the included studies precluded investigating 
their influence (as was identified by the Delphi survey, Chapter Three) such as 
patients’ beliefs regarding illness and treatment, previous use of treatments, 
practitioner skills and communication between practitioner and patient. It is 
difficult, based on the thesis findings, therefore, to comment on the evidence for 
the importance of these factors. The large variation in the size of responses to 
treatment in RCTs that remained unexplained suggests that a large proportion of 
these responses could be related to factors other than the ones studied in this 
thesis. Research into the range of other factors and their influence is therefore 
needed to further understand their role.  
 
 
9.4 Recommendations for future research 
 
A number of recommendations could be drawn for future research, in addition to a 
number of recommendations that have already been mentioned earlier in this 
chapter such as those related to the outcome measures used and follow up times.  
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9.4.1 Overall symptom progression and studying non-specific factors 
 
In this thesis non-specific factors and their effects were studied through secondary 
analyses of data from studies that were not designed to examine these factors. It 
is therefore important to corroborate the findings presented in this thesis or 
provide clearer evidence based on prospective studies particularly designed to 
examine these factors. Developing methods to prospectively study the effects of 
non-specific factors is outside the aims and objectives of this thesis. However, it is 
perhaps a natural extension to pass comments on the methods of trials to study 
these factors. 
  
Methods have been used to assess the effects of the placebo treatments used in 
RCTs by subtracting the effects in no-treatment arms from those in the placebo 
arms. As was mentioned in Chapter Two, these methods would narrowly identify 
the ‘placebo effect’ of the placebo or sham treatments and not the effects of the 
wider range of non-specific factors. Issues related to the variety of methods used 
to study the ‘trial effect’ have also been addressed in Chapter Eight. To 
prospectively study the effects of non-specific factors on symptom progressions, 
methods have been proposed such as those by Quilty et al (2003) and Campbell 
et al (2005). These proposals included Zelen’s design and various modifications 
of it, which require randomisation without prior consent in part of the study 
population. An example method, without a Zelen component,  that could be 
suggested here would involve randomising patients to active and placebo 
treatment arms and adding a non-specific factor to examine, for example an 
‘enhanced consultation style’ which would employ optimum communication 
consultation skills (Figure 9.1).  
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Figure 9.1      Trial design to study the effects of non-specific factors 
 
 
 
The design would result in four arms: active treatment, active treatment with 
added ‘enhanced consultation’; placebo treatment; placebo treatment with added 
‘enhanced consultation’. This should enable estimation of the effect of the 
enhanced consultation used in conjunction with the placebo and with the active 
Randomisation 
Placebo + enhanced 
consultation 
Placebo 
treatment 
Active 
treatment 
Active + enhanced 
consultation 
Difference between size of 
responses in these arms = 
size of effect of enhanced 
consultation used with active 
treatment 
Difference between size of 
responses in these arms = 
size of effect of enhanced 
consultation used with 
placebo treatment 
Difference between the size of effects 
of active and placebo treatments, 
without the ‘enhanced consultation’, = 
the size of the active treatment effect 
Difference between the size of effects 
of ‘enhanced consultation’ calculated in 
stage A = the interaction between the 
context effect and treatment effect 
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treatment (Stage A). The size of the effect of the active treatment is estimated as 
shown in Stage B. This design should also enable estimating the difference in the 
effects of the enhanced consultation used in conjunction with different treatments. 
Assuming that trial quality was adequate then any difference in the effects of 
enhanced consultation used in conjunction with active and with placebo (or 
another active treatment) (Stage C) could be attributed to the interaction between 
this factor and the treatment used.  
 
Methods would need to be modified or developed to examine other non-specific 
factors. This illustrates the complexity of this subject area but is an important 
challenge for future research. 
 
9.4.2 Duration of pain episode 
Clear evidence in this thesis suggests that patients respond to treatments 
differently depending on the duration of the current episode. The lack of a similarly 
clear and consistent evidence for history of back pain might be explained by the 
caveats associated with the studied data, as already discussed in Chapter Seven. 
One recommendation that could be made, therefore, is to study (in a clinical trial) 
the history of back pain using a uniform scale, that would include both the 
presence of back pain in the past and the frequency of previous back pain (e.g. 
duration or number of previous episodes in a continuous variable that could be 
compared across trials).  
 
The second recommendation is related to the issue that has already been 
discussed in Chapter Seven with relation to the degree of association between 
pain duration and history of back pain. It would be interesting to provide empirical 
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evidence for this link and to use any such evidence to design a scale to measure 
the two characteristics combined.   
 
9.4.3 The quality of trials 
The findings in this thesis related to the quality of RCTs on back pain raise issues 
that are relevant for future research. The quality of reporting of clinical trials was 
found to be commonly inadequate. Repeated calls have been made to improve 
reporting since the formal issuing of the CONSORT statement in 1996 with no 
clear evidence on the impact of these calls. This thesis adds further evidence for 
the negative impact of inadequate reporting on the ability to provide clear 
evidence from published trials. 
 
The finding that the quality of a large number of back pain trials was poor might 
arguably be explained by the ‘suitability’ of quality assessment tools for different 
types of trials (e.g. efficacy versus pragmatic trials) and for trials using different 
types of treatments (e.g. pharmacological versus manual treatments). This issue, 
which was discussed in Chapter Five, has been recognised and attempts to 
modify quality assessment tools to suite a range of trials and treatments have 
been made. However, the trials included in this thesis were on a wide range of 
treatments and it might not have been possible to compare the quality across 
included trials had different quality tools been used.  
 
It is pertinent to mention here that authors have historically been restricted in their 
publications by the size of their reports represented by the text word counts 
prescribed by printed journals. This might be one explanation for the less than 
complete reporting. The advent of the ‘on-line’ publications, whether through 
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exclusively on-line journals or complementary on-line versions of the printed 
journals, might present a solution for this problem and it would be interesting to 
establish the evidence for it in due course.  
 
 
9.5 Final summary  
 
This thesis presented evidence for the large overall improvement of back pain 
symptoms in clinical trials and cohort studies on back pain. The pattern of 
improvement was common to all types of treatment, index, active comparator, 
usual care, waiting list or placebo and pharmacological or non-pharmacological. 
The quality of studied trials was moderate with a widespread inadequate reporting 
of information on important aspects of methodology which did not clearly improve 
after the publication of the CONSORT statement in 1996. 
 
The course of back pain symptoms in clinical trials, or the overall change in 
outcome scores over time, represents the effects of the specific treatment used as 
well as the effects of all other non-specific factors related to the patient, the 
symptoms, the practitioner and the setting. The approach in this thesis was to 
study the context effect in the context of using treatment and therefore the focus 
was on the overall (within-arm) symptom progressions. 
 
The association between non-specific factors and responses to treatment was 
studied using published aggregated data as well as individual patient data of 
RCTs. Synthesised evidence was shown for the association of back pain episode 
duration and history of back pain with symptom progressions. Trend, but not clear 
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evidence, was found for the association of gender and presence of preference for 
treatment with symptom progression. Evidence was not found for a larger 
improvement in back pain symptoms in RCTs compared with cohort studies 
attributed to what is described as the ‘trial effect’. 
 
The non-specific factors studied were selected based on the available data. The 
role of other factors, such as previous use of treatment, patient beliefs regarding 
illness, practitioner skills and patient-practitioner interaction, could not be 
assessed for the lack of relevant or sufficient data. This could explain the large 
variation in the size of responses to treatments that remained unexplained by the 
factors studied.     
 
Obtaining a large pool of individual patient data from clinical trials on back pain 
would allow studying the effects of non-specific factors on within-arm responses to 
treatments replicating the approach adopted in this thesis. To study factors such 
as communication skills, newly designed prospective studies, such as the design 
described above, needs to be considered. Such design would also allow 
exploration of the possibility of the interaction between the effects of non-specific 
factors and the particular treatment used. 
 
Beyond the specific findings this thesis provides, it also provides a framework for 
a methodological approach to study the effects of non-specific factors in clinical 
trials.  
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Appendix 4.2a  Summary of trials (n 118) included in the systematic review presented in Chapter Four. Citations of trials are  
detailed in Appendix 4.2b 
 
 
 
 
Author and country  
 
 
 
Setting 
 
 
 
Age (y) 
 
 
 
Treatment 
 
 
Age (y) mean 
(SD)  
 
 
Female 
(%) 
Actual duration 
of NSLBP 
(weeks) mean 
(SD) 
Sample of 
trial arm 
at 
baseline 
        
Andersson et al, USA Members of a health 
organisation 
20-59 Osteopathic manipulative treatment 29 (10.6) 59  83 
   Standard medical care  37 (11) 56  72 
Bannwarth et al, France General practice   18-55 Adrenaline triphosphate tablets 90 mg  43 (9.9) 59 7.4 (2) 81 
   Placebo tablets 41 (8.9) 58 7 (2) 80 
Bendix et al, Denmark General practice  Functional restoration (PT + OT + Psychological) 40 66  48 
   Outpatient intensive physical training: Aerobics + strengthening exercises + fitness machines 
43 69  51 
Beurskens et al, Netherlands Physiotherapy + General 
practice 
18 + Continuous motorised lumbar traction 39 (10) 44   
   Sham traction 42 (11) 43   
Birbara et al, USA Not clear 18-75 Etoricoxib tablets 60 mg 52 (13.3) 63 629 (546) 103 
   Etoricoxib tablets 90 mg 52 (12.4) 63 562 (561.6) 107 
   Placebo tablets 51 (13.7) 55 556 (520) 109 
Blomberg et al, USA General practice + 
occupational healthcare 
20-60 Osteopathic techniques: (manipulation, mobilisation, muscle stretching) & 
autotraction for some & steroid injection for non-responders  
   48 
   Conventional treatment: mainly physiotherapy (exercise), activation and advice    53 
Brennan et al, USA Physical therapy/Rehab 
unit 
18-65 Manipulation treatment  38 (10) 45 2 46 
   Specific exercise treatment: instructed to do directional exercises 37 (11.1) 34 2.4 70 
   Stabilization treatment: Trunk strengthening and stabilising exercises     
Bronfort et al, USA College outpatient clinic 20-60 Spinal manipulation & trunk strengthening exercise 41 (10.5) 54 156 71 
   NSAID & Trunk strengthening exercise 40 (8.9) 44 104 52 
   Spinal manipulation & Stretching exercise 41 (9.3) 39 119.6 51 
Burton et al, UK General practice 17-70 The Back Book + usual care (GP & osteopathic care)  11  83 
   The traditional Handy Hints & usual care (GP & osteopathic care)  12  79 
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Cambron et al & Gudavalli et al, 
USA 
Chiropractic clinic + 
hospital clinic + General 
population 
18 + Chiropractic flexion distraction procedure 42 (11.4) 34  123 
   Active trunk exercise program 41 (12.8) 41  112 
Carr et al, UK Physiotherapy + General 
practice + Hospital 
consultants 
 Individual physiotherapy 43 (11.2) 62  119 
   Back to fitness group programme: progressive stretching & strengthening exercises & CBT 
42 (10.6) 59  118 
Cherkin et al, USA General practice 20-64 Physical therapy: McKenzie approach 42 (10.7) 47  133 
   Chiropractic manipulation 40 (9.4) 53  122 
   Educational booklet 40 (11.2) 42  66 
Childs et al, USA Air Force 18-60 Manipulation (High velocity thrust spinal manipulation) + exercise 33 (11.2) 43 3 70 
   Exercise  35 (10.6) 41 4.3 61 
Chiradejnant et al, Australia Physiotherapy  Therapist (Physiotherapist) selected mobilisation 47 (16.4)  26.3 (77) 70 
   Randomly selected mobilisation 54 (16.4)  13 (40) 70 
Chok et al, Singapore Physiotherapy + 
Orthopaedic clinics + 
A/E  
20-55 Physical therapy (endurance exercise at the PT department) + back hot pack 38 (9.7) 20 4 (2) 38 
   Back hot pack (Home) 34 (8.1) 29 4 (2) 28 
Cleland et al, USA General practice 18-60 Lumbar spine mobilisation & exercise 40 (12.2) 71 19 (12.5) 14 
   Lumbar spine mobilisation & exercise & slump stretching 39 (11.3) 69 15 (8) 16 
Coats et al, USA, Canada Not clear 18 + Valdecoxib tablets 40 mg  48.6 (13.3) 55 603 (556.4) 148 
   Placebo tablets 48.7 (12.6) 59 567 (520) 145 
Constant et al, France General practice Unlimited Spa therapy & usual GP care    63 
   Waiting list group & usual GP care    63 
Cramer et al, USA Chiropractic clinic  Chiropractic treatment    17 
   Detuned USS & cold pack + soft tissue massage    19 
Damush et al 2003 (2 papers), 
USA 
General practice 18 + Self management program & usual care 45 72  76 
   Usual care (not clearly defined) 46 75  87 
Defrin et al, Israel Occupational healthcare  Shoe insert 43 (11.8)  634 (478.4) 22 
   Usual care (not clearly defined) 48 (6.9)  910 (670.8) 11 
Delitto et al, USA Physiotherapy  Extension-mobilisation, matched and specifically directed (targeted)  37 (12) 50 1 (0.9) 14 
   Flexion exercises, generalised, non-specific  27 (10) 33 2 (0.9) 10 
Descarreaux et al, Canada General population  Specific exercise program (increased muscular force and extensibility of trunk and 
hip muscles.) 
33.1 33  10 
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   Common back pain exercise 35 33  10 
Dreiser et al, France General practice 18-60 Diclofenac - K 12.5, 2 tablets 41 (10.9) 52  124 
   Ibuprofen tablets 200 mg 41 (11.6) 48  122 
   Placebo tablets, 2 tablets 41 (11.3) 53  126 
Faas A, Netherlands General practice 16-65 Usual GP care 36 41  155 
   Usual GP care & Placebo USS by physiotherapist 38 42  162 
   Usual GP care & Exercise instructions + advice 36 47  156 
Frost et al, UK Physiotherapy   18 + Routine physiotherapy & advice book 42 (14.9) 58  144 
   Advice from physiotherapist & advice book 40 (13) 47  142 
Geisser et al, USA University spinal 
programme 
18-65 Manual therapy & Specific exercise (self corrections, stretching, strengthening) 39 (12.8) 67 284 (493) 26 
   Sham Manual therapy & Specific exercise 39 (9.4) 56 370 (447.8) 25 
   Manual Therapy & Non-specific exercise 37 (14.4) 80 370 (476.1) 24 
   Sham Manual Therapy & non-specific exercise 46 (9.5) 61 284 (305.1) 25 
Gemmell et al, USA Chiropractic clinic 18-65 Activator adjustment chiropractic 54 (9.5)   14 
   Meric adjustment chiropractic 52 (10.3)   16 
George et al, USA Physical therapy 18-55 Standard care physical therapy 37 (10.1) 53 4 (2.3) 32 
   Fear-avoidance based physical therapy 40 (10) 62 4 (2.3) 34 
Giles et al, Australia Hospital outpatients + 
General practice + self 
referral 
17 + Spinal manipulation 39 (18.5) 49 431.6 35 
   Acupuncture 38 (18.8) 44 234 34 
   Medications (Celebrex, Vioxx or paracetamol) 200-400, 12.5-25, 4g 39 (8.9) 42 332.8 40 
Glomsrod et al, Norway Physicians clinics and 
General population 
18-50 Active back school (Lectures and back exercises) 41 (6.1) 65  37 
   Usual medical care 39 (6.6) 57  35 
Goldby et al, UK General practice + 
hospital physicians 
18-65 Spinal stabilisation & Attending the back school 43 (10.7) 68  84 
   Manual therapy & Attending the back school 41 (11.7) 69.9  89 
   Education (Booklet: Back in action) & Attending the back school 42 (13) 67.5  40 
Grunnesjo et al, Sweden Sick-listed population + 
General practice 
 Stay active (Ortho surgeons + physiotherapists) 41 (8.5) 35 4 (3.8) 72 
   Stay active & manual therapy (GPs + physiotherapists) 42 (8.9) 51 4 (3.8) 88 
Guillemin et al, France General practice  Spa therapy   59 (2.3) 65  52 
   Usual GP care 58 (2.3) 56  52 
Haas M, USA General population 60 + Chronic disease self management program (CDSMP) (workshops) 79 (7.5) 82  60 
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   Waiting list control 76 (7.5) 88  49 
Hansen et al, Denmark Airline  21-64 Intensive dynamic back muscle exercise 40.5 32 25.7 60 
   Conventional physiotherapy (CP) 38.4 32 28.6 59 
   Semi-hot pack & intermittent traction 41.9 32 28.6 61 
Hay et al, UK General practice 18-64 A brief programme of pain management (general fitness and exercise at clinic and 
home, explanation about pain mechanisms, distress, encouragement of positive 
coping strategies, overcoming fear of “hurt=harm”, and implementation of a graded 
return to usual activities) 
40 (12.0) 50  201 
   Physiotherapy including manual therapy techniques 41 (11.6) 55  201 
Heymans et al, Netherlands Occupational healthcare 18-65 Usual Dutch occupational physician care 41 (9.6) 17 35 103 
   Low intensity back school 41 (10.2) 22 35 98 
   High intensity back school 40 (9.5) 23 35 98 
Hawk et al, USA General population 18 + Flexion-distraction chiropractic manipulation (FDT) & trigger point   51(14.2) 52 208 54 
   Sham manipulation & effleurage 53 (15.2) 63 364 57 
Helmhout et al, Netherlands Army  High intensity treatment group: high intensity progressive resistance training of 
isolated lumbar extensor muscle groups 
41 (10) 0  41 
   Low intensity treatment group: low intensity progressive resistance training of isolated lumbar extensor muscle groups 
40 (9) 0  40 
Hemmila et al, Finland Not clear  Physiotherapy    34 
   Bone setting (is a form of manipulative therapy still practiced by uneducated Finnish folk healers) 
   44 
   Exercise    35 
Hseih et al, USA General population 18 + Joint manipulation & myofascial therapy 48 (13.7) 33 12 (7.2) 52 
   Joint manipulation  47 (14) 33 12 (7.2) 48 
   Myofascial therapy 49 (14.8) 33 12 (6.8) 51 
   Back school 48 (13.7) 40 11 (6.6) 48 
Hoiriis et al, USA General population 21-59 Chiropractic adjustments & placebo medicine 42 (9.7) 50 3 (1.3) 34 
   Muscle relaxants & sham adjustments (mimic chiropractic adjustments with respect to dialogue, visit length, and physical contact. 
41 (10.1) 53 4 (1.5) 36 
   placebo medicine & sham adjustments (mimic chiropractic adjustments with respect to dialogue, visit length, and physical contact. 
43 (9.8) 53 4 (1.4) 40 
Hurley et al, UK Physiotherapy + General 
practice + self referral 
18-65 Manipulation therapy (Passively move intervertebral joint within or beyond its 
range) 
40 (11.6) 57 7.5 (3.1) 80 
   Interferential therapy (Electrical stimulation) 40 (12.1) 62 7.6 (3) 80 
   
Manipulation & interferential therapy 41 (11.3) 60 8.3 (2.8) 80 
     
Hurley et al, UK Physiotherapy + General 
practice + self referral 
18-65 Interferential therapy painful area + back book 35 62 5 18 
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   Interferential therapy spinal nerve + back book 35 59 7 22 
   Back book only 30 45 4 22 
Hurwitz et al, USA Managed care facility 18+ Chiropractic care only 52 (16.5) 49  169 
   Chiropractic care & physical modalities (Heat/cold, USS) 54 (16.8) 58  172 
   Medical care (excluding physical treatment) only 49 (16.5) 47  170 
   Medical care & physical modalities (Heat/cold, USS) 49 (16.7) 54  170 
Hurwitz et al, USA Network of healthcare 18 + Chiropractic care only 52 (16.5) 49  340 
   Chiropractic care & physical modalities (Heat/cold, USS) 53 (16.8) 58  340 
Jellema et al, Netherlands General practice 18-65 Minimal intervention strategy (Assessing psychosocial risks, providing information 
on back pain and treatments & advice on self care) 
43 (11.1) 48 1.7 143 
   Usual GP care 42 (12) 47 1.7 171 
Kaapa H, Finland Occupational healthcare 22-75 Multidisciplinary rehabilitation: guided, group programme. : CBT, relaxation, back 
school education & physical therapy 
46 (7.9) 100 72 (112.5) 59 
   Individual physiotherapy 47 (7) 100 63 (103.5) 61 
Kankaanpaa et al, Finland Occupational healthcare   Active rehabilitation: guided exercises in a dept + behavioural support  40 (8.5) 34  30 
   Passive treatment: which they considered as minor to the active arm, e.g. massage and thermal treatment 
39 (7.3) 33  24 
Karjalainen et al 2003 & 2004, 
Finlands 
General practice 25-60 Mini-intervention (Specific back exercises, reduce patient concerns & encourage 
physical activity) 
44 59  56 
   Mini-intervention & worksite visit 44 57  51 
   Usual  GP care 43 60  57 
Katz et al, 2003& 2004, USA General practice + 
hospital patients 
18-75 Rofecoxib 25mg tablets 53 (13.2) 63 634 (624) 233 
   Rofecoxib 50 mg tablets 53 (12.9) 62 608 (613.6) 229 
   Placebo tablets 45 (12.7) 63 666 (698) 228 
Katz et al, USA Hospital pain clinic + 
general population 
18 + Bupropion SR tablets 150 mg 50 (10) 57  26 
   Placebo tablets 51 (11.4) 39  28 
Kerr et al, UK General practice  Acupuncture 43 (11.5) 50 86 (84.9) 30 
   Placebo TENS (non-functioning) 43 (12) 65 73 (77.4) 30 
Ketenci et al, Turkey Physical therapy and 
rehabilitation 
20-60 Thiocolchicoside tablets 8 mg 37 42  38 
   Placebo oral (morning) & TZ (evening) 37 63  32 
   Placebo oral (morning and evening) 40 52  27 
Kofotolis et al, Greece Not clear  Rhythmic stabilisation training 41 (6.4) 100 30 (6.2) 28 
   Combination of isotonic exercises 42 (7.7) 100 33 (8.3) 28 
   No treatment, instructed to avoid structured exercises or activities 42 (8.4) 100 35 (8.4) 30 
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Koumantakis et al, UK Orthopaedic clinics + 
General practice 
 Stabilization enhanced exercise (Exercises of the stabilizing muscles in the back) 39 (11.4)  12 29 
   General exercise (Exercises of the back extensors and flexors) 35 (9.7)  12 26 
Kuukkanen et al, Finland Occupational healthcare  Intensive training: intensive progressive exercises guided at the gym + home 
exercises 
 62  29 
   Home exercise only: same as intensive, but unguided  48  29 
   Control: usual activities, no trial exercises  54  28 
Leclaire et al, Canada Private physiatrist clinic 18-50 Standard care (rest, analgesics, physio) & Swedish back school 32 (7.7) 43  82 
Standard care (rest, analgesics, physio) 32 (8) 41  86 
Lee et al, Korea Not clear  Pulsed electromagnetic therapy (PEMT) 75 (5) 70 540 (661.5) 17 
   Sham (Same machine, magnetic coil removed) 74 (4) 26 410 (499.5) 19 
Licciardone et al, USA General population 21-69 Osteopathic manipulative treatment 49 (12) 69  48 
   Sham manipulation (Light touch & simulated osteopathic manipulation) 52 (12) 57  23 
   No trial intervention (=usual back pain care) 49 (12) 65  20 
Lindstrom et al, Sweden Occupational healthcare  Swedish back school & workplace visit + graded exercise (CBT approach)      24  51 
   Usual care: rest& analgesics & physical treatment             38  52 
Linton et al, Sweden General practice + 
general population 
18-60 Back pain pamphlet  45 71  70 
   Comprehensive information package 44 74  66 
   CBT intervention 44 70  107 
Long et al, Canada Physical therapy  18-65 Matched direction exercise 43 (9.6) 51 14 (19.8) 80 
   Opposite direction exercise 42 (10.3) 49 18 (21.8) 69 
   Evidence based care 42 (10.8) 43 15 (17.6) 80 
Malmivaara et al, Finland Occupational healthcare   Complete bed rest (but for essential things) 40.8 60 0.7 67 
   Back mobilising exercises 41.1 71 0.6 52 
   Ordinary activities 39.1 70 0.6 67 
Mannion et al 1999& 2001, 
Finland 
General population < 65 Modern active individual physiotherapy: strengthening, coordination and aerobics 
exercises, instructions on ergonomic principles + home exercises 
46 (10.1) 61 520 (468) 46 
   Muscle reconditioning on training devices (small groups) 45 (9.7) 54 504 (473.2) 47 
   Low impact aerobic/stretching (groups) 44 (10.1) 55 676 (520) 44 
Maul et al, Switzerland Occupational healthcare 20-55 Back school & exercise 38 (8)   97 
   Back school    39 (10)   86 
Mayer et al, USA General population + 
General practice 
18-55 Heat wrap alone, 8h/d 29 (9.9) 68  25 
   Exercise  33 (10.3) 60  25 
   Heat wrap & exercise 32 (11.8) 63  24 
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   Booklet 31 (10.9) 92  26 
Mehling et al, USA General practice 20-70 Breath therapy 50 (12.1) 70 51 (26.6) 16 
   Physical therapy: soft tissue mobilisation, joint mobilisation and exercises 49 (12.5) 58 57 (26.6) 12 
Melancon et al, USA Rural physician's practice 18-63 Massage therapy (Soft tissue massage) 39 46  30 
   Traditional therapy (traditionally provided at US hospitals) = usual physicians care 38 45  30 
Moffett et al, UK General practice 18-60 Progressive exercise programme: group, Stretching, low impact aerobics & 
strengthening exercises, of all main muscles 
41 (9.2) 57  85 
   Usual GP care 43 (8.6) 56  98 
Moseley L, Australia Physiotherapy + General 
practice    
 Physiotherapy   43 (7) 64  29 
   Usual GP care 38 (7) 54  28 
Muehlbacher et al, Germany General population 18 + Topiramate tablets 50 mg 49 (5.4) 40 130 48 
   Placebo tablets 47 (5) 35 104 48 
Nadler et al, USA Physiotherapy + general 
population 
18-55 Wearable heat wrap 36 (11.6)   95 
   Oral placebo tablets 2 37 (10.8)   96 
   Ibuprofen tablets 400 mg 36 (11.6)   12 
   Unheated wrap 35 (11.3)   16 
Nadler et al, USA General population 18-55 Wearable heat wrap 42 (9.4) 64  33 
   Placebo tablets 2  42 (9.8) 62  34 
   Ibuprofen tablets 400 mg 43 (2.7) 75  4 
   Unheated wrap 34 (8.4) 80  5 
Nadler et al, USA Not clear 18-55 Continuous low level heat wrap therapy 8 hours/d 36 (10.5) 58  113 
   Ibuprofen tablets 400 mg 35 (11.3) 57  113 
   Acetaminophen tablets 500 mg, 2 tablets 37 (10.4) 60  106 
   Placebo tablets, 2 tablets 37 (9.3) 58  20 
   Unheated wrap 38 (9.1) 60  19 
Niemisto et al 2003& 2005, 
Finland 
General population 24-46 Manipulation, exercise & physician consultation 37 (5.6) 55 312 102 
   Physician consultation only 37 (5.6) 53 312 102 
Nordeman et al, Sweden General practice + 
physical therapy dept 
 Early access to physio (Individualised, exercise, advice, group education) 39 (12.1) 63  32 
   Waiting list control 41 (11.1) 50  28 
Pallay et al, USA General practice + 
specialists 
18-75 Etoricoxib 90 mg tablets 53.3 (12.7) 59 634 (514.8) 106 
   Etoricoxib 60 mg tablets 53.3 (12.3) 68 619 (629.2) 109 
   Placebo tablets 51.8 (13.5) 61 598 (629.2) 110 
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Peloso et al, USA Outpatients 18 + Tramadol & Acetamenophen combination tablets 375/325 2 PRN 58 (11.5) 64  167 
   Placebo tablets 2 PRN 58 (13.6) 61  169 
Penttinen et al, Finland Occupational healthcare 35-50 Back school & peer support  48  47 
   Back school only  45  46 
Perrot et al, France Not clear 18 + Tramadol / Paracetamol combination tablets 37.5/325 mg 57 (15.3) 64.4  59 
   Tramadol tablets 50 mg 45 (14.6) 51.7  60 
Pohjolainen et al, Finland Hospital patients + 
Occupational healthcare 
 Oral Nimesulide & Placebo tablets* 100mg 42 (7.5)   52 
   Ibuprofen tablets 600mg 42.5   52 
Pope et al, USA Health centre + general  
population 
18-55 Spinal manipulation    70 
   Soft tissue massage    37 
   Transcutaneous muscle stimulation (=interferential therapy? 405)    28 
   Corset    29 
Preyde M, Canada General practice + 
general population 
18-81 Comprehensive massage: soft tissue manipulation, remedial exercises & Posture 
education) 
48 (16.2) 56 12 (9.1) 25 
   Soft tissue manipulation only 47 (18.4) 56 15 (8.2) 25 
   Remedial exercise & posture education 48 (12.9) 41 13 (11.1) 25 
   Sham laser therapy 42 (16.6) 54 13 (8.8) 25 
Rasmussen et al, Sweden Physiotherapy 18-60 Stabilizing training (Individual) (Cognitive + stabilisation of spinal muscles) 39 (12) 70  24 
Manual treatment (Individual) (Other muscles exercises, no manipulation) 37 (10) 78  23 
Ruoff et al, USA Not clear 25-75 Tramadol/ Acetamenophen combination tablets 37.5/325 mg, 2 tablets 54 (11.9) 67  161 
Placebo tablets 2 tablets 54 (12) 59  157 
Rozenberg et al, France Rheumatology clinics + 
General practice 
18-65 Bed rest 44 (12.3) 49  137 
Normal activity 44 (11.8) 57  140 
Rittweger et al, Germany General population 40-60 Isodynamic lumbar extension 50 (6.6) 44 603 (520) 30 
Vibration exercise (On a machine with a vibrating platform) 54 (3.4) 52 754 (530.4) 30 
Riipinen et al, Finland General population 24-46 Manipulation exercise & physician consultation (combination) 39 (5.4) 55  102 
   Physician consultation only 37 (6.5) 53  102 
Ritvanen et al, Finland General population 20-60 Traditional chiropractic bone setting 41 (4.9) 45  33 
   Physical therapy 42 (6.8) 43  28 
Rossignol et al, Canada Workers compensation 
board 
 Coordination of primary healthcare program 37 (9.7) 33  54 
Usual GP care 38 (10.2) 23  56 
Rossignol et al, France General practice  Placebo tablets 40 (9.8) 58  81 
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   Atepadene tablets 90 mg 43 (9.9) 59  80 
   The back book 44 (9.5) 59  76 
   Atepadene & the back book 41 (10.9) 53  81 
Rydeard et al,  Physicians clinics + 
physiotherapy + general 
population 
22-55 Specific exercise treatment (Pilates, muscle activation) 37 (9) 57 286 21 
   Waiting list control 34 (8) 72 468 18 
Schnitzer et al, USA Not clear 25-75 Tramadol tablets 100 mg    127 
   Placebo tablets    127 
Sherman et al, USA Group health cooperative 
health insurance + 
general population 
20-64 Yoga 44 (12) 68  36 
   Exercise 42 (15) 63  35 
   Self care book 44 (13) 67  30 
Soukup et al, Norway General practice + 
general population + 
referrals 
18-50 Mensediesk exercise group intervention 40 53 676 (474.8) 34 
   Waiting list group 40 49 578 (320.7) 35 
Staal et al & Hlobil et al, 
Netherlands 
Occupational healthcare  Graded activity (Physiotherapy + OT) 39 (9) 5 8.5 67 
   Usual OT care 37 (8) 8 8 67 
Stam et al, UK General practice 18-65 Spiroflor SRL gel 3g 41 (13.6) 45  83 
   Cremor Capsici Compositus FNA 3g 41 (12.8) 48  78 
Steenstra et al, Netherlands Occupational healthcare 18-65 Graded exercise program based on CBT 41 (9.2) 65  55 
   Usual care by occupational healthcare therapist 43 (8.2) 54  57 
Storheim et al, Norway General practice + 
general population 
20-60 Cognitive interaction 41 (9.4) 47  34 
   Exercise (Back exercises and focus on ergonomic principles) 42 (9.2) 53  30 
   Usual GP care 39 (11.9) 55  29 
Suni et al, Finland Occupational healthcare  Training group (exercises) 48 (5.8) 0  52 
   Usual care (waiting list, received same treatment after 12 ms) 47 (5.3) 0  54 
Szpalski et al, Belgium Not clear  Tenoxicam, 20 mg od injection then tabs 38 (9.2) 38  37 
   Placebo tablets, od, injection then tab 39 (10.4) 33  36 
Thomas et al 2005& 2006, UK General practice 18-65 Short course of acupuncture 42 (10.8) 62 17 (13.5) 159 
   Usual GP care 44 (10.4) 58 17 (14.6) 80 
Torstensen et al, Norway Social security offices 20-65 Medical exercise therapy (MET) 42 (11.2) 52  71 
Conventional physiotherapy (CP) 43 (12) 48  67 
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Self exercise 40 (11.4) 51  70 
Triano et al, USA Chiropractic clinic 18 + High velocity low amplitude spinal manipulation    47 
   High velocity low force mimic    39 
   Back education programme     43 
Tsui et al, Hong Kong Physiotherapy 20-55 Electro-acupuncture & back exercise 40 (12.1) 76 39 (31.8) 14 
   Electrical heat acupuncture + back exercise 39 (9.2) 71 54 (54.5) 14 
   Back exercise only 41 (8.3) 62 50 (41.6) 14 
Turner et al, USA General practice + 
physicians + general 
population 
20-65 Relaxation training (group)    24 
   Cognitive therapy (group)    23 
   Cognitive therapy & Relaxation training (group)    25 
   Waiting list control    30 
Underwood et al, UK General practice 16-70 McKenzie technique + general advice 35 34 1 35 
   General advice only 40 45 1 40 
Wand et al, UK General practice + A/E 
patients 
 Assess & Advice & Physiotherapy 34 (9) 44  43 
   Assess & Advice & wait 35 (7.9) 55  51 
Webster et al, USA Not clear 18-70 Placebo tablets 48.7 61  101 
   Oxycodone QDS 47.9 61  206 
   Oxytrex QDS 47.8 62  206 
   Oxytrex BD 47.9 62  206 
Weiner et al, USA General population 65 + PENS & Physical therapy    74 (4.6) 65 551 (577.2) 17 
   Sham PENS & Physical therapy  74 (5.7) 41 863 (852.8) 17 
Werners et al, Germany General practice  Interferential therapy: electrotherapy, to stimulate muscles fibres 38 (9.4) 43  68 
   Motorised lumbar traction & massage 39 (9.5) 49  72 
Williams et al, USA Physicians + general 
population 
18 + Education (Lectures in physio/OT and written hand-outs on back pain) 48 (10.7) 71  30 
   Yoga 49 (5.8) 65  30 
Wright et al, UK Occupational healthcare 
+ General practice 
 The back book & verbal advice + usual GP care 44 (11.5) 60  56 
   The back book & verbal advice & single manipulation or injection & individual and group exercise 
38 (13.5) 47  55 
Yelland et al, Australia General practice 21-70 Glucose lignocaine injection 52 (10.6) 59 769.6 (556.8) 28 
   Exercise (Alternating: flexion and extension of spine and hips) 49 (10.4) 55 718 (483.6) 26 
   Saline injection 50 (9.8) 56 759 (499.2) 27 
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   Normal activity 51 (11.2) 58 733 (551.2) 29 
Yokoyama M, Japan Not clear  PENS: percutaneous electrical nerve stimulation 60 (12) 61 15 (7) 17 
PENS & TENS 58 (14) 53 15 (8) 17 
TENS 50 (13) 56 13 (6) 18 
Zerbini C, Multinational Not clear  Etoricoxib tablets 60 mg 52 (14.7) 72 432 (457.6) 224 
Diclofenac tablets 50 mg 52 (12.8) 72 432 (468) 222 
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Andersson GB, Lucente T, Davis AM, Kappler RE, Lipton JA, Leurgans S (1999). 
A comparison of osteopathic spinal manipulation with standard care for patients 
with low back pain. New Eng J Med; 341:1426-1431. 
  
Bannwarth B, Allaert FA, Avouac B, Rossignol M, Rozenberg S, Valat JP (2005).  
A randomized, double-blind, placebo controlled study of oral adenosine  
triphosphate in subacute low back pain. J Rheumatology; 32:1114-1117. 
 
Bendix T, Bendix A, Labriola M, Haestrup C, Ebbehøj N (2000). Functional  
restoration versus outpatient physical training in chronic low back pain: a  
randomized comparative study. Spine; 25:2494-2500. 
 
Beurskens AJ, de-Vet HC, Köke AJ, Lindeman E, Regtop W, van-der-Heijden GJ  
et al (1995). Efficacy of traction for non-specific low back pain: a randomised  
clinical trial. Lancet; 346:1596-1600. 
 
Birbara CA, Puopolo AD, Munoz DR, Sheldon EA, Mangione A, Bohidar NR et al  
(2003). Treatment of chronic low back pain with etoricoxib, a new cyclo- 
oxygenase-2 selective inhibitor: improvement in pain and disability--a  
randomized, placebo-controlled, 3-month trial. J Pain; 4:307-315. 
 
Blomberg S, Svärdsudd K, Tibblin G (1994). A randomized study of manual  
therapy with steroid injections in low-back pain. Telephone interview follow-up of  
pain, disability, recovery and drug consumption. Eur Spine J; 3:246-254. 
 
Brennan GP, Fritz JM, Hunter SJ, Thackeray A, Delitto A, Erhard RE (2006).  
Identifying subgroups of patients with acute/subacute "nonspecific" low back  
pain: results of a randomized clinical trial. Spine; 31:623-631. 
 
Bronfort G, Goldsmith CH, Nelson CF, Boline PD, Anderson AV (1996). Trunk  
exercise combined with spinal manipulative or NSAID therapy for chronic low  
back pain: a randomized, observer-blinded clinical trial. J Manip Physio  
therapeutics;19:570-582. 
 
Burton AK, Waddell G, Tillotson KM, Summerton N (1999). Information and  
advice to patients with back pain can have a positive effect. A randomized  
controlled trial of a novel educational booklet in primary care. Spine; 24:2484- 
2491. 
 
Cambron JA, Gudavalli MR, Hedeker D, McGregor M, Jedlicka J, Keenum M et  
Al (2006). One-year follow-up of a randomized clinical trial comparing flexion  
distraction with an exercise program for chronic low-back pain. J Alt Comp Med;  
12:659-668. 
267 
 
Carr JL, Klaber-Moffett JA, Howarth E, Richmond SJ, Torgerson DJ, Jackson DA  
et al (2005). A randomized trial comparing a group exercise programme for back  
pain patients with individual physiotherapy in a severely deprived area. Dis  
Rehab; 27:929-937. 
 
Cherkin DC, Deyo RA, Battié M, Street J, Barlow W (1998). A comparison of  
physical therapy, chiropractic manipulation, and provision of an educational  
booklet for the treatment of patients with low back pain. N Eng J Med; 339:1021- 
1029. 
 
Childs JD, Fritz JM, Flynn TW, Irrgang JJ, Johnson KK, Majkowski GR et al  
(2004). A clinical prediction rule to identify patients with low back pain most likely  
to benefit from spinal manipulation: a validation study. Ann Int Med; 141:920-928. 
 
Chiradejnant A, Maher CG, Latimer J, Stepkovitch N (2003). Efficacy of  
"therapist-selected" versus "randomly selected" mobilisation techniques for the  
treatment of low back pain: a randomised controlled trial. Aust J Physio; 49:233- 
241. 
 
Chok B, Lee R, Latimer J, Tan SB (1999). Endurance training of the trunk  
extensor muscles in people with subacute low back pain. Phys Ther; 79:1032- 
1042. 
 
Cleland JA, Childs JD, Palmer JA, Eberhart S (2006). Slump stretching in the  
management of non-radicular low back pain: a pilot clinical trial. Man Ther;  
11:279-286. 
 
Coats TL, Borenstein DG, Nangia NK, Brown MT (2004). Effects of valdecoxib in  
the treatment of chronic low back pain: results of a randomized, placebo- 
controlled trial. Clin Ther; 26:1249-1260. 
 
Constant F, Collin JF, Guillemin F, Boulangé M (1995). Effectiveness of spa  
therapy in chronic low back pain: a randomized clinical trial. J Rheumatology;  
22:1315-1320. 
 
Cramer GD, Humphreys CR, Hondras MA, McGregor M, Triano JJ (1993). The   
Hmax/Mmax ratio as an outcome measure for acute low back pain. J Man Physio  
Ther; 16:7-13. 
 
Damush TM, Weinberger M, Perkins SM, Rao JK, Tierney WM, Qi R et al (2004).  
Randomized trial of a self-management program for primary care patients with  
acute low back pain: short-term effects. Arthr Rheumatism; 49:179-186. 
 
Damush TM, Weinberger M, Perkins SM, Rao JK, Tierney WM, Qi R et al (2003).  
The long-term effects of a self-management program for inner-city primary care  
patients with acute low back pain. Arch Int Med; 163:2632-2638. 
268 
 
Defrin R, Ben BS, Aldubi RD, Pick CG (2005). Conservative correction of leg- 
length discrepancies of 10mm or less for the relief of chronic low back pain. 
Arch Phys Med Rehab; 86:2075-2080. 
 
Delitto A, Cibulka MT, Erhard RE, Bowling RW, Tenhula JA (1993). Evidence for  
use of an extension-mobilization category in acute low back syndrome: a  
prescriptive validation pilot study. Phys Ther; 73:216-222. 
 
Descarreaux M, Normand MC, Laurencelle L, Dugas C (2002). Evaluation of a  
specific home exercise program for low back pain. J Manip Physio Ther; 25:497- 
503. 
 
Dreiser RL, Marty M, Ionescu E, Gold M, Liu JH (2003). Relief of acute low back  
pain with diclofenac-K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and  
placebo-controlled clinical trial. Int J Clin Pharm Ther; 41:375-385. 
 
Faas A, Chavannes AW, van-Eijk JT, Gubbels JW (1993). A randomized,  
placebo-controlled trial of exercise therapy in patients with acute low back pain.  
Spine; 18:1388-1395. 
 
Frost H, Lamb SE, Doll HA, Carver PT, Stewart BS (2004). Randomised  
controlled trial of physiotherapy compared with advice for low back pain. BMJ;  
329:708. 
 
Geisser ME, Wiggert EA, Haig AJ, Colwell MO (2005). A randomized, controlled  
trial of manual therapy and specific adjuvant exercise for chronic low back pain.  
The Clin J Pain; 21:463-470. 
 
Gemmell HA, Jacobson BH (1995). The immediate effect of activator vs. meric  
adjustment on acute low back pain: a randomized controlled trial. J Manip Physio  
Ther; 18:453-456. 
 
George SZ, Fritz JM, Bialosky JE, Donald DA (2003). The effect of a fear- 
avoidance-based physical therapy intervention for patients with acute low back  
pain: results of a randomized clinical trial. Spine; 28:2551-2560. 
 
Giles LG, Muller R (2003). Chronic spinal pain: a randomized clinical trial  
comparing medication, acupuncture, and spinal manipulation. Spine; 28:1490- 
1502. 
 
Glomsrød B, Lønn JH, Soukup MG, Bø K, Larsen S (2001). "Active back school",  
prophylactic management for low back pain: three-year follow-up of a  
randomized, controlled trial. J Rehab Med; 33:26-30. 
 
Goldby LJ, Moore AP, Doust J, Trew ME (2006). A randomized controlled trial  
investigating the efficiency of musculoskeletal physiotherapy on chronic low back  
269 
 
disorder. Spine; 31:1083-1093. 
 
Grunnesjö MI, Bogefeldt JP, Svärdsudd KF, Blomberg SI (2004). A randomized  
controlled clinical trial of stay-active care versus manual therapy in addition to  
stay-active care: functional variables and pain. J Manip Physio Ther 2004; 27:  
431-441. 
 
Gudavalli MR, Cambron JA, McGregor M, Jedlicka J, Keenum M, Ghanayem AJ  
et al (2006). A randomized clinical trial and subgroup analysis to compare  
flexion-distraction with active exercise for chronic low back pain. Eur Spin J;  
15:1070-1082. 
 
Guillemin F, Constant F, Collin JF, Boulange M (1994). Short and long-term  
effect of spa therapy in chronic low back pain. BJ Rheumatology; 33:148-151. 
 
Haas M, Groupp E, MuenchJ, KraemerD, BrummelSmith K, SharmaR, Ganger B, 
Attwood M, Fairweather A (2005). Chronic disease self-management program for 
low back pain in the elderly. J Manip Physio Ther; 28: 228-237. 
 
Hansen FR, Bendix T, Skov P, Jensen CV, Kristensen JH, Krohn L et al (1993).  
Intensive, dynamic back-muscle exercises, conventional physiotherapy, or  
placebo-control treatment of low-back pain. A randomised, observer-blind trial.  
Spine; 18:98-108. 
 
Hay EM, Mullis R, Lewis M, Vohora K, Main CJ, Watson P et al (2005).  
Comparison of physical treatments versus a brief pain-management programme  
for back pain in primary care: a randomised clinical trial in physiotherapy  
practice. Lancet; 365:2024-2030. 
 
Hawk C, Long CR, Rowell RM, Gudavalli MR, Jedlicka J (2005). A randomized  
trial investigating a chiropractic manual placebo: a novel design using  
standardized forces in the delivery of active and control treatments. J Alt Comp  
Med; 11:109-117. 
 
Helmhout PH, Harts CC, Staal JB, Candel MJ, de-Bie RA (2004). Comparison of 
a high-intensity and a low-intensity lumbar extensor training program as minimal 
intervention treatment in low back pain: a randomized trial. Eur Spine J;13:537-
547. 
 
Hemmilä HM, Keinänen-Kiukaanniemi SM, Levoska S, Puska P (2002). Long- 
term effectiveness of bone-setting, light exercise therapy, and physiotherapy for  
prolonged back pain: a randomized controlled trial. J Manip Physio Ther; 25:99- 
104. 
 
Heymans MW, de-Vet HC, Bongers PM, Knol DL, Koes BW, van Mechelen W  
(2006). The effectiveness of high-intensity versus low-intensity back schools in  
270 
 
an occupational setting: a pragmatic randomized controlled trial. Spine; 31:1075- 
1082. 
 
Hlobil H, Staal JB, Twisk J, Köke A, Ariëns G, Smid T et al (2005). The effects of  
a graded activity intervention for low back pain in occupational health on sick  
leave, functional status and pain: 12-month results of a randomized controlled  
trial. J Occup Rehab; 15:569-580. 
 
Hoiriis KT, Pfleger B, McDuffie FC, Cotsonis G, Elsangak O, Hinson R et al 
(2004). A randomized clinical trial comparing chiropractic adjustments to muscle 
relaxants for subacute low back pain. J Manip Physiol Ther; 27:388-398. 
 
Hsieh CY, Adams AH, Tobis J, Hong CZ, Danielson C, Platt K et al (2002).  
Effectiveness of four conservative treatments for subacute low back pain: a  
randomized clinical trial. Spine; 27:1142-1148. 
 
Hurley DA, McDonough SM, Dempster M, Moore AP, Baxter GD (2004). A  
randomized clinical trial of manipulative therapy and interferential therapy for  
acute low back pain. Spine; 29:2207-2216. 
 
Hurley DA, Minder PM, McDonough SM, Walsh DM, Moore AP, Baxter DG  
(2001). Interferential therapy electrode placement technique in acute low back  
pain: a preliminary investigation. Arch Phys Med Rehab; 82:485-493. 
 
Hurwitz EL, Morgenstern H, Harber P, Kominski GF, Belin TR, Yu F et al (2002).  
A randomized trial of medical care with and without physical therapy and  
chiropractic care with and without physical modalities for patients with low back  
pain: 6-month follow-up outcomes from the UCLA low back pain study. Spine;  
27:2193-2204. 
 
Hurwitz EL, Morgenstern H, Harber P, Kominski GF, Belin TR, Yu F et al (2002).  
Second Prize: The effectiveness of physical modalities among patients with low  
back pain randomized to chiropractic care: findings from the UCLA low back pain  
study. J Manip Physiol Ther; 25:10-20. 
 
Jellema P, van-der-Windt DA, van-der-Horst HE, Twisk JW, Stalman WA, Bouter  
LM (2005). Should treatment of (sub)acute low back pain be aimed at  
psychosocial prognostic factors? Cluster randomised clinical trial in general  
practice. BMJ; 331:84. 
 
Kääpä EH, Frantsi K, Sarna S, Malmivaara A (2006). Multidisciplinary group  
rehabilitation versus individual physiotherapy for chronic nonspecific low back  
pain: a randomized trial. Spine; 31:371-376. 
 
Kankaanpää M, Taimela S, Airaksinen O, Hänninen O (1999). The efficacy of  
active rehabilitation in chronic low back pain. Effect on pain intensity, self- 
271 
 
experienced disability, and lumbar fatigability. Spine; 24:1034-1042. 
 
Karjalainen K, Malmivaara A, Mutanen P, Roine R, Hurri H, Pohjolainen T  
(2004). Mini-intervention for subacute low back pain: two-year follow-up and  
modifiers of effectiveness. Spine; 29:1069-1076. 
 
Karjalainen K, Malmivaara A, Pohjolainen T, Hurri H, Mutanen P, Rissanen P et  
Al (2003). Mini-intervention for subacute low back pain: a randomized controlled  
trial. Spine; 28:533-540. 
 
Katz N, Rodgers DB, Krupa D, Reicin A (2004). Onset of pain relief with  
rofecoxib in chronic low back pain: results of two four-week, randomized,  
placebo-controlled trials. Current medical research and opinion; 20:651-658. 
 
Katz N, Ju WD, Krupa DA, Sperling RS, Bozalis RD, Gertz BJ et al (2003).  
Efficacy and safety of rofecoxib in patients with chronic low back pain: results  
from two 4-week, randomized, placebo-controlled, parallel-group, double-blind  
trials. Spine; 28:851-858. 
 
Katz J, Pennella VJ, Hetzel RD, Kanazi GE, Dworkin RH (2005). A randomized,  
placebo-controlled trial of bupropion sustained release in chronic low back pain.  
J Pain 2005; 6:656-661. 
 
Kerr DP, Walsh DM, Baxter D (2003). Acupuncture in the management of chronic  
low back pain: a blinded randomized controlled trial. Clin J Pain; 19:364-370. 
 
Ketenci A, Ozcan E, Karamursel S (2005). Assessment of efficacy and  
psychomotor performances of thiocolchicoside and tizanidine in patients with  
acute low back pain. Inter J Clin Pract; 59:764-770. 
 
Kofotolis N, Kellis E (2006) Effects of two 4-week proprioceptive neuromuscular  
facilitation programs on muscle endurance, flexibility, and functional performance  
in women with chronic low back pain. Phys Ther; 86:1001-1012. 
 
Koumantakis GA, Watson PJ, Oldham JA (2005). Trunk muscle stabilization  
training plus general exercise versus general exercise only: randomized  
controlled trial of patients with recurrent low back pain. Phys Ther; 85:209-225. 
 
Kuukkanen T, Mälkiä E (2000). Effects of a three-month therapeutic exercise  
programme on flexibility in subjects with low back pain. Physio Res Inter; 5:46- 
61. 
 
Leclaire R, Esdaile JM, Suissa S, Rossignol M, Proulx R, Dupuis M (1996). Back 
school in a first episode of compensated acute low back pain: a clinical trial to 
assess efficacy and prevent relapse. Arch Phys Med Rehab; 77:673-679. 
 
272 
 
Lee PB, Kim YC, Lim YJ, Lee CJ, Choi SS, Park SH et al (2006). Efficacy of  
pulsed electromagnetic therapy for chronic lower back pain: a randomized,  
double-blind, placebo-controlled study. J Inter Med Res; 34:160-167. 
 
Licciardone JC, Stoll ST, Fulda KG, Russo DP, Siu J, Winn W et al (2003).  
Osteopathic manipulative treatment for chronic low back pain: a randomised  
controlled trial. Spine; 28:1355-1362. 
 
Lindström I, Ohlund C, Nachemson A (1995). Physical performance, pain, pain  
behavior and subjective disability in patients with subacute low back pain. Scand  
J Rehab Med; 27:153-160. 
 
Linton SJ, Andersson T (2000). Can chronic disability be prevented? A  
randomised trial of a cognitive-behavior intervention and two forms of information  
for patients with spinal pain. Spine; 25:2825-2831. 
 
Long A, Donelson R, Fung T (2004). Does it matter which exercise? A  
Randomized control trial of exercise for low back pain. Spine; 29:2593-2602. 
 
Malmivaara A, Häkkinen U, Aro T, Heinrichs ML, Koskenniemi L, Kuosma E et al  
(1995). The treatment of acute low back pain--bed rest, exercises, or ordinary  
activity? N Eng J Med; 332:351-355. 
 
Mannion AF, Müntener M, Taimela S, Dvorak J (1999). A randomized clinical trial  
of three active therapies for chronic low back pain. Spine; 24:2435-2448. 
 
Mannion AF, Müntener M, Taimela S, Dvorak J (2001) Comparison of three  
active therapies for chronic low back pain: results of a randomized clinical trial  
with one-year follow-up. Rheumatology; 40:772-778. 
 
Maul I, Läubli T, Oliveri M, Krueger H (2005). Long-term effects of supervised  
physical training in secondary prevention of low back pain. Eur Spine J; 14:599- 
611. 
 
Mayer JM, Ralph L, Look M, Erasala GN, Verna JL, Matheson LN et al (2005).  
Treating acute low back pain with continuous low-level heat wrap therapy and/or  
exercise: a randomized controlled trial. Spine J; 5:395-403. 
 
Mehling WE, Hamel KA, Acree M, Byl N, Hecht FM (2005). Randomized,  
controlled trial of breath therapy for patients with chronic low-back pain. Alt Ther  
Health Med; 11:44-52. 
 
Melancon B, Miller LH (2005). Massage therapy versus traditional therapy for low  
back pain relief: implications for holistic nursing practice. Hol Nursing pract;  
19:116-121. 
 
273 
 
Moffett JK, Torgerson D, Bell SS, Jackson D, Llewlyn PH, Farrin A et al (1999).  
Randomised controlled trial of exercise for low back pain: clinical outcomes,  
costs, and preferences. BMJ; 319:279-283. 
 
Moseley L (2002). Combined physiotherapy and education is efficacious for  
chronic low back pain. Aust J Physio 2002; 48:297-302. 
 
Muehlbacher M, Nickel MK, Kettler C, Tritt K, Lahmann C, Leiberich PK et al  
(2006). Topiramate in treatment of patients with chronic low back pain: a  
randomised, double-blind, placebo-controlled study. Clin J Pain; 22:526- 
531. 
 
Nadler SF, Steiner DJ, Erasala GN, Hengehold DA, Abeln SB, Weingand KW  
(2003). Continuous low-level heat wrap therapy for treating acute nonspecific low  
back pain. Arch Phys Med Rehab; 84:329-334. 
 
Nadler SF, Steiner DJ, Petty SR, Erasala GN, Hengehold DA, Weingand KW  
(2003). Overnight use of continuous low-level heat wrap therapy for relief of low  
back pain. Arch Phys Med Rehab; 84:335-342. 
 
Nadler SF, Steiner DJ, Erasala GN, Hengehold DA, Hinkle RT, Beth GM et al  
(2002). Continuous low-level heat wrap therapy provides more efficacy than  
Ibuprofen and acetaminophen for acute low back pain. Spine; 27:1012-1017. 
 
Niemistö L, Lahtinen ST, Rissanen P, Lindgren KA, Sarna S, Hurri H (2003). A  
randomized trial of combined manipulation, stabilizing exercises, and physician  
consultation compared to physician consultation alone for chronic low back pain.  
Spine; 28:2185-2191. 
 
Niemistö L, Rissanen P, Sarna S, Lahtinen ST, Lindgren KA, Hurri H (2005).  
Cost-effectiveness of combined manipulation, stabilizing exercises, and  
physician consultation compared to physician consultation alone for chronic low  
back pain: a prospective randomized trial with 2-year follow-up. Spine; 30:1109  
1115. 
 
Nordeman L, Nilsson B, Möller M, Gunnarsson R (2006). Early access to  
physical therapy treatment for subacute low back pain in primary health care: a  
prospective randomized clinical trial. The Clin J Pain; 22:505-511. 
 
Pallay RM, Seger W, Adler JL, Ettlinger RE, Quaidoo EA, Lipetz R et al (2004).  
Etoricoxib reduced pain and disability and improved quality of life in patients with  
chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheum;  
33:257-266. 
 
Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal N (2004). Analgesic  
efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in  
274 
 
treatment of chronic low back pain: a multicenter, outpatient, randomized, double  
blind, placebo controlled trial. J Rheum ; 31:2454-2463. 
 
Penttinen J, Nevala PN, Airaksinen O, Jääskeläinen M, Sintonen H, Takala J  
(2002). Randomized controlled trial of back school with and without peer support.  
J Occup Rehab; 12:21-29. 
 
Perrot S, Krause D, Crozes P, Naïm C (2006). Efficacy and tolerability of  
paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with  
tramadol (50 mg) monotherapy in patients with subacute low back pain: a  
multicenter, randomized, double-blind, parallel-group, 10-day treatment study.  
Clin Ther; 28:1592-1606. 
 
Pohjolainen T, Jekunen A, Autio L, Vuorela H (2000). Treatment of acute low  
back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of  
a randomized, double-blind comparative trial versus ibuprofen. Spine; 25:1579- 
1585. 
 
Pope MH, Phillips RB, Haugh LD, Hsieh CY, MacDonald L, Haldeman S (1994).  
A prospective randomized three-week trial of spinal manipulation,  
transcutaneous muscle stimulation, massage and corset in the treatment of  
subacute low back pain. Spine; 19:2571-2577. 
 
Preyde M (2000). Effectiveness of massage therapy for subacute low-back pain:  
a randomized controlled trial. CMAJ; 162:1815-1820. 
 
Rasmussen BE, Nilsson WL, Arvidsson I (2003). Stabilizing training compared  
with manual treatment in sub-acute and chronic low-back pain. Man Ther; 8:233- 
241. 
 
Rozenberg S, Delval C, Rezvani Y, Olivieri AN, Kuntz JL, Legrand E et al (2002).  
Bed rest or normal activity for patients with acute low back pain: a randomized  
controlled trial. Spine; 27:1487-1493. 
 
Riipinen M, Niemistö L, Lindgren KA, Hurri H (2005). Psychosocial differences as  
predictors for recovery from chronic low back pain following manipulation,  
stabilizing exercises and physician consultation or physician consultation alone.  
J Rehab Med; 37:152-158. 
 
Rittweger J, Just K, Kautzsch K, Reeg P, Felsenberg D (2002). Treatment of  
chronic lower back pain with lumbar extension and whole-body vibration  
exercise: a randomized controlled trial. Spine; 27:1829-1834. 
 
Ritvanen T, Zaproudina N, Nissen M, Leinonen V, Hänninen O (2007). Dynamic  
Surface electromyographic responses in chronic low back pain treated by  
traditional bone setting and conventional physical therapy. J Manip Physio Ther;  
275 
 
30:31-37. 
 
Rossignol M, Abenhaim L, Séguin P, Neveu A, Collet JP, Ducruet T et al (2000).  
Coordination of primary health care for back pain. A randomised controlled trial.  
Spine; 25:251-258. 
 
Rossignol M, Allaert FA, Rozenberg S, Valat JP, Avouac B, Peres G et al (2005).  
Measuring the contribution of pharmacological treatment to advice to stay active  
in patients with subacute low-back pain: a randomised controlled trial.  
Pharmacoepidemiology and drug safety; 14:861-867. 
 
Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M (2003).  
Tramadol/acetaminophen combination tablets for the treatment of chronic lower  
back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient  
study. Clin ther; 25:1123-1141. 
 
Rydeard R, Leger A, Smith D (2006). Pilates-based therapeutic exercise: effect  
on subjects with nonspecific chronic low back pain and functional disability: a  
randomized controlled trial. J Ortho Sports Phys Ther; 36:472-484. 
 
Schnitzer TJ, Gray WL, Paster RZ, Kamin M (2000). Efficacy of tramadol in  
treatment of chronic low back pain. J Rheum; 27:772-778. 
 
Sherman KJ, Cherkin DC, Erro J, Miglioretti DL, Deyo RA (2005). Comparing  
yoga, exercise, and a self-care book for chronic low back pain: a randomized,  
controlled trial. Ann Int Med; 143:849-856. 
 
Soukup MG, Glomsröd B, Lönn JH, Bö K, Larsen S (1999). The effect of a  
Mensendieck exercise program as secondary prophylaxis for recurrent low back  
pain. A randomized, controlled trial with 12-month follow-up. Spine; 24:1585  
1591. 
 
Staal JB, Hlobil H, Twisk JW, Smid T, Köke AJ, van Mechelen W (2004). Graded  
activity for low back pain in occupational health care: a randomized, controlled  
trial. Ann Int Med; 140:77-84. 
 
Stam C, Bonnet MS, van-Haselen RA (2001). The efficacy and safety of a  
homeopathic gel in the treatment of acute low back pain: a multi-centre,  
randomised, double-blind comparative clinical trial. Br Homoeo J; 90:21-28. 
 
Steenstra IA, Anema JR, Bongers PM, de-Vet HC, Knol DL, van Mechelen W  
(2006). The effectiveness of graded activity for low back pain in occupational  
healthcare. Occu Envir Med; 63:718-725. 
 
Storheim K, Brox JI, Holm I, Koller AK, Bø K (2003). Intensive group training  
Versus cognitive intervention in sub-acute low back pain: short-term results of a  
276 
 
single-blind randomized controlled trial. J Rehab Med; 35:132-140. 
 
Suni J, Rinne M, Natri A, Statistisian MP, Parkkari J, Alaranta H (2006). Control  
of the lumbar neutral zone decreases low back pain and improves self-evaluated  
work ability: a 12-month randomized controlled study. Spine; 31:E611-E620. 
 
Szpalski M, Hayez JP (1994). Objective functional assessment of the efficacy of  
tenoxicam in the treatment of acute low back pain. A double-blind placebo- 
controlled study. BJ Rheum; 33:74-78. 
 
Thomas KJ, MacPherson H, Ratcliffe J, Thorpe L, Brazier J, Campbell M et al  
(2005). Longer term clinical and economic benefits of offering acupuncture care  
to patients with chronic low back pain. Health Technology Assessment; 9:iii-x, 1. 
  
Thomas KJ, MacPherson H, Thorpe L, Brazier J, Fitter M, Campbell MJ et al  
(2006). Randomised controlled trial of a short course of traditional acupuncture  
compared with usual care for persistent non-specific low back pain. BMJ;  
333:623. 
 
Torstensen TA, Ljunggren AE, Meen HD, Odland E, Mowinckel P, Geijerstam S  
(1998). Efficiency and costs of medical exercise therapy, conventional  
physiotherapy, and self-exercise in patients with chronic low back pain. A  
pragmatic, randomized, single-blinded, controlled trial with 1-year follow-up.  
Spine; 23:2616-2624. 
 
Triano JJ, McGregor M, Hondras MA, Brennan PC (1995). Manipulative therapy  
versus education programs in chronic low back pain. Spine; 20:948-955. 
 
Tsui ML, Cheing GL (2004). The effectiveness of electroacupuncture versus  
electrical heat acupuncture in the management of chronic low-back pain. J Alt  
Comp Med; 10:803-809. 
 
Turner JA, Jensen MP (1993). Efficacy of cognitive therapy for chronic low back  
pain. Pain; 52:169-177. 
 
Underwood MR, Morgan J (1998). The use of a back class teaching extension  
exercises in the treatment of acute low back pain in primary care. Family  
Practice; 15:9-15. 
 
Wand BM, Bird C, McAuley JH, Doré CJ, MacDowell M, De-Souza LH (2004).  
Early intervention for the management of acute low back pain: a single-blind  
randomized controlled trial of biopsychosocial education, manual therapy, and  
exercise. Spine; 29:2350-2356. 
 
Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N (2006).  
Oxytrex minimizes physical dependence while providing effective analgesia: a  
277 
 
randomised controlled trial in low back pain. J Pain; 7:937-946. 
 
Weiner DK, Rudy TE, Glick RM, Boston JR, Lieber SJ, Morrow LA et al (2003).  
Efficacy of percutaneous electrical nerve stimulation for the treatment of chronic  
low back pain in older adults. J Am Ger Soc; 51:599-608. 
 
Werners R, Pynsent PB, Bulstrode CJ (1999). Randomized trial comparing  
interferential therapy with motorized lumbar traction and massage in the  
management of low back pain in a primary care setting. Spine; 24:1579-1584. 
 
Williams KA, Petronis J, Smith D, Goodrich D, Wu J, Ravi N et al (2005). Effect  
of Iyengar yoga therapy for chronic low back pain. Pain; 115:107-117. 
 
Wright A, Lloyd DA, Williams S, Ellis R, Strike P (2005). Individual active  
treatment combined with group exercise for acute and subacute low back pain.  
Spine 2005; 30:1235-1241. 
 
Yelland MJ, Glasziou PP, Bogduk N, Schluter PJ, McKernon M (2004).  
Prolotherapy injections, saline injections, and exercises for chronic low-back  
pain: a randomized trial. Spine; 29:9-16. 
 
Yokoyama M, Sun X, Oku S, Taga N, Sato K, Mizobuchi S et al (2004).  
Comparison of percutaneous electrical nerve stimulation with transcutaneous  
electrical nerve stimulation for long-term pain relief in patients with chronic low  
back pain. Anesth Analg; 98:1552-6 
 
Zerbini C, Ozturk ZE, Grifka J, Maini M, Nilganuwong S, Morales R et al (2005).  
Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain  
and disability in patients with chronic low back pain: results of a 4-week,  
multinational, randomised, double-blind study. Cur Med Res Op; 21:2037-2049. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
278 
 
 
 
 
Appendix 4.3a  Overall symptom progression (VAS for pain) up to 52 week 
follow up in one randomly selected treatment arm from each 
trial.  
Each line represents a response line within a trial arm.  
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Appendix 4.3b  Overall symptom progression (RMDQ) up to 52 week follow 
up in one randomly selected treatment arm from each trial  
Each line represents a response line within a trial arm.  
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Appendix 4.3c  Overall symptom progression (ODI) up to 52 week follow up in 
one randomly selected treatment arm from each trial  
Each line represents a response line within a trial arm.  
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Appendix 5  Trials’ quality assessment criteria used for Cochrane systematic reviews and the 
modifications that have been introduced for use in Chapter Five. 
 
Original Modified 
1. Was the method of randomization adequate?  
2. Was the treatment allocation concealed?  
3. Were the groups similar at baseline regarding  
    the most important prognostic factors?  
4. Was the patient blinded to the intervention? 
5. Was the care provider blinded to the  
    intervention? 
6. Was the outcome assessor blinded to the  
    intervention? 
7. Were co-interventions avoided or similar?  
 
8 Was the compliance acceptable in all groups?  
9. Was the drop-out rate described and  
   acceptable?  
10. Was the timing of the outcome assessment in  
   both groups comparable?  
11. Did the study include an intention to treat  
   analysis? 
1m. Was the method of randomization adequate? 
2m. Was the treatment allocation concealed? 
-------- 
 
3m. Was the patient blinded to the intervention? 
4m. Was the care provider blinded to the   
    intervention? 
-------- 
 
5m. Were co-interventions prevented/avoided? 
6m. Were co-interventions standardised? 
7m. Was compliance acceptable? 
8m. Was the drop-out rate acceptable? 
 
9m. Was the timing of the outcome assessment in  
    all groups comparable? 
10m. Was the analysis based on intention-to-treat  
    analysis? 
Instructions for completion 
1. A random (unpredictable) assignment 
sequence. Examples of adequate methods are 
computer generated random number table and 
use of sealed opaque envelopes. Methods of 
allocation using date of birth, date of admission, 
hospital numbers, or alternation should not  be 
regarded as appropriate. 
2. Assignment generated by an independent 
person not responsible for determining the 
eligibility of the patients. This person has no 
information about the persons included in the trial 
and has no influence on the assignment sequence 
or on the decision about eligibility of the patient. 
3. In order to receive a ‘yes’, groups have to be 
similar at baseline regarding demographic factors, 
duration and severity of complaints, percentage of 
patients with neurological symptoms and value of 
main outcome measure(s). 
4. The reviewer determines if there was enough 
information about the blinding of the patient to 
score a “yes”. 
5. The reviewer determines if there was enough 
information about the blinding of the care provider 
to score a “yes”. 
 
6. The reviewer determines if there was enough 
information about the blinding of the outcome 
assessor to score a “yes”. 
7. Co-interventions should either be avoided in the 
trial design or comparable between the index and 
control groups. 
-- -- -- -- 
8. The reviewer determines if the compliance to 
the interventions is acceptable, based on the 
reported intensity, duration, number, and 
frequency of sessions for both the index 
intervention(s) and control intervention(s). 
9. The number of participants who were included 
in the study but did not complete the observation 
period or were not included in the analysis must 
be described and reasons given. If the percentage 
of withdrawals and drop-outs does not exceed 
20% for short-term follow-up and 30% for long-
term follow-up and does not lead to substantial 
bias, a “yes” is scored. (N.B., these percentages 
Instructions for completion  
1m. For cluster trials only: Examples of adequate 
methods are computer generated random number 
table and use of sealed opaque envelopes. 
Methods of allocation using date of birth, date of 
admission,  
    hospital numbers, or alternation should not be 
regarded as appropriate. 
2m. Same as point (1) for all other random trials.   
 
 
 
 
3m. Assignment generated by an independent 
person not responsible for determining the 
eligibility of the patients. This person has no 
information about the persons included in the trial 
and has no influence on the assignment sequence 
or on the decision about eligibility of the patient. 
-- -- -- --  
4m. The reviewer determines if there was enough 
information about the blinding of the patient to 
score a “yes”. 
5m. The reviewer determines if there was enough 
information about the blinding of the care provider 
to score a “yes”. 
-- -- -- -- 
6m. The reviewer determines if co-interventions 
were avoided in the trial design to score a “yes”.  
7m. The reviewer determines if co-interventions 
were comparable between the index and control 
groups and standardised to score a “yes”. If item 6 
is yes, then item 7 is not applicable. 
8m. The reviewer determines if the compliance to 
the interventions is acceptable, based on the 
reported intensity, duration, number, and 
frequency of sessions for both the index 
intervention(s) and control intervention(s). 
9m. The number of participants who were included 
in the study but did not complete the observation 
period or were not included in the analysis must 
be described and reasons given. If the percentage 
of withdrawals and drop-outs does not exceed 
20% for short-term follow-up and 30% for long-
term follow-up and does not lead to substantial 
bias, a  “yes” is scored. (N.B., these percentages 
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are arbitrary, not supported by literature). 
10. Timing of outcome assessment should be 
identical for all intervention groups and for all 
important outcome assessments. 
11. All randomized patients are reported/analyzed 
in the group they were allocated to by 
randomization for the most important moments of 
effect measurement (minus missing values) 
irrespective of non-compliance and co-
interventions. 
 
are arbitrary, not supported by literature). 
10m. Timing of outcome assessment should be 
identical for all groups and for all important 
outcome assessments. 
11m. All randomised patients are reported / 
analyzed in the group they were allocated to by 
randomization for the most important moments of 
effect measurement (minus missing values) 
irrespective of non-compliance and co- 
interventions. 
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Appendix 6 Summary of trials (n 44) that provided data for pain intensity outcome and were included in the meta-
regression analyses presented in Chapter Six. Full citations of included trials are presented in Appendix 4.2b 
 
 
 
 
Author and country  
 
 
 
Setting 
 
 
 
Age (y) 
 
 
 
Treatments 
 
 
Age (y) 
mean (SD)  
 
 
Female 
(%) 
 
Actual duration 
of LBP (weeks) 
mean (SD) 
Sample of 
trial arm 
at 
baseline 
Bendix et al, Denmark General practice  Functional restoration (PT + OT + Psychological) 40 66  48 
Outpatient intensive physical training: Aerobics + strengthening exercises + fitness 
machines 
43 69  51 
Burton et al, UK General practice 17-70 The Back Book + usual care (GP & osteopathic care)  11  83 
The traditional Handy Hints & usual care (GP & osteopathic care)  12  79 
Cambron et al, USA Chiropractic clinic + 
hospital clinic + general 
population 
18 + Chiropractic flexion distraction procedure 42 (11.4) 34  123 
Active trunk exercise program 41 (12.8) 41  112 
Chok et al, Singapore Physiotherapy + 
orthopaedic clinics + A/E  
20-55 Physical therapy (endurance exercise at the PT department) + back hot pack 38 (9.7) 20 4 (2) 38 
Back hot pack (Home) 34 (8.1) 29 4 (2) 28 
Constant et al, France General practice Unlimited Spa therapy & usual GP care    63 
Waiting list group & usual GP care    63 
George et al, USA Physical therapy 18-55 Standard care physical therapy 37 (10.1) 53 4 (2.3) 32 
Fear-avoidance based physical therapy 40 (10) 62 4 (2.3) 34 
Geisser et al, USA University spinal 
programme 
18-65 Manual therapy & Specific exercise (self corrections, stretching, strengthening) 39 (12.8) 67 284 (493) 26 
Sham Manual therapy & Specific exercise 39 (9.4) 56 370 (447.8) 25 
Manual Therapy & Non-specific exercise 37 (14.4) 80 370 (476.1) 24 
Sham Manual Therapy & non-specific exercise 46 (9.5) 61 284 (305.1) 25 
Glomsrod et al, Norway Physicians clinics and 
general population 
18-50 Active back school (Lectures and back exercises) 41 (6.1) 65  37 
Usual medical care 39 (6.6) 57  35 
Goldby et al, UK General practice + 
hospital physicians 
18-65 Spinal stabilisation & Attending the back school 43 (10.7) 68  84 
Manual therapy & Attending the back school 41 (11.7) 69.9  89 
Education (Booklet: Back in action) & Attending the back school 42 (13) 67.5  40 
Hay et al, UK General practice 18-64 A brief programme of pain management (general fitness and exercise at 
clinic and home, explanation about pain mechanisms, distress, 
encouragement of positive coping strategies, overcoming fear of 
“hurt=harm”, and implementation of a graded return to usual activities) 
40 (12.0) 50  201 
   Physiotherapy including manual therapy techniques 41 (11.6) 55  201 
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Heymans et al, Netherlands Occupational healthcare 18-65 Usual Dutch occupational physician care 41 (9.6) 17 35 103 
Low intensity back school 41 (10.2) 22 35 98 
High intensity back school 40 (9.5) 23 35 98 
Hseih et al, USA General population 18 + Joint manipulation & myofascial therapy 48 (13.7) 33 12 (7.2) 52 
   Joint manipulation  47 (14) 33 12 (7.2) 48 
   Myofascial therapy 49 (14.8) 33 12 (6.8) 51 
   Back school 48 (13.7) 40 11 (6.6) 48 
Hurley et al, UK Physiotherapy + General 
practice + self referral 
18-65 Manipulation therapy (Passively move intervertebral joint within or beyond its range) 40 (11.6) 57 7.5 (3.1) 80 
Interferential therapy (Electrical stimulation) 40 (12.1) 62 7.6 (3) 80 
Manipulation & interferential therapy 41 (11.3) 60 8.3 (2.8) 80 
Hurwitz et al , USA Managed care facility 18+ Chiropractic care only 52 (16.5) 49  169 
   Chiropractic care & physical modalities (Heat/cold, USS) 54 (16.8) 58  172 
   Medical care (excluding physical treatment) only 49 (16.5) 47  170 
   Medical care & physical modalities (Heat/cold, USS) 49 (16.7) 54  170 
Hurwitz et al, USA Network of healthcare 18 + Chiropractic care only 52 (16.5) 49  340 
Chiropractic care & physical modalities (Heat/cold, USS) 53 (16.8) 58  340 
Jellema et al, Netherlands General practice 18-65 Minimal intervention strategy (Assessing psychosocial risks, providing information 
on back pain and treatments & advice on self care) 
43 (11.1) 48 1.7 143 
Kaapa et al, Finland Occupational healthcare 22-75 Multidisciplinary rehabilitation: guided, group programme. : CBT, relaxation, back 
school education & physical therapy 
46 (7.9) 100 72 (112.5) 59 
Individual physiotherapy 47 (7) 100 63 (103.5) 61 
Kankaanpaa et al, Finland Occupational healthcare   Active rehabilitation: guided exercises in a dept + behavioural support  40 (8.5) 34  30 
Passive treatment: which they considered as minor to the active arm, e.g. massage 
and thermal treatment 
39 (7.3) 33  24 
Karjalainen et al, Finland General practice 25-60 Mini-intervention (Specific back exercises, reduce patient concerns & encourage 
physical activity) 
44 59  56 
Mini-intervention & worksite visit 44 57  51 
Usual  GP care 43 60  57 
   Usual GP care     
Kerr et al, UK General practice  Acupuncture 43 (11.5) 50 86 (84.9) 30 
   Placebo TENS (non-functioning) 43 (12) 65 73 (77.4) 30 
Kuukkanen et al, Finland Occupational healthcare  Intensive training: intensive progressive exercises guided at the gym + home 
exercises 
 62  29 
Home exercise only: same as intensive, but unguided  48  29 
Control: usual activities, no trial exercises  54  28 
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Leclaire et al, Canada Private physiatrist clinic 18-50 Standard care (rest, analgesics, physio) & Swedish back school 32 (7.7) 43  82 
Standard care (rest, analgesics, physio) 32 (8) 41  86 
Lindstrom et al, Sweden Occupational healthcare  Swedish back school & workplace visit + graded exercise (CBT approach)      24  51 
Usual care: rest& analgesics & physical treatment             38  52 
Linton et al, Sweden Mixed: General practice 
+ General population 
18-60 Back pain pamphlet  45 71  70 
Comprehensive information package 44 74  66 
CBT intervention 44 70  107 
Mannion et al, Finland General population < 65 Modern active individual physiotherapy: strengthening, coordination and aerobics 
exercises, instructions on ergonomic principles + home exercises 
46 (10.1) 61 520 (468) 46 
Muscle reconditioning on training devices (small groups) 45 (9.7) 54 504 (473.2) 47 
Low impact aerobic/stretching (groups) 44 (10.1) 55 676 (520) 44 
Maul et al, Switzerland Occupational healthcare 20-55 Back school & exercise 38 (8)   97 
Back school    39 (10)   86 
Mehling et al, USA General practice 20-70 Breath therapy 50 (12.1) 70 51 (26.6) 16 
Physical therapy: soft tissue mobilisation, joint mobilisation and exercises 49 (12.5) 58 57 (26.6) 12 
Moseley et al, Australia Mixed: Physiotherapy + 
General practice    
 Physiotherapy   43 (7) 64  29 
   Usual GP care 38 (7) 54  28 
Niemisto et al, Finland General population 24-46 Manipulation, exercise & physician consultation 37 (5.6) 55 312 102 
Physician consultation only 37 (5.6) 53 312 102 
Nordeman et al, Sweden Mixed: General practice 
+ physical therapy dept 
 Early access to physio (Individualised, exercise, advice, group education) 39 (12.1) 63  32 
Waiting list control 41 (11.1) 50  28 
Peloso et al, USA Outpatients 18 + Tramadol & Acetamenophen combination tablets 375/325 2 PRN 58 (11.5) 64  167 
   Placebo tablets 2 PRN 58 (13.6) 61  169 
Rasmussen et al, Sweden Physiotherapy 18-60 Stabilizing training (Individual) (Cognitive + stabilisation of spinal muscles) 39 (12) 70  24 
Manual treatment (Individual) (Other muscles exercises, no manipulation) 37 (10) 78  23 
Rittweger et al, Germany General population 40-60 Isodynamic lumbar extension 50 (6.6) 44 603 (520) 30 
Vibration exercise (On a machine with a vibrating platform) 54 (3.4) 52 754 (530.4) 30 
Ritvanen et al, Finland General population 20-60 Traditional chiropractic bone setting 41 (4.9) 45  33 
Physical therapy 42 (6.8) 43  28 
Rossignol et al, Canada Workers compensation 
board 
 Coordination of primary healthcare program 37 (9.7) 33  54 
Usual GP care 38 (10.2) 23  56 
Ruoff  et al, USA Not clear 25-75 Tramadol/ Acetamenophen combination tablets 37.5/325 mg, 2 tablets 54 (11.9) 67  161 
   Placebo tablets 2 tablets 54 (12) 59  157 
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Soukup et al, Norway Mixed: General practice 
+ General population + 
Referrals 
18-50 Mensediesk exercise group intervention 40 53 676 (474.8) 34 
Waiting list group 40 49 578 (320.7) 35 
Staal et al, Netherlands Occupational healthcare   Graded activity (Physiotherapy + OT) 39 (9) 5 8.5 67 
   Usual OT care  37 (8) 8 8 67 
Torstensen et al, Norway Social security offices 20-65 Medical exercise therapy (MET) 42 (11.2) 52  71 
Conventional physiotherapy (CP) 43 (12) 48  67 
Self exercise 40 (11.4) 51  70 
Tsui et al, Hong Kong Physiotherapy 20-55 Electro-acupuncture & back exercise 40 (12.1) 76 39 (31.8) 14 
Electrical heat acupuncture + back exercise 39 (9.2) 71 54 (54.5) 14 
Back exercise only 41 (8.3) 62 50 (41.6) 14 
Turner et al, USA General practice + 
Physicians + general 
population 
20-65 Relaxation training (group)    24 
Cognitive therapy (group)    23 
Cognitive therapy & Relaxation training (group)    25 
Waiting list    30 
Wand et al, UK General practice + A/E 
patients 
 Assess & Advice & Physiotherapy 34 (9) 44  43 
Assess & Advice & wait 35 (7.9) 55  51 
Werners et al, Germany General practice  Interferential therapy: electrotherapy, to stimulate muscles fibres 38 (9.4) 43  68 
Motorised lumbar traction & massage 39 (9.5) 49  72 
Yelland et al, Australia General practice 21-70 Glucose lignocaine injection 52 (10.6) 59 769.6 (556.8) 28 
Exercise (Alternating: flexion and extension of spine and hips) 49 (10.4) 55 718 (483.6) 26 
Saline injection 50 (9.8) 56 759 (499.2) 27 
Normal activity 51 (11.2) 58 733 (551.2) 29 
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Appendix 7.1   Within-arm change in RMDQ, mean(SD), in trials’ IPD 
 
 
 
Trials 
 Baseline 4weeks 6weeks 13weeks 27weeks 52weeks 
 
 
Treatment arms 
 
 
n 
 
 
Mean (SD) 
 
 
n 
  
Change  
 
 
n 
  
Change  
 
 
n 
  
Change  
 
 
n 
  
Change  
 
 
n 
  
Change  
Mean (SD) Mean(SD) Mean (SD) Mean(SD) Mean (SD) Mean(SD) Mean (SD) Mean(SD) Mean (SD) Mean(SD) 
                   
Hay et al Manual physiotherapy 201 13.29 (4.88)       162 5.14 (5.83) 8.06 (6.03)    165 4.41 (5.49) 8.79 (6.09) 
Brief pain management  201 13.77 (4.82)       157 5.97 (5.93) 7.83 (6.63)    164 5.17 (5.75) 8.8 (6.37) 
Heymans et 
al 
Occupational health care 102 9.75 (5.04)       78 9.40 (6.55) 0.52 (10.22) 71 7.10 (6.27) 2.77 (9.53) 84 6.61 (5.91) 3.27 (9.26) 
Low intensity back school 94 7.93 (3.94)       73 8.41 (5.80) 0-.53 (8.20) 71 6.45 (6.09) 1.75 (8.53) 87 7.01 (6.54) 0.77 (8.73) 
High intensity back school 91 8.07 (3.89)       70 9.16 (6.46) -0.82 (8.56) 66 7.94 (5.91) 0.40 (7.44) 73 6.56 (6.22) 1.60 (8.15) 
Johnson et al community-based treatment 
program of 
group sessions led 
physiotherapists  
 
116 10.62 (3.91)       110 7.40 (5.33) 3.15 (5.64) 105 6.46 (4.67) 3.96 (4.45 ) 101 6.69 (5.64) 3.81 (5.44) 
Back pain educational booklet 
and usual GP care. 
118 10.89 (3.96)       113 8.02 (5.28) 2.79 (4.63) 98 8.03 (5.35) 2.73 (4.77) 94 7.97 (5.48) 2.66 (4.80) 
Moffett et al Exercise programme 89 6.65 (4.01)    85 3.44 (3.34) 3.21 (3.57)    77 3.02 (3.59) 3.48 (4.66) 83 2.93 (3.42) 3.64 (4.37) 
Routine GP care 98 5.56 (3.94)    94 3.68 (4.00) 1.63 (3.78)    86 3.90 (4.43) 1.20 (4.56) 88 3.74 (4.48) 1.34 (4.24) 
UKBEAM Best GP care 338 8.97 (3.87) 268 7.52 (4.83) 1.29 (3.88)    256 6.58 (5.04) 2.10 (4.37)    248 5.92 (5.05) 2.80 (4.64) 
Exercise 310 9.21 (4.35) 239 6.72 (4.92) 2.26 (3.93)    225 5.42 (4.83) 3.56 (4.13)    216 5.99 (5.63) 3.23 (4.30) 
Manipulation 353 8.91 (3.98) 325 6.70 (4.98) 2.17 (4.08)    287 5.09 (5.03) 3.64 (4.78)    273 5.08 (5.17) 3.85 (5.03) 
Combined exercise and 
manipulation 
332 8.99 (3.92) 286 6.50 (4.48) 2.41 (3.65)    259 4.84 (4.85) 4.07 (4.27)    258 4.77 (5.02) 4.07 (4.57) 
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Appendix 7.2 Within-arm differences in change in ODI scores (mean, 95% CI) according to the selected characteristics in 
Thomas et al trial.  
 
   13weeks  52weeks 
 
Characteristics 
Treatment 
arms  
 
n 
 
Unadjusted 
 
Adjusted 
  
Unadjusted 
 
Adjusted 
        
Age, younger 
than 43 years 
Acupuncture 75:71 -4.30 (-8.97,0.38) -4.07 (-8.86, 0.73) 69:65 -4.23 (-9.71, 1.25) -4.09 (-9.76, 1.58) 
 Usual care 34:37 -3.06 (-10.32, 4.20) -2.92 (-10.37, 4.52 26:31 -0.08 (-7.82, 7.98) -0.28 (-8.48, 7.93) 
        
Gender, male Acupuncture 53:93 -2.93 (-7.82, 1.97) -2.36 (-7.35, 2.63) 49:85 -1.61 (-7.34, 4.12) 0.73 (-6.62, 5.17) 
 Usual care 29:42 -2.83 (-10.21, 4.56) -2.71 (-10.25, 4.91) 19:38 2.76 (-5.55, 11.08) 2.94 (-5.71, 11.59) 
        
History of LBP, 
absent 
Acupuncture 22:124 1.80 (-4.80, 8.40) 2.77 (-3.85, 9.38) 22:112 -0.64 (-8.11, 6.82) 0.07 (-7.77, 7.61) 
 Usual care 12:59 -0.84 (-10.57, 8.88) -1.87 (-11.82, 8.09) 10:47 0.79 (-9.55, 11.14) 1.22 (-9.46, 11.89) 
        
n: number in the comparable groups. 
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Appendix 8   Literature search strategy for cohort studies 
 
 
Back pain_Prognosis_Cohorts_Primary care (12/04/2011)  
   
1. exp Low back pain/ OR exp back pain/ 
2. exp Pain/ 
3. (back AND pain).ti,ab [Limit to: Core clinical journals (AIM) and Humans and English 
Language]  
4. 1 AND 2 AND 3 
 
5. exp Prognosis/ 
6. exp disease progression/ 
7. predict.ti,ab 
8. factor.ti,ab 
9. model.ti,ab 
10. evolution.ti,ab 
11. history.ti,ab 
12. course.ti,ab 
13. determinant.ti,ab 
14. pattern.ti,ab 
15. screen.ti,ab 
16. long-term.ti.ab 
17. progress.ti,ab 
18. modif.ti,ab 
19. mediate.ti,ab 
20. OR/ 4-16  
21. 4 AND 20 
 
22. (epidemiology AND studies).ti,ab 
23. exp Epidemiology studies/ 
24. cohort.ti,ab 
25. retrospective.ti,ab 
26. prospective.ti,ab 
27. longitudinal.ti,ab 
28. inception.ti,ab 
29. observation.ti,ab 
30. outcome.ti,ab 
31. OR/ 22-30  
32. 21 AND 31 
 
33. exp Primary Health Care/ 
34. exp Family Practice/ 
35. exp Physicians, Family/ 
36. exp Community Health Services/ 
37. "General Practice".ti,ab 
38. "family practice".ti,ab 
39. "family physician".ti,ab 
40. AMBULATORY CARE/ 
41. “ambulatory adj2 care”.ti,ab 
42. OR/ 33-41   
 
43. 32 AND 42 
